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Summary 
For asthma, an interesting pattern of gender differences across the life span has been 
documented with higher prevalence rates in boys compared to girls, a reversing of the 
gender ratio in puberty, and a female preponderance in early adulthood. The picture is less 
clear for later adulthood, and, in women, for the menopausal transition. This gender-
differential life course of asthma has been related, amongst other, to reproductive 
pathologies and hormonal factors. However, there is a range of further pathways likely to be 
relevant for gender differences, such as genetic, immunologic mechanisms, systemic 
inflammation, obesity and metabolic factors, differential time-activity patterns leading to 
different exposures, different help seeking, or gender biases in diagnosis and treatment. 
This PhD project makes use of the on-going Swiss Cohort Study on Air Pollution and Lung 
and Heart Diseases in Adults (SAPALDIA), covering 20 years of longitudinal observation in a 
population aged 18-60 years at baseline in 1991.  It assesses gender differences in asthma 
incidence and investigates two gender-related pathways which have a hypothesized impact 
on gender differences in asthma incidence and can be tested in the SAPALDIA cohort: 
firstly, reproductive pathologies and early menarche, and secondly the role of 
overweight/obesity as measured by lifetime history of body silhouettes.  
Asthma incidence was higher in women than in men but decreased with increasing age. The 
female predominance was considerably stronger in non-sensitised adults compared with 
those with allergic sensitisation. The association between reproductive pathologies as well 
as early menarche and asthma incidence remained inconclusive. The risk of new-onset 
asthma increased in men and women with a larger body silhouette in late adulthood. In 
women, this risk appeared present between age 45 and menopause and was most 
pronounced at age 60.  
The completion of this PhD project, embedded in on-going research activities of the 
SAPALDIA cohort and linked to the European Respiratory Health Survey, contributes to 
open questions regarding asthma incidence in later adulthood and regarding gender-related 
differences. This study is among the few to report the cumulative incidence of adult-onset 
asthma by sex/gender in a population-based study with a high proportion of people aged 
>50 years of age. Our study is also the first to assess the role of overweight/obesity as 
measured by body silhouettes for asthma incidence in men and women.  Given the 
importance of asthma in terms of disease burden as well as the epidemic of obesity, 
knowledge on these sex/gender related pathways is crucial and adds a further argument for 
obesity prevention strategies.  
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1. Introduction 
 
1.1 Sex/Gender in biomedical and health-related research 
Much progress has been made since forty years ago when the terms ‘sex’, ‘gender’ and 
‘science’ had not been formally conjoined, nor had the implications of such a conjunction 
been subject to any kind of serious analytical or historical scrutiny (Keller, 2001, p. 98). 
Today, not only has the study of gender become its own academic discipline and been taken 
up in fields such as cultural studies, psychology, anthropology, art history, film theory, 
sociology and science studies among many others, but increasingly, in the United States 
and the European Union, sex and gender have come to be seen as invaluable dimensions of 
biomedical and health-related research.  
 
1.1.1 History of incorporating sex/gender into biomedical and health-related research 
It may seem hard to believe, but up until the 1960’s, drugs were typically only tested on 
middle-aged white men (Schiebinger, 2008, p. 16). It was assumed that the absence of other 
groups such as women, ethnic minorities, or individuals of different age groups did not 
matter much, because the findings from studying the ‘normative standard’ could simply be 
generalized to the entire population (Epstein, 2007, p. 4). This was partly because men were 
often easier target groups to recruit—being physicians or men in the military, but it was also 
because they do not have menstrual cycles or the ability to get pregnant. This means that 
they are ‘hormonally stable’—menstrual cycles will not confound data on drug effects in 
clinical trials. And without the possibility of pregnancy, drugs can be tested without concern 
that they may harm an unborn child. Although this may be true, and therefore testing on 
middle-aged white men may be easier, this type of medical practice is not only tremendously 
unfair but it is also dangerous. One of the results of this ‘one-size fits all approach’ to 
medicine is that adverse drug reactions occur twice as often in women as in men 
(Schiebinger, 2008, p. 16). 
 
These obvious shortcomings, however, have not corrected themselves; it has taken hard 
work and dedication to make legislative changes both in the United States and the European 
Union. Since the mid-1980’s a diverse assortment of reformers in the United States have 
protested against biomedical practices, “arguing that expert knowledge about human health 
is dangerously flawed and that health research practices are fundamentally unjust because 
of the inadequate representation of other groups in clinical trials” (Epstein, 2007, p. 4). This 
diverse group of reformers, which included grassroots advocacy groups, clinicians, 
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scientists, professional organizations, and government health officials  managed to generate 
institutional reforms in the American biomedical sciences (Epstein, 2007, p. 4). The most 
pertinent achievements were policy changes made within the National Institute of Health 
(NIH) and the Federal Drug Administration (FDA). In 1993, the NIH passed the Revitalization 
Act that legislated the mandatory inclusion of women and ‘members of minority groups’ as 
research subjects in NIH-funded studies (Epstein, 2007, p. 82). And in the same year the 
FDA reversed their restriction of including women ‘of childbearing potential’ in trials of 
experimental drugs, out of concern for possible fetuses (Sismondo, 2010, p. 5). More 
recently, in 2014, the NIH announced policies requiring that both sexes be studied in NIH-
funded pre-clinical trials (Clayton, 2016) and effective January 2016, the NIH has 
implemented a policy that requires scientists to account for the possible role of sex as a 
biological variable in vertebrate animals and human studies (Tannenbaum et al., 2016). 
Furthermore, since 2010, the Canadian Institutes of Health Research (CIHR) have 
requested applicants to consider sex and gender in their research and are even planning to 
include sex and gender as a component of the review criteria (Schiebinger et al., 2015).  
 
In Europe we are seeing a similar trend, although the focus of reforms has been less on race 
and ethnicity as it has been in the United States, and more on woman and pediatric 
populations. In the European Union “attention to sex and gender aspects in biomedical and 
health-related research has become a major initiative of the EU gender equality policy for 
research” (Klinge, 2008, p. 183). Following the three-year lobbying actions of ‘Women’s 
International Studies Europe’ (WISE), the European Commission requested a Gender 
Impact Assessment of their Fifth Framework Programme in the year 2000. This unique 
opportunity was seized by a select group of social and natural scientists from Maastricht 
University who through their Gender Impact Assessment and successive involvement in the 
European Commission transformed the way that European research is conducted, theorized, 
and practiced. Differences between men and women are now taken into account in 
condition-specific aspects such as pathogenesis, patterns of symptoms and presentation of 
symptoms, treatment options and prognosis (Klinge and Bosch, 2005, p. 379). And much 
like policy reforms within the NIH and FDA, studies that were funded under the 6th 
Framework Programme of the European Commission had to, according to policy regulation, 
pay explicit attention to sex and gender issues. As a sign of how established sex and gender 
analysis has become, in December 2013, The European Commission launched Horizon2020 
identifying 137 areas of science and technology where gender analysis could benefit 
research (Schiebinger et al., 2015). Most recently, in 2016, the SAGER guidelines, 
addressing peer-reviewed journal’s editorial policy for reporting sex and gender-sensitive 
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research was released (Heidari et al., 2016) and in Germany, a large-scale funding scheme 
and call for applicants for ‘gender-sensitive studies in prevention and health services 
research’ has been launched in spring 2016 by the German Federal Ministry for Education 
and Research (see https://www.bmbf.de/foerderungen/bekanntmachung-1175.html). 
 
1.1.2 Analytical frameworks for examining sex/gender in biomedical and health-
related research  
 
Yet these policies have often been introduced with little attention to the concepts of sex and 
gender and the theoretical frameworks and methodologies that relate to them. Feminist 
scholars have long theorized about the role of sex/gender in science, however they are 
either largely ignored by the mainstream scientific community or it is felt by scientists that the 
work by these scholars remain too theoretical for application. One way of summarizing 
available analytical frameworks for examining sex/gender in biomedical and health-related 
research, is given below based on the work by Singh and Klinge (2015) who identified three 
key feminist methodological frameworks that have been used to guide scientific practice in 
the field. 
1. The strong objectivity framework. This term was first coined by the feminist 
philosopher Sandra Harding (Harding, 1991). The analytical framework encourages 
researchers to think reflexively about social values, especially assumptions based on 
gender and racial norms, and emphasizes that these social values affect our choices 
at every stage of scientific inquiry. This framework does not completely reject the 
concepts of objectivity and neutrality, but rather, it makes adjustments to the scientific 
method. In the strong objectivity framework, part of the scientific process should be to 
acknowledge and think reflexively about the cultural context and socially constructed 
values that inform research questions and designs.  
2. The partial perspectives framework. This framework is informed by post-structuralist 
feminist theory. This framework actually does reject the notion of objectivity and 
seeks to deconstruct the scientific method by locating all players and networks of 
power involved- including non-human actors (Latour, 1987). It emphasizes that a 
biological world is not simply awaiting scientific discovery by the scientific genius but 
rather is historically produced through a network of human and non-human actors. 
Language used by scientific researchers to access and observe the world is 
mediated by social power relations and thereby this framework attempts to 
deconstruct the concepts of sex, gender, race and ethnicity in order to open up new 
paths for research. 
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3. The gendered innovations framework. The term ‘gendered innovations’ was first 
coined by feminist science historian Londa Schiebinger starting with her work in 2009 
at Stanford University that has now developed into an international project co-funded 
by the European Commission (“Gendered Innovations | Stanford University,” n.d.). 
To counterbalance the neglect of sex/gender in science, this perspective promotes 
the analysis of sex/gender in science from a positive and practical standpoint. The 
gendered innovations website promotes a) that sex/gender analysis will lead to 
innovation and better science and b) provides case studies and practical methods for 
doing so. These scholars attempt to operationalize feminist conceptions of sex and 
gender and to move beyond simply identifying bias. What distinguishes this 
framework from previous frameworks is that “challenges in pitfalls conducting sex-
and gender-sensitive research, originally identified in the social sciences, are 
translated to the practice of biomedical and health research” (Nieuwenhoven and 
Klinge, 2010, p. 313). It is this analytical framework which forms the backbone of 
sex/gender analysis in this PhD thesis.  
 
1.1.3 Definition of sex/gender  
One of the challenge that epidemiologists, among other scientists face, is clarifying the 
concepts of sex and gender and how these two concepts relate to health (Doyal, 2003). This 
confusion has led many to use the two terms interchangeably, creating what Hammarström 
& Annadale refer to as a ‘conceptual muddle’ (2012). As is also emphasized on the 
gendered innovations website, it is analytically important to distinguish the terms sex and 
gender (“Analyzing Sex | Gendered Innovations,” n.d.), and the two words are not 
interchangeable as is often assumed (Doyal, 2003). Doyal (2003) calls for differentiating very 
carefully between the biological and the social in order to fully understand health problems 
and develop appropriate interventions (Doyal, 2003) 
Sex refers to biological differences between men and women such as chromosomes (XX 
and XY), internal and external sex organs (ovaries, testes) and hormonal profiles (of 
oestrogens and androgens) (Singh and Klinge, 2015). Biological sex differences are often 
viewed as dichotomous, either male or female, although variability is substantial (Fausto-
Sterling, 2000). Intersex syndromes exist, as do women and men with a hormonal or gene 
expression profile that is close to the other sex (Regitz-Zagrosek, 2012). Sex can be defined 
according to genetic chromosomal make-up, germ cells, morphology, or even non-genetic 
determination systems apparent in many species such as thermal sex-determination, age-
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based sex determination or social sex-determination (“Analyzing Sex | Gendered 
Innovations,” n.d.).  
Gender, on the other hand, refers to the socially constructed roles and relations, personality 
traits, attitudes, behaviors and values that are ascribed to the two sexes in a different 
manner (Krieger, 2003; Singh and Klinge, 2015) and shape ‘feminine’ and ‘masculine’ 
behaviors (“Gender | Gendered Innovations,” n.d.) . For example, all women will at some 
point experience menopause, however the value attachment to menopause has a large 
cross-cultural variation (“Sex and Gender, what’s the difference ?,” n.d.). And as an example 
from the epidemiology of cancer, sex differences in biology mean that only women are at risk 
of developing cancer of the cervix and only men are at risk from cancer of the prostate. 
However, biology cannot explain why men are currently more likely than women to develop 
lung cancer - for this we would have to look at the social concept of gender and ask 
questions such as do gender roles mean that men smoke more than women? (Doyal, 2003) 
1.1.4 Conceptual approaches for analyzing sex/gender 
Analyzing sex involves six steps (“Analyzing Sex | Gendered Innovations,” n.d.): 
1. Reporting the sex of research subjects involved. As mentioned above, this is even a 
requirement by a growing number of funding agencies and peer-reviewed journals. 
Reporting the sex of research subjects, even in same sex studies, is important for 
identifying research gaps, preventing over generalizations, and for conducting meta-
analysis.  
2. Recognizing differences that exist within groups of females and males. Both 
biological and sociocultural factors may differ greatly within each sex over the 
lifetime- for example in the US men are taller than women, however the height 
difference between a 90th percentile and 10th percentile man or a 90th percentile 
women and 10th percentile women is more than the difference between the average 
height difference between men and women. 
3. Collecting and reporting data on factors intersecting with sex. There are many 
sociocultural factors which intersect with sex that are important to take into 
consideration. When these factors are not taken into consideration there may be an 
overemphasis on sex. For example in the development of prostheses for total knee 
anthroplasty, designers observed a statistically significant difference between men 
and women’s knee anatomy and so produced a ‘gendered knee’. However, what they 
overlooked is that in this case, height is a more important variable for matching 
patients to prostheses than sex.  
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4. Analyzing and reporting results by sex. Sex-specific analysis should be conducted 
and reported.  
5. Report null findings. Researchers should report when sex differences are not 
detected in their analyses to reduce publication bias. Where relevant, researchers 
should note when data regarding sex differences are statistically inconclusive, 
especially in the context of factors intersecting with sex. 
6. Meta-analysis. It is important to report clear results so that the study can be used for 
meta-analysis. Meta-analysis can increase statistical power, but can also compound 
error if factors intersecting with sex and gender are overlooked. 
Gender attitudes and behaviors ‘reside’ and are (re)produced at various levels – in 
individuals, social institutions, and wider society and cultures. When gender assumptions are 
invisible and remain unexamined, they may introduce bias into research and can undermine 
the scientific method (“Analyzing Gender | Gendered Innovations,” n.d.). Gender aspects 
relate to 
1. Researchers’ assumptions and behaviors as these relate to the proposed research 
2. Research subjects and user’s gender needs, assumptions, and behaviors as these 
relate to the proposed research 
3. How 1 and 2 intersect 
It is also important that researchers can investigate how sex and gender intersect with other 
significant factors (“Interactions between Sex & Gender | Gendered Innovations,” 2016). 
Researchers should identify other intersecting factors that are important because this can 
reveal sub-group differences which may be missed if one only looks at gender or sex as a 
variable (“Interactions between Sex & Gender | Gendered Innovations,” 2016). For example, 
accounting for socioeconomic status may reveal that women of high socioeconomic status 
have similar health outcomes to men of low socioeconomic status. 
And finally, as important as it is to realize that sex and gender are two analytically distinct 
concepts, in practice, they often interact and rarely does an observed difference between 
men and women involve only gender or only sex (“Interactions between Sex & Gender | 
Gendered Innovations,” 2016; Krieger, 2003). Some investigators use the term “sex/gender” 
to refer to the inter-relatedness of sex and gender i.e. that the phenomenon are 
simultaneously biological and social (Fausto-Sterling, 2012; Krieger, 2003; Springer et al., 
2012a). While the causal link between ‘sex’ and ‘gender’ is often thought to flow 
automatically from biological to social difference, recent research has forcefully 
demonstrated that the influence often operates in the other direction (Krieger, 2013; Krieger 
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et al., 2013a, 2013c; Springer et al., 2012a). As Wade (2013, p. 287) states: “biology is, 
literally, the flesh and blood of society” and “the social is the natural” (Lorber, 1994). 
Unmeasured aspects of gender will always be present and usually we will be unaware of the 
specific ways in which gendering of activities, as through nutrition and psychology, affects 
cellular level processes (Springer et al., 2012a). Or as Martin (1991) has shown, how 
gendered stereotypes of femininity and masculinity can influence something we would often 
consider to be biologically determined: how the sperm and egg interact. Another such 
example is from neuroscientist Lisa Eliot (2009) who argues that sex differences in mental 
rotation ability are probably the result of the fact that we fail to teach mental rotation in 
school and boys have a greater likelihood of learning it elsewhere through activities like 
building toys, video games, and sports (Cherney and London 2006; Kersh et al. 2008) 
(Wade, 2013, p. 288). 
Messing and Stellman (Messing and Mager Stellman, 2006)(2006), among others, have 
urged epidemiologists to avoid the use of the term sex as a broad proxy for biology as if the 
term conveyed a mechanism for generating male-female differences. One such approach is 
that of embodiment, coined by epidemiologist Nancy Kreiger (2005). Embodiment addresses 
why and how historically contingent, spatial, temporal, and multilevel processes become 
embodied and generate population patterns of health, disease, and wellbeing, including 
social inequalities of health. Krieger (2013b) has shown how the abolition of Jim Crow Laws,  
laws which legalized racial discrimination in the US, affected US Black infant death rates and 
has questioned gene-centric approaches to conceptualizing biology, using the example of 
breast cancer (Krieger, 2013).  Embodiment thus entails more than simply ‘phenotypes’, or 
‘genotypes’, and a vaguely defined (and implicitly external) ‘environment’ eliciting ‘gene-
environment interactions (Krieger, 2005). 
1.1.5 Benefits of incorporating sex/gender into biomedical and health-related research 
Not only is the ‘one-size-fits-all’ approach unethical because it is unrepresentative of the 
overall population, but beyond that, the assumption that findings from a ‘normative standard’ 
of middle aged white men can be generalized to the entire population is a dangerous one.  
Many effects of pharmacological interventions differ in women and men and require different 
doses. For example, the American Heart Association recommended aspirin therapy to high 
risk adults in order to reduce the incidence of coronary heart disease, based on a number of 
trials in which only 20% of the subjects were women (Klinge, 2010). However, a sex-specific 
meta-analysis by Berger (2006) showed that aspirin therapy reduces the risk of myocardial 
infarction in men only, whereas the risk of an ischemic heart stroke is lowered only in 
women. The recommendation should therefore only have applied to men and in fact was 
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harmful to women, because the use of aspirin increases the risk of bleeding events (Klinge, 
2010). In fact adverse drug reactions occur twice as often in women as in men (Schiebinger, 
2008).  
 
Gender medicine takes into account the effects of sex and gender on the health of women 
and men while recognizing that it may not be possible at every step to differentiate among 
the influences of sex and gender. The major goal is to improve health and health care for 
both women and for men (Regitz-Zagrosek, 2012). Medical literature is abound in evidence 
of physiological and pathophysiological differences between males (men) and females 
(women) affecting development, progression, presentation, and symptomatology of diseases 
beyond those defined by reproduction. Women and men differ in biology, roles and the 
responsibilities that society assigns to them: this affects the risks they take, their 
vulnerability, their efforts to improve their health, and the ways in which health systems 
respond to their needs (WHO/Europe, 2011). Therefore, it is only logical that in development 
and testing of novel diagnostics and therapeutics, sex and gender should be considered as 
important variables (Raz and Miller,2012).  
More attention to sex and gender analysis in biomedical and public health related research 
could lead to less biased outcomes (Heidari et al., 2012; Raz and Miller, 2012; Roberts, 
2010) and enhance human knowledge and technical systems by opening them up to new 
perspectives, new questions, and new missions (Schiebinger, 2008). Gender Medicine 
promises a better understanding of health and disease, more evidence based and precise 
knowledge, more effective therapies, and better health outcomes for women and men 
(Klinge, 2010). Attention to sex and gender, even in preclinical research, will lead to more 
adequate research data (Klinge and Bosch, 2005) and will lead to better health care (Klinge, 
2010). 
 
1.2 Asthma: what is it? 
Asthma is a heterogeneous disease of the bronchial tubes in the lungs. Its main 
characteristic is reversible airflow obstruction, clinically manifest by varying expression and 
severity of recurrent attacks of breathlessness, wheezing, chest tightness, and coughing, 
particularly at night or in the early morning. Asthma is usually, but not always, associated 
with airway hyper responsiveness and airway inflammation(“GINA Report, Global Strategy 
for Asthma Management and Prevention | GINA,” 2011).   
The initial diagnosis of asthma is based on identifying both a history of asthma symptoms 
such as wheeze, shortness of breath, chest tightness, and cough, as well as variable 
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expiratory airflow limitation often measured spirometer tests. There is no single test or 
pathognomic feature which defines the presence or absence of asthma, and the variability of 
the disease means that symptoms may or may not be present on the day of examination. 
Therefore, diagnosis of asthma is ideally made on the basis of clinical history, physical 
examination and respiratory function tests over a period of time (Pearce and Douwes, 2013). 
In their recent report for asthma management and prevention, the Global Initiative for 
Asthma (GINA) (2016) provides detailed guidelines for the diagnosis of asthma (see box 1-1 
and 1-2).  
Asthma most commonly develops in early childhood, but more than three-quarters of 
children who develop asthma symptoms before age 7 no longer have symptoms by age 16. 
However asthma can develop at any stage in life, including adulthood (“The Global Asthma 
Report,” 2014). Increasingly asthma is viewed as a heterogeneous disease, including a 
number of phenotypes (GINA, 2016):  
a) Allergic asthma: this is the most easily recognized asthma phenotype. It often starts 
in childhood and is associated past and/or family history of allergic disease. 
Examination of the induced sputum of these patients before treatment often reveals 
eosinophilic airway inflammation. Patients with this asthma phenotype usually 
respond well to inhaled corticosteroids (ICS) treatment.  
b) Non-allergic asthma: some adults have asthma that is not associated with allergy. 
The cellular profile of the sputum of these patients may be neutrophilic, eosinophilic 
or contain only a few inflammatory cells. Patients with non-allergic asthma often 
respond less well to ICS. 
c) Late-onset asthma: some adults, particularly women, present asthma for the first time 
in adult life. These patients tend to be non-allergic, and often require higher doses of 
ICS or are relatively refractory to corticosteroid treatment 
d) Asthma with fixed airway limitation: some patients with long-standing asthma develop 
fixed airway limitation that is thought to be due to airway wall remodeling 
e) Asthma with obesity: some obese patients with asthma have prominent respiratory 
symptoms and little eosinophilic airway inflammation  
Although these asthma phenotypes are recognized and often characterized, to date 
there is no strong relationship between specific pathological features and particular 
clinical patterns or treatment responses. More research is needed to understand the 
clinical utility of phenotypic classification of asthma and their eventual relation to 
sex/gender.  
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1.2.1 Asthma: global burden of disease  
Asthma is a chronic condition with important consequences in terms of disease burden and 
health care resources needed, affecting up to 334 million people of all ages worldwide (“The 
Global Asthma Report,” 2014; WHO, 2006). The incidence of adult asthma is approximately 
4/1000 person-years, being higher in women than in men (Eagan et al., 2005). Data on 
asthma incidence in those aged >50 is scarce. 
The International Study of Asthma and Allergies in Childhood (ISAAC) found that about 14% 
of the world’s children are likely to have had asthma symptoms in the last year (Lai et al., 
2009). The highest prevalence (≥20%) was generally observed in Latin America and in 
English-speaking countries of Australasia, Europe and North America as well as South 
Africa. The lowest prevalence (<5%) was observed in the Indian sub-continent, Asia-Pacific, 
Eastern Mediterranean, and Northern and Eastern Europe. In Africa, 10-20% prevalence 
was mostly observed. In adults aged 18-45 years, the WHO World Health Survey which was 
conducted in 2002-2003, found that 4.3% adults had a doctor-diagnosed asthma- varying 
widely among the 70 countries included, ranging from 0.2% in China to 21% in Australia (To 
et al., 2012) Much less is known about the prevalence of asthma in middle-aged and older 
adults. This reflects both the insufficiency of data but also the difficulty in older age to 
distinguish asthma from chronic obstructive pulmonary disease (COPD). There are also no 
internationally standardized comparisons of asthma prevalence in the elderly. 
Asthma is of substantial burden to people, often causing a reduced quality of life. The 
burden of asthma, measured by disability and premature death, is greatest for children aged 
10-14 and the elderly aged 75-79 (“The Global Asthma Report,” 2014). Asthma is the 14th 
most important disorder in the world in terms of the extent and duration of disability (“The 
Global Asthma Report,” 2014). Among people aged less than 45 years, most of the burden 
of disease is disability. However, for people in older age groups, premature death due to 
asthma contributes to more burden of disease (“The Global Asthma Report,” 2014). Those 
aged ≥45 years of age have been found to have a significantly higher risk of asthma 
treatment failure (Dunn et al., 2015). According to the Global Asthma Report (2014) the 
burden of disease is similar in males and females at ages below 30-34 years but at older 
ages the burden is reported to be higher in men than in women, the reason for this burden is 
unclear. One possibility is more pronounced acceleration of decline in lung function in males 
with non-allergic adult-onset asthma (Amelink et al., 2012). 
Asthma attacks can be life-threatening. In 2005, 255’000 persons died of asthma (WHO, 
2006). Lung function is a major determinant of health and independent living in adult life, and 
low lung function in adults with asthma is associated with increased overall mortality 
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(Panizza et al., 2006). Rates of death from asthma rise almost exponentially from mid-
childhood to old age, so the majority of asthma deaths occur after middle age. However, 
there is potential diagnostic confusion in the elderly with COPD (“The Global Asthma 
Report,” 2014). In the US, the rate of asthma related hospitalizations have been found to be 
higher in young boys and middle-aged women and additionally, the rate of respiratory failure 
was found to be lower among older women compared to men (Zein et al., 2016). Zein et al 
(2016) found there were distinct bimodal distributions for hospitalization age, with an initial 
peak at 5 years and a second at 50 years - males comprising the majority of individuals in 
the first peak, but women in the second one. In the United States asthma hospitalization 
rates are 50% higher for African American’s than for Caucasian patients (Cohn et al., 2006) 
and more women than men are hospitalized (American Lung Association, 2007). 
The historical view that asthma is a disease of high-income countries no longer holds: most 
people affected are in low-and middle-income countries, and its prevalence is estimated to 
be increasing fastest in those countries (“The Global Asthma Report,” 2014). Asthma has a 
global distribution with a relatively higher burden of disease in Australia and New Zealand, 
some countries in Africa, the Middle East and South America, and North-Western Europe.  
The economic impact of asthma is also substantial, both through direct costs such as cost of 
medication and treatments, and indirect costs such as loss of school or work days and 
decrease in productivity. Research suggests that contribution of ‘presenteeism’ (individual 
loss of function when at work) is larger than absenteeism (inability or come to work) in 
patients with asthma (“The Global Asthma Report,” 2014). In Europe the estimated total cost 
of asthma is €19.3 billion among those aged 15 – 64 years (in 2011 Euros) (“The Global 
Asthma Report,” 2014). In England for example, 69% of parents or partners of children with 
asthma report taking time off work because their children had asthma complications (Clark, 
2010). No information was provided in this study whether those taking time off work tended 
to be women or men.  
 
1.2.2 Asthma management 
Currently, asthma cannot be cured, and there is limited evidence based options to prevent 
its development. However, when asthma is successfully managed, the person with asthma 
will have no or only very mild symptoms, no attacks, no emergency department visits, no 
limitation of exercise or activity, no loss of sleep due to asthma, minimal use an asthma 
reliever medicine (<2 times a week), and the least side effects possible of asthma 
medication. The person will have no impediments to their lifestyle due to asthma, and will be 
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able to attend their place of education or work with no time off due to asthma. National 
asthma strategies are aimed at achieving successful management for all people with asthma 
(“The Global Asthma Report,” 2014). Asthma management therefore focuses primarily on 
achieving clinical control and preventing future exacerbations. Asthma medication can be 
grouped into the following three categories (“GINA Report, Global Strategy for Asthma 
Management and Prevention | GINA,” 2011): 
a) Controller medications: these are used for regular maintenance treatment. They 
reduce airway inflammation 
b) Reliever (rescue) medications: these are provided to all patients for as-needed relief 
or breakdown of symptoms 
c) Add-on therapies for patients with severe asthma 
Controlled asthma management has been shown to lead to a significant loss in economic 
burden compared to uncontrolled asthma management (“The Global Asthma Report,” 2014). 
Essentially the cornerstone of asthma management is to achieve good symptom control, 
maintain normal activity levels, minimize future risk of exacerbations, fixed airflow limitations 
and side effects (“GINA Report, Global Strategy for Asthma Management and Prevention | 
GINA,” 2011). For the best outcomes, regular daily treatment should be initiated as soon as 
possible after the diagnosis of asthma is made, as evidence suggests that early initiation of 
low dose of inhaled corticosteroids (ICS) have greater improvement in lung function than if 
symptoms have already been present for 2-4 years (Busse et al., 2008; Selroos et al., 1995) 
and that after this time, even higher doses of ICS were required (Selroos et al., 1995). 
Furthermore, patients not taking ICS who experience a severe asthma exacerbation have a 
greater long-term decline in lung function that who have already started ICS (O’Byrne et al., 
2009). In adults the reported excess decline in lung function in those with asthma may be 
reduced by regular use of inhaled steroids (Lange et al., 2006), particularly those with high 
total IgE (de Marco et al., 2007). And for patients with occupational asthma, early removal 
from exposure to the sensitizing agent and early treatment increase the probability of 
recovery (Baur et al., 2012).  
Sex/gender differences in asthma management and treatment were reported - female 
patients seem to suffer more from symptoms however male patients are more likely to be 
diagnosed with the disease (Hublet et al., 2006). Women are more likely to regularly use a 
peak flow meter, have a regular clinician for their asthma care, and to have written asthma 
management plans than men (Naleway et al., 2006), however report significantly lower 
health status, more acute visits for asthma (Sinclair and Tolsma, 2006), higher 
hospitalization rates (Lin and Lee, 2008), and obtain fewer asthma medications than males 
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at all ages (Krishnan et al., 2001; Stempel et al., 1996; Williams et al., 2001). In teenagers, it 
has also been shown that the social construction of femininities meant that asthma were not 
seen as a threat to personal and social identity of girls as they were viewed in the majority of 
boys, who made every effort to maintain asthma outside their personal and social identities 
(Williams, 2000). 
 
1.2.3 Causes of asthma  
A wide variety of factors are known to affect asthma, but no one specific cause, either 
biological or environmental has been identified. Studies indicate the contribution of both 
genetic and non-genetic factors (Moffatt et al., 2010). When considering non-genetic factors 
affecting asthma, it is important to distinguish between the triggers of asthma attacks and the 
causes of the underlying asthmatic process or trait, of which much less is known.  
The heritability estimates for asthma range from 40% to 60% (Adcock and Barnes, 2011). 
Individuals with a family history of asthma are more likely to develop asthma (Burke et al., 
2003), and parental asthma is a stronger predictor of asthma in offspring than parental atopy 
(Pearce and Douwes, 2013). However, this could also reflect lifestyle factors that may be 
similar within a family household. Low socioeconomic status, for example, may be 
associated with risk factors for development of disease, exposures that exacerbate disease 
and poor access to and utilization of health services that lead to poor control of disease 
(Jarvis, 2014; Rona, 2000). The genetic contribution to asthma is very complex, and the 
importance of both genetic and environmental factors are indicated (Adcock and Barnes, 
2011; Boezen et al., 2014; “The Global Asthma Report,” 2014) 
Asthma used to be thought of as an allergic disease, where allergen exposure causes 
sensitization to allergens and continuous exposure leads to the processes in the airway 
which lead to asthmatic symptoms.  The 'hygiene hypothesis' postulates that growing up in a 
more microbiological hygienic environment may increase the risk of developing respiratory 
allergies, and has been prompted by evidence that overcrowding and unhygienic conditions 
were associated with lower prevalence of atopy, eczema, hay-fever and asthma (Brooks et 
al., 2013; Pearce and Douwes, 2013; Platts-Mills et al., 2005). A number of studies have 
found consistently low prevalence of allergies and asthma in farmers' children (Riedler et al., 
2001; von Mutius and Vercelli, 2010), and a protective effect in those consuming farm milk 
(Loss et al., 2011; Waser et al., 2007). Studies on the association between presence of pets 
has been shown to have a protective effect for atopy, but findings in relation to asthma are 
still unclear (Kerkhof et al., 2009). 
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While allergy is a potential underlying factor for up to half the people with asthma, the 
remainder have no allergic feature (“The Global Asthma Report,” 2014). Recent research 
has shifted attention from allergens that may cause sensitization and/or provoke asthma 
attacks, to factors that may 'program' the initial susceptibility to asthma, through allergic or 
non-allergic mechanisms (Pearce and Douwes, 2013). Although allergic sensitization is an 
important risk factor for asthma, the link between atopy and asthma might have been 
overestimated, particularly for adult asthma (Antó et al., 2010a). Also, clinical studies 
suggest that women might be at increased risk for non-allergic asthma (Barnes, 2009; Novak 
and Bieber, 2003a; The ENFUMOSA Study Group, 2003), a finding confirmed in the ECRHS 
study (Leynaert et al., 2012). In low and middle income countries the proportion of people 
which non-allergic asthma is greater than in high-income countries (“The Global Asthma 
Report,” 2014). These non-allergic mechanisms are currently not well understood.  
The evidence for a role of tobacco smoke in asthma is strongest for increases in severity in 
children who already have asthma, whereas the evidence for the initial occurrence of asthma 
is less conclusive (Pearce and Douwes, 2013). Females are known to have a higher degree 
of airway hyperresponsiveness (AHR) than males, which has been related to increased 
susceptibility to the effect of environmental exposures, such as tobacco smoke, irritants and 
allergens (Boezen et al., 2004; Kauffmann and Becklake, 2000; Langhammer et al., 2003; 
Leynaert et al., 1997). In the SAPALDIA study, the higher prevalence of 
hyperresponsiveness in women was however largely explained by lung size (Schwartz et al., 
2002). The role of other indoor air pollutants such as cooking on an indoor fire, as causes of 
the asthmatic tendency is less clear and less consistent than for tobacco smoke (“The 
Global Asthma Report,” 2014). 
The role of outdoor air pollutants (particulate matter, ozone, nitrogen dioxide and sulfur 
dioxide) in asthma and other diseases has been extensively studied and debated (Brauer et 
al., 2007; Künzli et al., 2009; McConnell et al., 2010; Pearce and Douwes, 2013). Künzli et al 
(2009) have shown an association between traffic-related pollution and adult-onset asthma 
among never smokers. However, overall the role of traffic related air pollution in adult-onset 
asthma is less conclusive than for childhood asthma (Jacquemin et al., 2012).  Boezen et al 
(2005) identified that in individuals with AHR and high serum total IgE, males were more 
likely to cough and have upper respiratory symptoms (URS) , whereas females were likely to 
have peak expiratory flow (PEF) decrements in the morning in response to air pollution 
exposure. It is clear that air pollution can provoke exacerbations in pre-existing asthma, 
however the weight of evidence does not currently support a major role for outdoor air 
pollution as a cause of the initial development of asthma (Pearce and Douwes, 2013). Little 
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is currently known about the contribution of indoor air pollutants (other than environmental 
tobacco smoke) to the incidence and prevalence of asthma (Pearce and Douwes, 2013) 
Although it has been concluded that the evidence for a causal association between 
dampness and respiratory morbidity is strong, it is not clear whether indoor dampness 
causes or exacerbates pre-existing respiratory conditions such as asthma (Pearce and 
Douwes, 2013). Occupational asthma (OA) is the most common occupational respiratory 
disease in developed countries (Dykewicz, 2009; Pearce and Douwes, 2013). Segregation 
of tasks by gender can occur in the workplace which results in differing exposures in men 
and women (Messing and Mager Stellman, 2006; Stellman, 1999) however whether women 
and men differ in their susceptibility is unclear  (Dimich-Ward et al., 2006). Viral infections 
are common causes of exacerbations of asthma (Pearce and Douwes, 2013) and there is 
also a strong association  of viral infections and hospital admission for asthma in both 
children and adults (Pearce and Douwes, 2013; Szabo et al., 2013). However it is unclear 
whether viral infections cause asthma (Kuehni et al., 2009; Nijs et al., 2013). Low socio-
economic status (SES) has been related to an increased risk of asthma (Bråbäck et al., 
2005). It has been hypothesized that families living at or below the poverty threshold are 
more likely to live in substandard housing and have higher exposure rates to allergen and 
asthma triggers (Cohn et al., 2006).  
Asthma has a complex underlying pathology which is still not fully understood and has been 
labeled as a syndrome rather than a disease, given the different etiologies of childhood and 
adult asthma (Eder et al., 2006). In order to understand the mechanisms underlying the 
many variants of asthma, it is essential to identify the factors that initiate, modulate and 
maintain the condition (Boschetto et al., 2003). Sex- and gender-related differences are an 
important determinant of the clinical manifestations of airway pathologies, and therefore 
should be considered both in epidemiological and clinical studies (Baraldo and Saetta, 
2003). Substantial evidence suggests that sex- and gender-related factors affect incidence, 
susceptibility, severity, and management of asthma (Anne L. Fuhlbrigge, Benita Jackson, 
2002; Buist and Mapp, 2003; Eagan et al., 2005; Postma, 2007; Williams, 2000).  
1.3 Sex/gendered life course of asthma  
Gender differences in asthma follow an interesting pattern across the life course, with higher 
incidence rates in boys compared with girls, a reversing of the gender ratio in puberty, and a 
female preponderance in early and middle adulthood (Carey et al., 2007; De Marco et al., 
2002; De Marco et al., 2005; Eagan et al., 2005; Torén et al., 2011; Leynaert et al., 2012) 
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(figure 1.1), while the course of asthma in later adulthood is less clear. The higher asthma 
prevalence in boys compared to girls is consistently reported (Anne L. Fuhlbrigge, Benita 
Jackson, 2002; Becklake, 2003). This reversal in the sex ratio after puberty does not seem 
to be caused by a loss of established asthma in boys, but rather, by the late incidence of 
asthma among girls (Nicolai et al., 2003). Besides fetal maturation processes related to 
phosphor-lipid profile and surfactant production resulting in a more mature state at birth in 
females, a differential somatic growth pattern of lungs in boys and girls seems underlying: 
large airways tend to grow faster than parenchymal tissue in young females whereas in 
young males, the growth of large airways tends to lag behind that of the parenchyma, a 
phenomenon known as dysanaptic growth, resulting in relatively narrower airways in young 
males than in young females (Merkus et al., 1996). Also, gender differences in the 
development of the immune system have been recognized which are reflected in atopy, a 
marker of allergic status and an important risk factor for asthma, usually measured by total 
serum IgE or allergen-specific IgE (Becklake, 2003). Levels of total IgE in girls seem to be 
consistently lower than those in boys. By contrast, allergen-specific IgE are less consistent 
across studies, probably related to regional differences in the prevalent indoor and outdoor 
antigens (Baldacci et al., 2001). A reversing of the gender ratio of asthma occurs in puberty 
(Almqvist et al., 2008; Arbes et al., 2004; Becklake and Kauffmann, 1999; Crawford and 
Beedham, 1976; Kauffmann and Becklake, 2000), again possibly due to a differential lung 
growth pattern: growth of lungs ceases in teenage women while it continues to increase until 
approximately the mid-twenties in young men (Becklake, 2003). In adulthood, a female 
preponderance of up to 2:1 has been described (Becklake and Kauffmann, 1999; de Marco 
et al., 2000a; Eagan et al., 2005; Rhodes et al., 2005). Around the fifth or sixth decade, the 
gender difference seems to disappear or even reverse again (Arbes et al., 2004). However, 
the course of asthma in later adulthood is less clear, partly due to scarcer research, partly 
due to a lack of standardized definitions of asthma and more difficult differentiation from 
COPD in older age, complicating estimates and comparisons (Eagan et al., 2005). Also, in 
women, evidence on the dynamic across the menopausal transition is still conflictive(Zemp 
et al., 2012, p. 2012): some studies found a decrease of incidence in post-menopause 
compared to pre-menopause (Songür et al., 2010; R. J. Troisi et al., 1995), others no 
association (Jarvis and Leynaert, 2008; F. G. Real et al., 2008), or even an increase 
(Bobette Matulonga et al., 2016; Gómez Real et al., 2006; Lange et al., 2001; Triebner et al., 
2014).  
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Figure 1.1: Interaction between gender and age in prevalence of asthma 
Figure adapted from Carey at al (2007) 
Introduction 
 
 
18 
 
1.4 Possible reasons for sex/gender differences in asthma 
The explanation of  the higher incidence of asthma in women than in men (de Marco et al., 
2000b, p. 200; Eagan et al., 2005; Leynaert et al., 2012; Torén et al., 2011) (table 1.1)  and 
the gender-differential life course of lung development and asthma is yet insufficient und 
under-researched.  
The differences have been related primarily to reproductive status and reproductive 
hormones (Buist and Mapp, 2003; Kauffmann and Becklake, 2000; Macsali et al., 2012; F. 
G. Real et al., 2008; van den Berge et al., 2009) (see section 1.4.1). However, further 
potential pathways are likely to contribute to the observed lifetime pattern (Zemp et al., 2014) 
(figure 1.1).  
Further mechanisms seem to be influential, such as developmental factors (Carey et al., 
2007; Postma, 2007, p. 200), airway caliber (Cohen et al., 2008; Leynaert et al., 1997),  
allergic sensitization (Goldhahn et al., 2009; Leynaert et al., 2012), misclassification with 
chronic obstructive pulmonary disease (COPD) (Chapman et al., 2001a; Watson et al., 
2004), as well as socio-cultural factors (WHO, 2003; Williams, 2000). Genetic pathways 
have also been suggested (Boezen et al., 2014; Dijkstra et al., 2006; Postma and 
Koppelman, 2009) through T-lymphocyte-associated receptor genotype, single nucleotide 
polymorphisms, estrogen receptor alpha gene variants, or immunologic mechanisms 
(Melgert et al., 2007; Postma, 2007). Exposure to environmental and occupational 
exposures may differ in men and women (Bridevaux et al., 2007; Downs et al., 2005), 
possibly related to differential time-activity patterns, indoor or outdoor exposure (Kauffmann 
and Becklake, 2000; Kogevinas et al., 2007), or to different susceptibility related to airway 
caliber (Leynaert et al., 1997; Schwartz et al., 2002). Interaction between gender and 
behavioral factors, help seeking and management of asthma furthermore are likely to affect 
disease rates (Anne L. Fuhlbrigge, Benita Jackson, 2002; Williams, 2000), as it has been 
evidenced for a gender bias in diagnosis of asthma (Adams et al., 2003; Eagan et al., 2005; 
Kühni and Sennhauser, 1995).  
The aim of this PhD project (see chapter 2) is to determine the incidence of asthma for men 
and women across the entire adult life span in the Swiss cohort Study on Air Pollution and 
Lung and Heart Disease in Adults (SAPALDIA), and to address two hypothesized 
sex/gender related pathways: i) reproductive pathologies and ii) lifetime history of 
overweight/obesity as measured by body silhouettes. The literature is reviewed for these two 
pathways hereafter. 
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Author, 
year 
Study area Age 
groups, 
years (at 
baseline) 
Estimate of yearly incidence per 1000 
person-years 
Adjusted Ratio (95%CI) 
   Men Women Men Women 
       
Dodge 
(1980) 
Tucson, 
Arizona 
20-29 2 4   
  30-39 - 4   
  40-49 - 4   
  50-59 - 5   
  60-69 3 8   
  70+ 2 6   
       
Rønmark 
(1997)  
Norrbotten, 
Sweden 
35-36 7.1 9.4   
  50-51 7.0 10.1   
  65-66 8.5 9.2   
       
Lundback 
(2001) 
Norbotten, 
Sweden 
35-36 2.3 4.7   
  50-51 3.2 5.0   
  65-66 4.9 3.9   
       
 
DeMarco 
(2005) 
 
Italy 
ECHRS 
 
20-44 
   
1 
 
1.47 (0.89–2.44)* 
       
Chinn 
(2006a) 
Europe 
(ECHRS) 
20-44   1 1.47 (95% CI 1.04 - 2.07)
†
 
 
       
Torèn 
(2011) 
Sweden 16 -75    (2.1, 95% CI 1.7- 2.7)
†
 
 
       
Leynaert 
(2012) 
Europe 
(ECHRS) 
20-27 2.34 (1.32 to 3.37) 3.73 (2.48 - 4.98)  1.58 (0.91 to 2.75)
†
 
  28-35 1.59 (0.83 to 2.34) 4.42 (3.22 - 5.62)  2.76 (1.60 to 4.77)
†
 
  ≥36 2.98 (2.11 to 3.85) 4.16 (3.16 - 5.17)  1.40 (0.96 to 2.04)
†
 
       
Data are presented as: *odds ratio (95% confidence interval), 
†
Hazard ratio (95% confidence interval) 
Table adapted from Eagan et al (2005) and updated with studies conducted after 2005 
Table 1.1 Overview of longitudinal studies from general populations with a wide 
age span which allow for estimation adult incidence of asthma by sex 
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1.4.1 Sex/Gender-related pathway: reproductive histories and hormonal factors 
A potential role of sex differences in the etiology of asthma and allergies has been 
suspected because the lifetime prevalence of incidence of asthma is higher in boys than girls 
before puberty but switches to a female preponderance after puberty (de Marco et al., 2005; 
De Marco et al., 2002; Eagan et al., 2005; Leynaert et al., 2012; Torén et al., 2011; Vink et 
al., 2010). Asthma is more common in boys than in girls during early childhood, but during 
adulthood the prevalence, severity, healthcare utilization and impact on health-related quality 
of life have been found to be higher in women than in men. The specific mechanisms for 
these differences are unclear, but female sex hormones have thought to be implicated 
(Baibergenova et al., 2006; Forbes, 1999; Haggerty et al., 2003). Sex steroid hormones may 
explain known sex/gender-related variations in asthma prevalence and clinical manifestation 
(Nwaru and Sheikh, 2015). Animal studies have shown evidence that estrogen and 
progesterone have effects on asthma symptoms (Grossman, 1984). Therefore, hormonal 
factors might be expected to be associated with the clinical occurrence of asthma in 
humans. Given the association of reproductive factors with asthma, research has addressed 
hormonal blood levels. In fact, asthmatic women have been shown to have abnormal sex 
hormone levels: In 80% of asthmatics, blood concentrations of at least one of the measured 
hormones (estradiol, progesterone or cortisol) were out of range (Kos-Kudła et al., 2000; 
Rubio Ravelo et al., 1988). But to date, no study has been able to clearly relate the change 
in incidence to changes in hormonal levels (Leynaert et al., 2012). The impact of female sex 
hormones on bronchial responsiveness has not been well researched, and recent studies 
have added that other sex hormones may play a role, such as dehydroepiandrosterone 
sulfate (DHEAS), testosterone or sex hormone-binding globulin (SHBG). SHBG binds 
preferentially to androgens than to estrogens and a low SHBG level will result in higher free 
testosterone. Serum levels of DHEAS were found to be lower in asthmatic women than in 
non-asthmatic women (Kohny et al., 2005). It has been suggested that male-sex hormones 
have a protective effect in asthma (Leynaert et al., 2012). In pre- and postmenopausal 
women, free testosterone (FT) and even more strongly, SHBG have been associated with 
nearly all traditional risk factors for chronic disease, in particular cardiovascular diseases: 
body composition (BMI, waist hip ratio) (Sternfeld et al., 2008; Sutton-Tyrrell et al., 2005), 
glucose metabolism (plasma insulin levels, diabetes 2 and HbA1C) (Calderon-Margalit et al., 
2010; Ding et al., 2006; Kalish et al., 2003; Page-Wilson et al., 2009), lipid metabolism 
(Pugeat et al., 1995; Sutton-Tyrrell et al., 2005), as well as markers of inflammation (CRP, 
tPA, PAI-1) [58, 111]. SHBG seems to have a direct impact on high-density lipoprotein (HDL) 
production (Pugeat et al., 1995), and insulin has a direct inhibitory effect on SHBG (Sutton-
Tyrrell et al., 2005). An independent effect could lie in SHBG mediating androgen and 
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estrogen signaling at the cell membrane via signal transduction pathways (Sutton-Tyrrell et 
al., 2005). 
Several reproductive conditions and hormonal factors such as early menarche, irregular 
menses, early/surgical menopause and exogenous hormone intake have been found to be 
associated with respiratory health (Macsali 2012). Studies have consistently found an 
association between early menarche and new-onset of asthma (Lieberoth et al., 2014), with 
the exception of three studies (Burgess et al., 2007; Jartti et al., 2009; Wei et al., 2015). The 
cause for the observed association between early menarche and asthma is poorly 
understood. Some suggest that it could reflect genetic and early life environment as the 
timing of both events are affected by early life factors, or that menarche itself might induce 
immunological and hormonal changes as well as changes in airway function (Lieberoth et 
al., 2015). Higher levels of leptin and increased insulin resistance in women with early 
menarche may influence inflammation and innate immunity, potentially contributing to higher 
risk of asthma (Bouloumie et al., 1999; Jartti et al., 2009). Animal studies have provided 
evidence that estrogen and progesterone have effects on humoral and cellular immunity and 
smooth muscle function (Wei et al., 2015). Therefore, hormonal factors might be expected to 
be associated with the clinical occurrence of asthma in humans.  
 
The relationship between menopause and the menopausal transition to lung health is still not 
very well understood. The reasons for this are several. There has been a great focus on 
hormone replacement therapy (HRT) while the underlying condition—the menopausal 
transition—has been scarcely studied. In addition, study designs and populations have been 
heterogeneous (Macsali et al., 2012). The longitudinal analysis of the Nurses Health Study 
from the USA by Troisi et al  (1995) showed that postmenopausal women who were never 
users of replacement hormones had a significantly lower age-adjusted risk of asthma than 
premenopausal women (relative risk: 0.65, 95%CI 0.46- 0.92). In European Community 
Respiratory Health Survey (ECHRS), Real et al (2008) found that women not menstruating 
in the last 6 months had significantly lower forced expiratory volume (FEV), lower forced vital 
capacity (FVC) values and more respiratory symptoms, especially in relation to allergy, than 
women of similar age menstruating regularly. Jarvis and Leynaert (2008), in cross-sectional 
analysis of data from the Health Survey for England, found that menstrual cessation that was 
due to surgery was associated with the reporting of wheeze (OR 1.55, 95% CI: 1.09-2.20) 
even if women denied ever using HRT. No significant association of menopause with asthma 
prevalence or incidence was seen in the meta-analysis of Zemp et al except for women 
reporting HRT use (Zemp 2012). However, these findings were based on a small number of 
studies including only one large cohort. Most recently the study by Triebner at al. (2014) 
Introduction 
 
 
22 
 
found that the risk of new-onset asthma was significantly higher in women who were 
transitional or postmenopausal than pre-menopausal women, and furthermore, the number 
of respiratory symptoms was higher in postmenopausal women.  
 
Few prospective studies have examined HRT and change in pulmonary function over time 
as outcome, and none have found a positive effect of estrogen replacement therapy 
(Hepburn MJ, 2001; Lieberman et al., 1995). Early/surgical menopause, a major indication 
for use of hormonal therapy, is associated with asthma symptoms in a community-based 
British study (Jarvis and Leynaert, 2008) and with new-onset of asthma in a more recent 
study using data from the French Etude Epidémiologique auprès de femmes de la Mutuelle 
Générale de l'Education Nationale (E3N) cohort study (Bobette Matulonga et al., 2016). 
Concerning HRT and pulmonary function, Carlson et al  (2001), found among women older 
than 65 years, higher FEV1 and less airway obstruction in current HRT users than non-users 
suggesting that the association of HRT with lung function and asthma symptoms may be 
different in women with well-established post-menopause. Results from ECRHS/RHINE also 
point to a role of rather the peri-menopausal phase than menopause itself (Gómez Real et 
al., 2006). Concerning HRT and respiratory health, the literature shows puzzling results: 
while studies dealing with asthma and respiratory symptoms report increased risk related to 
HRT, especially among nonsmokers and lean women, those studying lung function indicate 
either a beneficial or at least a neutral association with HRT (Macsali et al., 2012) 
 
In summary, the presence of gender differences in asthma seems indeed to be related to 
reproductive and hormonal factors although this pathway is still not well understood. Gomez 
identified three groups with increased asthma risk: lean women entering the menopause; 
lean women using HRT; women in fertile age with irregular menstruation (F G Real et al., 
2008). Effects of sex hormones on the airways are however complex and the many 
discordant results may highlight this complexity. There is a shift away from focusing only on 
the change of estrogen levels over the reproductive life time to including markers of 
androgens and SHBG. There may also be further mechanisms interacting with hormones, 
such as inflammation, immunity and metabolism (Postma, 2007; F. G. Real et al., 2008). It 
has also been suggested that a common underlying pathology might lead to both asthma 
and gynecological morbidity (Jarvis and Leynaert, 2008; F. G. Real et al., 2008). 
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1.4.2 Sex/Gender-related pathway: obesity 
There is also a complex relationship between asthma and obesity. The relationship of 
asthma with obesity (David A Beuther and Sutherland, 2007; Tantisira and Weiss, 2001) and 
the fact that obesity has increased simultaneously with the increase in asthma gave rise to 
the question whether there is a metabolic component in asthma (Chinn et al., 2006a; Chinn 
and Rona, 2001; Forbes, 2005). Respective metabolic components might differ for men and 
women, and, in addition, are also linked with reproductive conditions (F G Real et al., 2008). 
Levels of estrogens are closely related to body fat mass and metabolic conditions (Simpson 
et al., 2005). SHBG has been shown to be associated inversely to CRP and HbA1C (Joffe et 
al., 2006) as well as with the lipid profile in postmenopausal women (Pugeat et al., 1995). 
Women with the polycystic ovary syndrome more often present diabetes, obesity or 
metabolic syndrome (Shaw et al., 2008). However, in women, the interrelations of obesity, 
the metabolic syndrome and menopausal transition, a phase which itself is associated with 
increased abdominal body mass and metabolic changes such as increased insulin 
resistance, are very intriguing (Carr, 2003; Dhabuwala et al., 2000). The increased estrogen 
levels associated with obesity are thought to be one mechanism to explain the strong 
association between female obesity and adult-onset of asthma (Weiss, 2005). Still, further 
mechanisms linking obesity with asthma (Tantisira and Weiss, 2001) are very diverse, 
ranging from directly-mechanical, enhanced immune responses, related genetic 
mechanisms, to other environmental factors, physical activity or birth weight. Gomez 
hypothesizes that estrogens and BMI interact on the airways in part through common 
pathways (F G Real et al., 2008), Postma postulates common genetic mechanisms (Postma, 
2007). 
 
There is a considerable body of epidemiological research on the relationship between 
asthma and obesity: Cross-sectionally, the diagnosis of asthma was associated with obesity 
in both childhood (Figueroa-Muñoz et al., 2001; Gennuso J, 1998) and adulthood (Chen et 
al., 1999; Epstein et al., 2000; Shaheen et al., 1999). In longitudinal studies, pre-existing 
obesity and increasing weight gain were shown to increase asthma risk in children and 
adults: In the US Growing Today cohort, comparing the highest to the lowest quintile of BMI, 
the relative risk of asthma was 2.3 in boys and 1.5 in girls (Camargo, C. A. et al., 1999). In 
the Nurses’ Health Study, BMI above 30 was associated with a 2.7 fold risk of asthma 
incidence (Camargo et al., 1999), gaining 10-20kg weight with a 1.4fold risk of developing 
asthma, gaining above 25kg weight with a 2.7fold risk (Camargo et al., 1999). Also, some 
intervention studies have documented improvements of asthma symptomatology, lung 
function parameters and reduced asthma medication with medically or surgically induced 
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reduction of obesity (Dhabuwala et al., 2000; Dixon et al., 1999; Macgregor and Greenberg, 
1993; Murr et al., 1995; Stenius-Aarniala et al., 2000).  
However, very few studies have evaluated the interaction of sex/gender and obesity on 
incident asthma, which is important given the different effect in women and men observed in 
previous studies on obesity and asthma (Beuther et al., 2006; Egan et al., 2013). Although 
studies have shown a steady dose-response relationship between incident asthma and 
increasing BMI, and most demonstrate the effect to be stronger in women than in men 
(Beckett et al., 2001; Camargo et al., 1999; Chen et al., 2002; Ford et al., 2004; 
Gunnbjörnsdóttir et al., 2004; HUOVINEN et al., 2003; Nystad et al., 2004; Romieu et al., 
2003a), the difference in the point estimates between men and women is usually small, and 
some studies have shown conflicting results. Some sex-specific association variability in 
previous studies may be due to use of BMI as a weight status measure. BMI does not seem 
to measure adiposity equally well in children and around puberty versus adults, and in men 
versus women, due to differences in factors such as muscle mass (Larsson et al., 2006). 
Use of further measures is needed to investigate the association between adiposity and 
asthma in a sex-stratified approach. 
1.5 Conclusion  
From literature reviewed in the introduction, it becomes apparent that asthma is an important 
chronic disease with relevant consequences in terms of disease burden and health care 
resources needed. Asthma most commonly develops in early childhood, however asthma 
can develop at any stage in life, including adulthood (“The Global Asthma Report,” 2014). In 
childhood boys have more asthma than girls, a switch then occurs around puberty, with 
more women having asthma than men in adulthood. Data on asthma incidence in those 
aged >50 is scarce. Zein et al (2016) found that there are distinct bimodal distributions for 
hospitalization age, with an initial peak at 5 years and a second at 50 years - males 
comprising the majority of individuals in the first peak, but women in the second one.It 
therefore remains crucial to further explore what some have characterized as a late-onset 
asthma phenotype (GINA, 2016; Koczulla et al., 2016; Wenzel, 2012) and to try and 
understand the risk factors related to it. 
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2. Research Questions, Aims & Methods  
2.1 SAPALDIA study 
The current PhD project makes use of data from the Swiss Cohort Study on Air Pollution and 
Lung and Heart Disease in Adults (SAPALDIA), covering 20 years of longitudinal 
observation of a well characterized cohort with a broad age range (from 18-60 years in 
SAPALDIA 1 in 1991, and 38-80 years in SAPALDIA 3 in 2011). The SAPALDIA study (see 
appendix 1) was initiated in 1991 in eight geographically diverse areas in Switzerland, 
representing populations from urban, rural and mountainous areas with different 
environmental exposure characteristics (figure 2.1). A total of 9651 persons (51% female) 
participated in the baseline study (SAPALDIA 1 (S1)) after having been recruited through 
random population sampling.  Re-assessments took place In 2002/2003 (SAPALDIA2 (S2), 
n= 8047) and in 2010/2011 (SAPALDIA 3 (S3), n=6088). Participants answered a detailed 
questionnaire and underwent health examinations including lung function testing, blood 
samples for serological tests and allergy skin testing. Starting in S2, the Women's Health 
Questionnaire of the European Community Respiratory Health Study was integrated (The 
European Community Respiratory Health Survey II Steering, 2002) which included detailed 
questions on women’s reproductive histories (appendix 3). In S3 the Women’s Health 
Questionnaire was integrated into the main questionnaire (appendix 4), and additional 
questions concerning reproductive pathologies (appendix 5) and pregnancy complications 
(appendix 6) were integrated into the family booklet questionnaire. Also starting in S3, 
participants were asked to assess their body silhouettes retrospectively from age 8 to current 
age (figure 6.1a and 6.1b). The protocol and participation rates have been described in 
further detail elsewhere (Ackermann-Liebrich et al., 2005; Martin et al., 1997). Ethical 
approval was obtained from the Swiss Academy of Medical Sciences, the regional 
committees, and written informed consent was obtained from all participants.  
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2.2 Research Questions & Hypothesis 
As highlighted in the introduction, there is a lack of knowledge on gender differences in 
asthma incidence particularly in higher ages, when differentiation from COPD is more 
difficult. Pathways explaining gender differences have hardly been addressed specifically 
while controlling for other relevant factors.  
This project aims to determine the incidence of asthma for men and women across the entire 
adult life span in the Swiss SAPALDIA cohort with an age range 18-60 at baseline, and to 
address two potentially sex/gender-related pathways which can be tested with the 
SAPALDIA data set: i) history of reproductive pathologies (pathway 1) ii) lifetime history of 
overweight/obesity as measured by body silhouettes (pathway 2) which are hypothesized to 
have an impact on asthma incidence and may explain observed sex/gender differences.  
 
We hypothesize that there are gender differences in asthma incidence in later adulthood and 
that reproductive pathologies are associated with asthma incidence (main hypothesis). 
Furthermore, we expect associations between obesity and asthma incidence, possibly 
having a differential impact according to gender.  
 
  
Figure 2.1: SAPALDIA Study Areas 
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2.3 Aims 
 
This PhD project specifically aims to: 
1. Determine the incidence of asthma in men and women across adulthood in the 
SAPALDIA cohort, for the period of observation from 1991 to 2010/11 (chapter 3) 
2. Investigate the impact of two possibly gender-related pathways on asthma incidence: 
a. assess the association between history of reproductive pathologies/indicators 
of hormonal dysbalances and incidence of asthma in women, and estimate 
the variance explained by reproductive factors in women (pathway 1) 
(chapters 4 & 5) 
b. assess the association between lifetime history of overweight/obesity as 
measured by body silhouettes and incidence of asthma in men and women, 
and estimate the variance explained by these factors in men and women 
(pathway 2) (chapter 6) 
 
2.4 Methods 
2.4.1 Analytical framework- Life-course perspective  
Throughout this project we take a life-course perspective when investigating gender 
differences in asthma incidence in adulthood. Life course approaches offer an 
interdisciplinary framework for guiding research on health, human development and aging 
(Kuh et al., 2003). It can be defined as the study of long term effects on later health or 
disease risk of physical or social exposures during gestation, childhood, adolescents, young 
adulthood and later adult life (Ben-Shlomo and Kuh, 2002; Klinge, 2010; Kuh et al., 2003; 
Lynch, 2003).  A life course approach takes into account the temporal and social 
perspective, investigating individuals’ experiences and their current and past patterns of 
health and disease, taking socio-cultural, environmental and economic context into account 
(WHO, 2000). It was built on the premise that various biological and social factors 
throughout life independently, cumulatively and increasingly influence health and disease in 
adult life. Using different methods, the aim is to identify the underlying biological, behavioral 
and psychosocial processes that operate across the lifespan (figure 2.2), addressing early 
life, childhood, adolescence, young adulthood, and the different phases in adulthood from 
reproductive to occupational life phases as well as old age. Each life stage affects health 
and disease development, thereby impacting on the chances of healthy aging. SAPALDIA 
with its rich data representing the general population and covering 20 years of follow-up 
allows us to take such a life-course approach. 
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Ben-Schlomo and colleagues (2016) characterize three main phases in life-course 
epidemiology, the first being a focus on the association of early life factors with clinical 
disease endpoints. Growing evidence suggests that there are critical periods of growth and 
development, not just in utero and early infancy but also during childhood and adolescence, 
when environmental exposures do more damage to health and long-term health potential 
than they would at other times (WHO, 2000). In this PhD project we try to include these 
critical periods by adjusting for variables such as early life respiratory infection and parental 
asthma. The second phase characterized by Ben-Schlomo and colleagues (2016) is the 
expansion to consider a wider range, and more integrated study, of outcomes, including 
different aspects of physiological  function and their natural history across life, and or 
biological, psychological and social risk factors acting independently, cumulatively or 
synergistically across different life stages. By assessing sex/gender differences in asthma 
incidence and the role of reproductive pathologies and lifetime history of overweight/obesity 
we hope to show  the long term health consequences of biological and social experiences in 
early and mid-adulthood, and whether these factors simply add additional risk or act 
interactively with early life biological and social factors, to attenuate or exacerbate long term 
risks of asthma (WHO, 2000). The third and most recent phase in the development of life 
course epidemiology is the application of a life-course epidemiological approach to the study 
of ageing (Ben-Shlomo et al., 2016). By using SAPALDIA data, we have the unique 
opportunity to address sex/gender differences in asthma incidence in those aged >50 years, 
on which very little data exists. With the number of older people with asthma predicted to rise 
in the next years (Gibson et al., 2010), it is crucial that we research asthma incidence and 
potential sex/gender differences in asthma-onset in this age group as well.  
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2.4.2 Analytical Framework: Sex/gender pathway model  
As set out in section 1.1.3 of the introduction, the term sex refers to biological characteristics 
that distinguish females from males, whereas gender refers to the array of socially 
constructed roles and relationships, personality traits, attitudes, behaviors and values that 
society ascribes to the sexes on a differential basis. Some health differences or disease 
manifestations are considered primarily biological, such as those related to genetic, 
immunological, metabolic or inflammatory processes, whereas others are understood as a 
mixture of biological and socio-cultural processes such as reproductive health, and others 
again are more clearly considered to result from gender, such as smoking patterns, 
occupational exposures, time-activity pattern, help seeking behavior, or gendered health 
care responses. Thus, “gender” implies a variety of possible pathways impacting on health 
and a clear-cut distinction between sex and gender is often not possible.  
Although we understand the need to clearly distinguish between the concepts of ‘sex’ and 
‘gender’, as emphasized in the introduction (section 1.1.3), it is also known that sex and 
Figure 2.2: Life-Course Perspective 
Adapted from WHO 2000 
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gender are entangled (Springer et al., 2012a). According to Springer et al (2012a, p. 1818)  
“a true appreciation of sex/gender in human health cannot rely on the dichotomization of 
people into males and females without attention to how sex and gender may be – and 
almost always are – entangled”, and biological measures may include effects of gender. 
There is an increasing conviction that the idea that our biology is immutable, difficult or 
impossible to change, is no longer a tenable position (Wade, 2013, p. 287). The evidence in 
support of this is so overwhelming that scientists now agree it makes no sense to talk about 
‘human nature’, except insofar as ‘…the social is the natural’ and vice versa (Lorber 1993, 
36). Biology is, as Wade states (2013, p. 287) “literally, the flesh and blood of society”. 
Theoretically, these new developments in the biological sciences mean reimagining biology 
“not as a limit on culture, but the very substance through which social forces exert an 
influence” (Wade, 2013, p. 287). 
We therefore try to identify pathways that sex and gender work through (figure 2.3)(appendix 
2), keeping in mind that it is not always possible to differentiate sex and gender in their 
effects on health at every step (Regitz-Zagrosek, 2012). We approach sex and gender as “a 
complex phenomenon that are simultaneously biological and social” (Springer et al., 2012b) 
This approach also allows us to identify other intersecting factors with sex/gender, such as 
atopy, smoking, obesity, education and occupational exposure. Identifying such intersecting 
factors is important, because as outlined in section 1.1.4,  this can reveal sub-group 
differences which may be missed if one only looks at gender or sex as a variable 
(“Interactions between Sex & Gender | Gendered Innovations,” 2016). As it is also a 
component of life-course epidemiology (Kuh et al., 2003), we try to test pathways linking 
exposures across the life course to later life health outcomes, but then with a special focus 
on sex and gender related pathways. Approaching sex/gender and asthma incidence 
through our pathway model allows us to integrate biological and social risk processes rather 
than draw a false dichotomy between them, the importance of which is also emphasized in a 
life-course approach (Kuh et al., 2003).  
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2.5 Definition of main outcome and predictors 
2.5.1 Asthma definition (outcome) 
Throughout the following chapters, asthma cases are defined as self-report of doctor 
diagnosed asthma based on a positive answer to the questions ‘have you ever had asthma?’ 
and ‘was this confirmed by a doctor?’ Although clinical assessment cannot be considered a 
true gold standard for defining asthma it represents the most appropriate standard for use in 
validating instruments for epidemiological studies (Pekkanen and Pearce, 1999).   
To determine the incidence of asthma in men and women across adulthood in the 
SAPALDIA cohort, for the period of observation from 1991 to 2010/11 (chapter 3), our 
Figure 2.3: Sex- and gender-related pathways producing gender differences 
in respiratory diseases and conditions 
Zemp et al (2014) (appendix 2) 
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primary definition was the 20-year cumulative incidence of doctor-diagnosed asthma from 
SAPALDIA 1 (1991 (S1)) – SAPALDIA 3 (2010/2011 (S3)). Those with doctor-diagnosed 
asthma at baseline (S1) were excluded and asthma incidence was defined as new-onset of 
doctor-diagnosed asthma in either of the two follow-up studies (S2 2002/2003 or S3 in 
2010/2011). To take into account possible variation in estimates due to our asthma definition 
we ran several sensitivity analyses with varying definitions of asthma (table 3.1).  
 
To assess the association between history of reproductive pathologies and incidence of 
asthma in women (chapter 4) we used the same definition as described above. We further 
investigated the role of early menarche and asthma incidence in women in more detail 
(chapter 5) in which asthma was defined in the same way as above, however new-onset of 
asthma was defined as new-onset of doctor-diagnosed asthma occurring at least 1 year after 
menarche rather than asthma occurring after baseline (S1 in 1991).  
And finally, to assess the association between lifetime history of overweight/obesity as 
measured by body silhouettes and asthma incidence in men and women (chapter 6), we 
used the same definition as described above (new-onset of doctor-diagnosed asthma). 
However, several doctor-diagnosed asthma incident variables were created, reflecting 
asthma occurring after the age at which body silhouettes were reported. We therefore 
created the following asthma incidence: asthma occurring after age 8, 30, 45, 60 and 
additionally in women after menarche and menopause.    
 
2.5.2 Sex/Gender (exposure) 
Sex/gender was defined based on self-report of being male or female. For further details on 
the theoretical framework used see section 2.4.2 above. 
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2.5.3 Allergic sensitization/atopy (exposure) 
Allergic sensitization (used interchangeably with atopy) was defined as a positive response 
to the skin prick test or Phadiatop test (Phadia, Uppsala, Sweden) at baseline. A positive 
skin prick test was indicated by an adjusted mean wheal diameter of ≥3mm to at least one of 
eight common allergens (grass, birch and Parietaria pollen, house dust mite, cat and dog 
epithelia and the moulds Alternaria and Cladosporium) (Martin et al., 1997; Wüthrich et al., 
1995). The Phadiatop test, an in vitro allergy screening test, detects the presence of specific 
serum IgE against 11 common aero-allergens (Cladosporium, Dermatophagoides 
pteronyssinus., Dermatophagoides farinae, cat, dog, horse, birch, timothy grass [Phleum 
pratense], mugwort [Artemisia], olive, Parietaria judaica [spreading pellitory]. The percentage 
binding of the phadiatop was determined and results classified as positive or negative based 
on a cut-off of 0.35 kU/L (Martin et al., 1997; Merrett and Merrett, 1987; Wüthrich et al., 
1995). Allergically sensitized subjects with doctor-diagnosed asthma were considered as 
having allergic asthma.  
2.5.4 Reproductive histories & early menarche (exposure) 
Reproductive risk factors developing in different stages throughout a women’s life are 
seldom singular experiences (Cao et al., 2015) and therefore we took a life-course approach 
and investigated the role of cumulative reproductive pathologies in  relation to asthma 
incidence. We hypothesized that these reproductive histories may represent underlying 
hormonal dysbalances or that they may be exposures or insults that gradually accumulate 
and cause asthma. To assess the association between a history of reproductive pathologies 
and asthma incidence in women (chapter 4) we created two reproductive pathology scores. 
Up to 10 reproductive pathologies were investigated: early menarche, irregular menses, 
polycystic ovarian syndrome (PCOS), endometriosis, infertility, pregnancy complications, 
early menopause, surgical menopause, hysterectomy, and an indicator for pre-menstrual 
syndrome (PMS).  Further details on how each of these individual reproductive pathologies 
were defined are given in section 4.2.3.  
From the above described individual indicators of reproductive pathologies, we created two 
scores (score 1 & score 2).  Score 1 included the following 10 reproductive pathologies: 
early menarche, irregular menses, PCOS, endometriosis, infertility, pregnancy 
complications, early menopause, surgical menopause, hysterectomy, and the PMS indicator. 
Score 1 was then categorized into: never having any of the 10 reproductive pathologies, 
having 1 of the reproductive pathologies, and having 2 or more reproductive pathologies. A 
second score was constructed excluding menopause related variables as they occur at a 
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later stage in a women’s life and might represent processes differing from those occurring in 
the earlier reproductive phase. Score 2 therefore comprised the following 7 pathologies: 
early menarche, irregular menses, PCOS, endometriosis, infertility, pregnancy 
complications, and the PMS indicator. Score 2 was also categorized into three categories: 
having none of the 7 reproductive pathologies, having 1 of the reproductive pathologies, and 
having 2 or more reproductive pathologies.  
We further investigated the role of early menarche and asthma incidence in women in more 
detail (chapter 5). The primary definition of early menarche used for our analysis, as also 
defined in other studies (Lieberoth et al., 2015, 2014; Salam et al., 2006a), was menarche 
<12 years as reported in either S2 (2002/2003) or S3 (2010/2011). For the purpose of a 
sensitivity analyses, three further definitions were created based on other literature findings 
(Table 5.1): age at menarche 1 standard deviation (SD) less than the mean (Al-Sahab et al., 
2011; Fida et al., 2012a; Wei et al., 2015), age at menarche 2 SD less than the mean 
(Burgess et al., 2007; Varraso et al., 2005a), and finally age at menarche 1 SD less than the 
language region specific mean (German, French and Italian), based on findings by Dratva et 
al (2007)  that age at menarche differs in these three Swiss language regions.  
2.5.5 Body silhouettes (exposure) 
Some sex-specific association variability in previous studies may be due to use of BMI as a 
weight status measure (see section 1.4.2). Because BMI does not seem to measure 
adiposity equally well in children and around puberty versus adults, and in men versus 
women, due to differences in factors such as muscle mass (Larsson et al., 2006), we used 
body silhouettes as our weight measurement to assess the association between lifetime 
history of overweight/obesity and incidence of asthma in men and women (chapter 6). Body 
silhouettes are thought to be a more efficient way of capturing weight history over the life-
course in adult cohorts and may better capture body composition.  
Starting in S3, participants were asked to retrospectively report on their body silhouette 
image at the following ages: 8, 45, and 60, and additionally in women at menarche and 
menopause (see figure 6.1a and 6.1b). The body silhouette images are based on those 
created by Stunkard et al. (1983) and range from number 1 (very lean) to number 9 (very 
obese). For our analysis, we assessed i) the association of reported body silhouette number 
at these specific ages with asthma incidence, and ii) the association of changes in body 
silhouette number over time with asthma incidence in men and women in a sex stratified 
approach. If participants were unsure of their exact body silhouette number, they could 
select two adjacent body silhouettes. For our analysis, we used body silhouettes as a 
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continuous variable, using the average of the two selected body silhouettes when 
participants selected two silhouettes. Based on findings by Bulik et al. (2001), we 
categorized participants who chose a body silhouette of 6 or more as being 
overweight/obese and used this dichotomous variable in our sensitivity analysis.  
Additionally, in order to assess the association between change in body silhouettes over 
time and asthma incidence, we created the following variables indicating the changes in 
silhouette score in men between ages 8-30, 30-45, 45-60, and in women between ages 8-
menarche, menarche-30, 30-45, 45-menopause, and menopause-60.  For the descriptive 
statistics, we grouped the number of changes into a score of the following four categories 
≤0, 0, 1, 2+, following the example of Romieu et al (2003a). For our statistical analysis, the 
number of changes in body silhouettes was used as a continuous variable, using the 
average of the two selected body silhouettes when participants selected two silhouettes.  
2.6 Statistical Analysis 
Asthma incidence and its association with sex/gender (chapter 3) and the potential pathways 
of a) reproductive pathologies (chapter 4 & 5) and b) overweight/obesity as measured by 
body silhouettes (chapter 6) were analyzed using logistic regression. All analyses were 
conducted using Stata V.12 (StataCorp LP, College Station, TX, USA). The specific 
covariates used, and additional sensitivity analyses which were run, are described for each 
analysis in more detail in chapters 3-6.  
2.7 Relevance of research 
Until now, most studies are not of a prospective nature which would allow us to separate 
new-onset of asthma from persistent or relapse of asthma. It is also not clear to what extent 
the incidence of asthma among adults is age-dependent—some studies indicate a flat rate 
or even increase in the age groups 20-50 years (Eagan et al., 2005). In their review, Eagan 
et al (2005) call for more prospective studies in populations with a wide age span, to settle 
the issue of the true incidence of asthma in the middle aged and beyond, and whether the 
incidence is also higher in women in this age group (Eagan et al., 2005) as there are very 
few studies with sex-specific estimates for new-onset of asthma.  This is exactly where this 
PhD project can contribute to existing knowledge. In chapter 3 we investigate sex/gender 
differences in adult-onset asthma using data from the prospective population based 
SAPALDIA cohort study in men and women aged 18-60 at baseline. 
Furthermore, in this PhD project we are able to take into account the interacting role of atopy 
in sex/gender differences in asthma. New-onset of non-allergic asthma appears to be 
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relatively frequent in adulthood (Leynaert et al., 2012). Clinical studies suggest that non-
allergic asthma may be more severe and difficult to control than allergic asthma, and that 
women might be at increased risk of non-allergic asthma (Leynaert et al., 2012). However, 
most of our knowledge on non-allergic asthma comes from clinical studies which often 
include patients with more severe asthma, and little is known on non-allergic asthma in the 
general population (Leynaert et al., 2012). The study by Leynaert et. al (2012) was the first 
to assess sex/gender differences in adult-onset asthma while taking into account allergic and 
non-allergic asthma. However their study population was aged 22-44 years at baseline and 
does not tell us about the role of atopy and sex/gender differences in adult-onset asthma 
after >50 years. This is again where our study in chapter 3 will contribute and provide new 
insights into sex/gender differences in adult-onset asthma and the role of atopy in those 
aged 18-60 years at baseline.  
And finally, sex and gender sensitive research is needed because sex and gender rank 
among the key factors that determine respiratory health, alongside socioeconomic status, 
ethnicity, and age (Zemp et al., 2014). Sex and gender affect biological vulnerability, access 
to medical care and public health services and responses of the health system and therefore 
it is crucial to consider which pathways are relevant given their differing implications (Zemp 
et al., 2014). Unraveling sex/gender related pathways in asthma may contribute to 
understanding the processes that initiate and perpetuate disease, leading to disease 
prevention and improved therapy (Osman, 2003).  
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Abstract 
 A higher incidence of asthma is reported in women compared to men, but evidence in later 
adulthood is limited. We aimed to determine the 20-year cumulative incidence of adult 
asthma in Switzerland and its relation to gender, taking into account age and allergic 
sensitization. 
 
We assessed incidence of self-report of doctor-diagnosed asthma between 1991/1992 and 
2010/2011 in 5128 subjects without asthma, aged 18-60 years at baseline. The age-related 
probability of asthma onset was analyzed by logistic regression adjusting for potential 
confounders and stratified by sex and allergic sensitization at baseline. 
 
Over 20 years, 128 (5.1%) men and 198 (7.5%) women newly reported doctor-diagnosed 
asthma. The adjusted odds ratio for female sex was 1.99 (95%CI 1.54-2.57) overall, 3.21 
(95%CI 2.12-4.85) among non-sensitized subjects, and 1.43 (95%CI 1.02-2.02) in sensitized 
subjects. The probability of asthma onset decreased with increasing baseline age in women 
but not in men. The higher probability of new asthma in sensitized compared to non-
sensitized men was unrelated to age, whereas in women it decreased with age.  
Asthma incidence was higher in women than in men but decreased with increasing age. The 
female predominance was considerably stronger in non-sensitized adults compared with 
those with allergic sensitization.  
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3.1 Introduction  
Asthma follows an interesting gender related life-course pattern, with higher incidence rates 
in boys compared with girls, a reversing of the gender ratio in puberty, and a female 
preponderance in early and middle adulthood (de Marco et al., 2005; De Marco et al., 2002; 
Eagan et al., 2005; Leynaert et al., 2012; Torén et al., 2011).  A wide range of pathways 
have been proposed for this pattern (Zemp et al., 2014), including genetics (Dijkstra et al., 
2006; Postma and Koppelman, 2009), developmental factors (Carey et al., 2007; Postma, 
2007, p. 200), hormonal changes and reproductive-life histories (Jenkins et al., 2006; 
Macsali et al., 2011a; F G Real et al., 2008), airway caliber (Cohen et al., 2008; Leynaert et 
al., 1997), allergic sensitization  (Goldhahn et al., 2009; Leynaert et al., 2012), differences in 
environmental exposures and susceptibility (Bridevaux et al., 2007; Downs et al., 2005), 
misclassification with chronic obstructive pulmonary disease (COPD) (Chapman et al., 
2001a; Watson et al., 2004), as well as socio-cultural factors (WHO, 2003; Williams, 2000). 
Asthma incidence seems to decrease with increasing age, and women are shown to have a 
higher incidence of asthma than men (de Marco et al., 2000b, p. 200; Eagan et al., 2005; 
Leynaert et al., 2012; Torén et al., 2011), but there is a lack of knowledge  particularly in the 
elderly (Eagan et al., 2005; Torén et al., 2011). In a review by Eagan et al. in 2005, a pooled 
estimate of adult asthma incidence of 4.6 per 1000 person-years in women and 3.6 per 1000 
person-years in men was reported (Eagan et al., 2005). Studies allowing asthma incidence 
estimations for those >50 years, showed an increasing trend with age overall, but sex-
specific trends were less conclusive. A study from the USA in the 1990’s reported a 
decreased incidence in both men and women above age 65 (Bauer et al., 1997), as did a 
more recent Swedish study with information up to age 75 (Torén et al., 2011).  
The age course of asthma incidence seems to differ in sensitized  and non-sensitized  
subjects (Leynaert et al., 2012) which may contribute to the inconclusive findings across 
age. Non-sensitized  asthma, which has a more severe clinical course in adults (Novak and 
Bieber, 2003b), appears to have a higher incidence in women than in men (Leynaert et al., 
2012) (Antó et al., 2010b), But is found to be less often treated compared to sensitized-
asthma (Knudsen et al., 2009). The number of prospective studies reporting sex-specific 
incidence rates into late adulthood is limited. In order to improve recognition and treatment, 
further investigation into gender differences in asthma in older populations is crucial. 
Making use of the on-going Swiss Cohort Study on Air Pollution and Lung and Heart 
Diseases in Adults (SAPALDIA), now covering 20-years of longitudinal observation of a 
population aged 18-60 years at baseline, we investigated the cumulative incidence of adult 
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asthma in Switzerland and its relationship to gender, taking into account age and allergic 
sensitization. 
 
Gender Differences in Adult-Onset Asthma 
 
 
41 
 
3.2 Methods 
3.2.1 Study Design and Population 
The SAPALDIA study (see appendix 1) was initiated in 1991 in eight geographically diverse 
areas in Switzerland (Aarau, Basel, Davos, Geneva, Lugano, Montana, Payerne, and Wald). 
A total of 9651 persons (51% female) aged 18-60 years participated in the baseline study 
(SAPALDIA 1 (S1)) after having been recruited through random population sampling.  Re-
assessments took place In 2002/2003 (SAPALDIA2 (S2), n= 8047) and in 2010/2011 
(SAPALDIA 3 (S3), n=6088). Participants answered a detailed questionnaire and underwent 
health examinations including blood samples for serological tests and allergy skin testing. 
The protocol and participation rates have been described in further detail elsewhere 
(Ackermann-Liebrich et al., 2005; Martin et al., 1997). This analysis includes 5128 subjects 
who reported no doctor-diagnosed asthma at baseline, provided complete information on 
doctor diagnosed asthma in at least S1 and 3 and had complete covariate information (figure 
3.1). Ethical approval was obtained from the Swiss Academy of Medical Sciences, the 
regional committees, and written informed consent was obtained from all participants.  
 
3.2.2 Definition of Asthma and Asthma Incidence 
The primary definition of asthma incidence used for this analysis (definition 1) was the 20-
year cumulative incidence of doctor-diagnosed asthma from S1-S3. Doctor-diagnosed 
asthma was defined as a positive answer to the questions ‘Have you ever had asthma?’ and 
‘Was this confirmed by a doctor?’  
For the purpose of a sensitivity analysis, additional asthma incidence definitions were made 
based on further restriction criteria, self-report of asthma, and inconsistencies in the 
reporting of first attack of asthma (table 3.1).  
3.2.3 Sex/Gender 
The main predictor of interest was self-report of being ‘male’ or ‘female’. We approach sex 
and gender as “a complex phenomenon, simultaneously biological and social” (Springer et 
al., 2012b) and make this visible through the term sex/gender. 
3.2.4 Age  
Baseline age was categorized into six age groups of roughly 10 years for the descriptive 
tables. For the models, baseline age was used as a continuous variable (age in years).  
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3.2.5 Allergic Sensitisation 
Allergic sensitization was defined as a positive response to the skin prick test or Phadiatop 
test (Phadia, Uppsala, Sweden) at baseline. A positive skin prick test was indicated by an 
adjusted mean wheal diameter of ≥3mm to at least one of eight common allergens (grass, 
birch and Parietaria pollen, house dust mite, cat and dog epithelia and the moulds Alternaria 
and Cladosporium) (Martin et al., 1997; Wüthrich et al., 1995). The Phadiatop test, an in vitro 
allergy screening test, detects the presence of specific serum IgE against 11 common aero-
allergens (Cladosporium, Dermatophagoides pteronyssinus., Dermatophagoides farinae, 
cat, dog, horse, birch, timothy grass [Phleum pratense], mugwort [Artemisia], olive, 
Parietaria judaica [spreading pellitory]. The percentage binding of the phadiatop was 
determined and results classified as positive or negative based on a cut-off of 0.35 kU/L 
(Martin et al., 1997; Merrett and Merrett, 1987; Wüthrich et al., 1995). Allergically sensitized 
subjects with doctor-diagnosed asthma were considered as having allergic asthma.  
3.2.6 Further covariates  
Smoking status at baseline and S3 was categorized as never-smoker, former-smoker and 
current-smoker. Smoking status at S3 was defined in a cumulative way, never-smokers 
being consistent never smokers across all three surveys, current smokers being smokers at 
S3, and ex-smokers being people who were smokers at S1 and/or S2, but not at  S3. 
Education was categorized into primary education (low), secondary or middle school 
education (intermediate), and having a technical or university degree (high). For the 
descriptive tables, education at baseline was used. In the models, cumulative education, (the 
highest educational level reported at S1/S2), was used. Body mass index (BMI) at baseline 
was calculated as weight in kilograms, divided by the square of height in meters. Parental 
asthma was defined as a positive answer to the question ‘did one or both of your parents 
ever have asthma?’ Early life-respiratory infection was defined as a positive answer to the 
question ‘'Did you have a serious respiratory infection before the age of 5 years?’ 
Occupational exposure was defined as a positive answer to at least one of the items in the 
question ‘At your working place, are you currently exposed to dust, 
gas/smoke/aerosols/fumes/vapors?’ All of these covariates were selected based on literature 
findings. 
 
3.2.7 Statistical Analysis 
The 20-year cumulative incidence was calculated as the number of incident asthma cases at 
S2 or S3 in our sample divided by the size of the sample. The age-related probability of new 
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onset of asthma was analyzed by logistic regression adjusting for sex, BMI, parental asthma, 
early-life respiratory infection, occupational exposure and study area as reported at baseline, 
along with cumulative smoking and cumulative education as described above. Analyses 
were also stratified by sex and allergic sensitization in S1 to see whether the patterns of 
determinants differed in men and women. Up to three-way interaction terms for sex, age, 
and allergic sensitization were used to produce figures 3.2a and 3.2b. Furthermore, we 
restricted the analysis to never smokers. In order to address potential bias in loss to follow-
up, inverse probability weighting was done. 
We conducted several sensitivity analyses. Firstly we ran our model using different asthma 
incidence definitions as described in table 3.1. Secondly, we assessed the correlation 
between the skin prick test and Phadiatop® test using the kappa statistic and ran our 
multivariate analysis using only the skin prick test or Phadiatop® test to define allergic 
sensitization. Thirdly, sensitivity analyses were done adding the following interval exposure 
variables: change in smoking status, change in BMI and change in occupational exposure 
from S1 to S3. Finally, we addressed the separate impact of paternal and maternal asthma 
in the final model, ran the model also without the variable on the report of early-life 
respiratory infection, and furthermore we assessed urbanity as a potential confounder.   
All analyses were conducted using Stata V.12 (StataCorp LP, College Station, TX, USA). 
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3.3 Results 
3.3.1 Study population 
Our study population consisted of 2500 men and 2628 women reporting no doctor-
diagnosed asthma at S1, providing complete information on doctor-diagnosed asthma in at 
least S1 and S3 and having complete covariate information (figure 3.1).  The characteristics 
of the study population by sex/gender are given in table 3.2.  There were slightly more 
females than males in the older age group (50-70 years). Males more frequently reported 
occupational exposure and higher education than females, whereas females more frequently 
reported early-life respiratory infections, never having smoked, and lower education. Older 
subjects, current smokers, subjects with higher BMI and subjects reporting occupational 
exposure and low education were slightly more likely to be excluded (table 3.2).  
 
3.3.2 Cumulative Incidence 
Over 20 years of follow-up, 326 (6.4%) participants newly reported doctor-diagnosed 
asthma, 128 men (5.1%) and 198 women (7.5%). Cumulative incidence was relatively stable 
in the sensitivity analysis using different asthma incidence definitions, ranging from 4.5% 
when using definition 5 to 6.4% when using definition 1 (supplementary table S3.1). When 
analyzed in men and women separately, the ranges were somewhat larger (3.6 to 5.1% in 
men and 5.3 to 7.5% in women). 
3.3.3 Determinants of Asthma Incidence 
3.3.3.1 Sex/gender 
The crude odds ratio (OR) for female sex was 1.50 (95% CI 1.20-1.87), and 1.62 (95% CI 
1.28.2.04) when adjusting for age and allergic sensitization. In the fully adjusted analyses, 
the OR for female sex was 1.99 (95% CI 1.54-2.57), (table 3.4 first column), being only 
slightly smaller in the analyses restricted to never-smokers (OR 1.78 95% CI 1.18-2.67) 
(table 3.4, second column). The likelihood of new-onset of asthma decreased significantly 
with increasing baseline age. Allergic sensitization was a strong determinant of asthma 
incidence (OR 3.04, 95%CI 2.40-3.85), and parental asthma was also a relatively strong 
determinant (OR 1.87, 95%CI 1.37-2.55). 
3.3.4 Stratified Analysis 
In stratified analysis by sex, allergic sensitization was a stronger predictor in men (OR 4.90 
95% CI 3.29 – 7.30) than in women (OR 2.28 95% CI 1.68 - 3.08) (table 3.4). The probability 
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of new onset of asthma significantly decreased with increasing baseline age in women but 
not in men (figure 3.2a). Early-life respiratory infection had a discrepant association, being 
protective in men and a risk factor in women. Former smokers had a higher likelihood of new 
onset of asthma than never-smokers (significant only in women).  
Interaction analyses showed significant terms between age and allergic sensitization in 
women but not in men (data not shown). When stratifying by allergic sensitization, the OR for 
female sex was 3.21 (95% CI 2.12-4.85) among non-sensitized subjects and 1.43 (95% CI 
1.02-2.01) in sensitized subjects. When stratifying by sex and allergic sensitization, the age 
pattern of the association differed (figure 3.2b). In women, a higher probability of new 
asthma was seen, particularly in younger rather than in older sensitized women, whereas in 
sensitized men, the age-related decrease was less pronounced and in non-sensitized men, 
the probability slightly increased with increasing age.  
When conducting inverse probability weighting for non-participation, results remained largely 
unchanged overall and in women and men separately (data not shown). 
3.3.5 Sensitivity Analyses 
In the sensitivity analysis using different asthma incidence definitions, the OR values for 
female sex, age and allergic sensitization were consistent across all models (table 3.3) being 
lowest when using definition 4 (1.82, 95% CI 1.39 - 2.38) and highest when using definition 
3b (2.08, 95% CI 1.55 - 2.78). The most pronounced change observed in other covariates 
was in the model using definition 5, where the OR values for allergic sensitization and 
parental asthma were lowest. There was, however, no indication for effect modification by 
parental asthma when conducting the analysis separately for subjects with and without 
parental asthma using definition 5 (data not shown).  
In further sensitivity analysis, we addressed whether skin prick test positivity and phadiatop 
positivity have a differential impact on asthma incidence. The OR values for skin prick test 
positivity and phadiatop positivity were very similar (2.9 95% CI 2.29- 3.71 and 3.1 95% CI 
2.44-3.94 respectively) and the OR for female sex remained almost identical (1.97 95% CI 
1.52-2.55 and 1.96 95% CI 1.51-2.55 respectively). Using interval exposure variables for 
smoking, BMI and occupational exposure, no significant change was observed in the female 
sex OR (supplementary table S3.2). Furthermore, we ran our multivariate analysis using 
paternal and maternal asthma as separate covariates (data not shown) and found paternal 
asthma to be a significant predictor in men and women whereas maternal asthma was 
significant only in women. Omitting the variable on early-life respiratory infection did not 
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change results. Finally, we additionally controlled for urbanity in the overall model. Urbanity 
was a predictor for new onset of asthma (OR 1.28 95% CI 1.02-1.62) however the 
association between female sex and asthma incidence remained identical.    
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3.4 Discussion 
3.4.1 Main Findings 
Over 20 years of follow-up, 5% of men and 7% of women aged 18-60 years at baseline 
newly reported doctor diagnosed asthma in this population-based cohort. When adjusting for 
relevant confounders, women were twice as likely as men to newly develop asthma. The 
association between sex/gender and asthma incidence was modified by allergic sensitization 
and age. Non-sensitized women were three times more likely to newly develop asthma than 
non-sensitized men. The likelihood of new-onset of asthma decreased with age. Sex/gender 
differences decreased with age as well, both in sensitized and non-sensitized subjects. This 
study is among the few to report cumulative incidence of adult-onset asthma by sex/gender 
in a population with a high proportion of people aged >50 years of age. The more 
pronounced decrease of incidence by age among sensitized compared to non-sensitized 
women, and the decreasing sex differences with age, are novel. 
3.4.2 Comparison to Other Studies 
The decreasing trend of new asthma onset with age is in contrast to the findings of the 
review by Eagan et al. (2005), which showed an increase of risk with greater age for studies 
with a wide age span and adjusted risk estimates. The age course, however, seemed less 
consistent in women for the two studies reporting sex-specific rates (Lundbäck et al., 2001; 
Rönmark et al., 1997). Furthermore, the age trend disappeared in one of the studies when 
subjects with chronic bronchitis at baseline were excluded (Lundbäck et al., 2001), 
suggesting confounding of asthma incidence chronic bronchitis in men. Our findings expand 
earlier SAPALDIA findings showing lower prevalence rates of asthma in men and women 
compared with below age 60 years  (Wüthrich et al., 2013) and are in line with a recent 
Swedish study (Torén et al., 2011), showing a decrease of asthma incidence across an age 
range of 16-75 years in men and women overall, and in never-smokers. In our study, the 
negative association with age was much more pronounced among women than men. It 
remained significant also when restricting the analysis to never-smokers (table 3.4) and 
when excluding subjects with COPD (data not shown). 
Findings from  the European Community Respiratory Health Survey (ECRHS) also pointed 
to a differential age course by allergic sensitization  for the baseline age range of 20-44 
years, with decreasing asthma incidence in sensitized subjects, but increasing asthma 
incidence in non-sensitized subjects (Leynaert et al., 2012). In our study, allergic 
sensitization was most influential due to the high probability of new asthma onset in the 
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youngest sensitized women (figure 3.2b), possibly due an underlying cohort effect. As 
suggested by Jarvis (2005) , the prevalence of sensitization to any allergen differs with age 
and cohort, with more recent birth cohorts showing  a higher prevalence of sensitization than 
earlier cohorts.  
The largest sex/gender difference in our study was seen in non-sensitized subjects. These 
findings are consistent with Leynaert et al. (2012) who have reported a higher incidence of 
non-allergic-asthma in women than in men throughout all reproductive years. However, 
Leynaert et al. (2012) found an increase in incidence over 10 years in non-sensitized men 
and women, at least in the age groups 31-40 years and 41-44 years. It is unlikely that 
differences in measurement methods explain this different pattern because the same 
methods were applied in ECRHS and SAPALDIA except that the Phadiatop® test in 
SAPALDIA included 11 allergens whereas ECHRS only included 4 (Burney et al., 
1994)(Martin et al., 1997). Although Leynaert et al. (2012)  used the Phadiatop® test alone 
to define allergic sensitization, whereas we used either a positive skin prick test or 
Phadiatop® test to define allergic sensitization, neither their sensitivity analysis using either 
a positive skin prick test or Phadiatop® test changed results, nor ours when we conducted 
our multivariate analysis with each test separately, changed results. Because earlier studies 
have shown that skin prick tests and serum allergen specific IgE may not have the same 
biological and clinical relevance (Bousquet et al., 2010) we tested the correlation of these 
two tests in our data, finding a kappa statistic of 0.66. Despite moderate agreement of the 
two tests, no change in the odds ratio for female sex or other covariates was observed when 
using the skin prick test or the Phadiatop® test alone. Sex/gender differences in other 
factors contributing to non-atopic asthma might affect the age course differently (Goldhahn 
et al., 2009). In fact, the proportion of non-atopic incident asthma cases was higher in 
women in ECRHS (65%) than in SAPALDIA (46%), as was the prevalence of occupational 
exposure in women of the age group ≤30 and 30-40 years (35% vs. 22%) whereas the 
prevalence of smoking was identical in both studies (31%). As for BMI, the adjustment for 
baseline BMI and change of BMI did not affect the female OR in neither ECRHS nor in 
SAPALDIA (supplementary table S3.2). However, in our study, when stratifying by sex and 
allergic sensitization, baseline BMI and change in BMI were predictors of asthma incidence 
only in non-sensitized women. Furthermore, additional control for urbanity did not change 
results.  
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3.4.3 Strengths & Limitations 
The strength of this study is its large data base representing general populations from urban, 
rural and mountainous areas with different environmental exposure characteristics, with 
standardized measurements and health questionnaire which was developed along with the 
ECHRS (Burney et al., 1994; Martin et al., 1997). As the study is of a prospective nature, 
recall bias is unlikely. However, there could be a differential reporting of asthma in men and 
women in higher age groups as suggested by Torèn et al. (2011). We can only speculate 
that this might have had an impact on the low probability of incident asthma in the oldest 
ages and the decreasing sex/gender differences with age.  
A limitation of this study, as with any longitudinal study, is loss to follow-up. Non-participants 
were more likely to smoke, to have a low education and a higher BMI and more likely to 
report occupational exposures (table 3.2). Therefore, our incidence estimate may represent 
an underestimation. Loss to follow-up would affect the female sex ratio only if this missing 
information is differential for women and men or if the probability for undergoing testing for 
allergic sensitization differed in men and women. As shown in table 3.2, we did see some 
differential loss to follow up in men and women; however, this was not the case for allergic 
sensitization, at least only marginally (p=0.09 for men). When conducting a sensitivity 
analyses using inverse probability weighting, it yielded largely the same results. Because, for 
our study population, full information on allergic sensitization was an inclusion criterion, all 
women and men of our study population were tested for allergic sensitization. We cannot 
rule out, however, whether subjects having allergic sensitization or a family history of asthma 
or another allergic condition were more likely to undergo testing and may be 
overrepresented in the analytic sample. Since there exists no gold standard for asthma, any 
definition has limitations. We used doctor-diagnosed asthma, which has been found to have 
high specificity and low sensitivity (Torén et al., 2004). Therefore, we would expect, if 
anything, an underreporting. Another issue is the exclusion criteria applied to have asthma-
free subjects at baseline. However, we found that results were neither sensitive to the choice 
of these criteria nor to the use of alternative asthma definitions (table 3.3).  
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3.5 Conclusion 
Overall, new onset of asthma over 20 years was positively associated with female sex in this 
population aged 18-60 years at baseline, and the association of sex/gender and asthma 
incidence was modified by allergic sensitization and age. A higher asthma incidence was 
seen among sensitized persons, particularly in younger women. Gender differences in 
asthma incidence were most pronounced in non-sensitized subjects. A clear age-related 
decline of asthma incidence and a differential pattern of this decline between sensitized and 
non-sensitized subjects were significant only in women, which needs further investigation. 
Firstly, the high asthma incidence observed in sensitized young women warrants 
explanation. Secondly, specific pathways explaining sex/gender differences should be 
researched, in particular in the lower age range between 20-40 years where we saw the 
largest sex/gender differences. For this age span the role of non-allergic pathways, such as 
reproductive pathologies which have been shown to be related to asthma (Macsali et al., 
2011a; F G Real et al., 2008) may be of particular interest.  
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Figure 3.1: Study Population 
Diagram of initial population, the reasons for exclusion and the population included in the 
analysis 
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Figure 3.2: Covariate-adjusted probability of incident asthma during follow-up as a function of baseline age, stratified by a) sex, and 
b) sex and allergic sensitization (sens.).
a) Adjusted for allergic sensitisation, body mass index (BMI), parental asthma, early-life respiratory diseases, occupational exposure, study area, cumulative 
smoking status and cumulative educational level, including an interaction term for sex and age. B) Adjusted for BMI, parental asthma, early-life respiratory diseases, 
occupational exposure, study area, cumulative smoking status and cumulative educational level, including up to three-way interaction terms for sex, age and allergic 
sensitisation  
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Table 3.1: Definitions of cumulative asthma incidence used for main analysis and 
sensitivity analysis 
 
Name Definition Study Population 
   
 
 
Definition 1: 
 
cumulative incidence of doctor-diagnosed 
asthma from SAPALDIA1-3  
 
outcome = 1 (asthma incident case) if: 
- doctor diagnosed asthma at 
SAPALDIA 2 (S2) or SAPALDIA 3 (S3)  
outcome = 0 (not asthma incident) if: 
- no doctor diagnosed asthma in S2 and 
S3 
 
 
o No doctor diagnosed 
asthma at SAPALDIA 1 
(S1) 
o Participation in SAPALDIA 
3 (S3) 
o Complete information on 
doctor diagnosed asthma in 
S1 and S3 
o No missing covariate 
information 
 
Definition 2 
 
definition 1, additionally adjusting for self-report 
and close indicators of asthma at baseline 
 
Definition 1, additionally: 
o No self-reported asthma at 
S1 
o No  current asthma 
medication at S1 
o No asthma attack last 12 
months at S1  
    
 
Definition 3a 
 
definition 2, additionally adjusting for asthma 
symptoms  
 
Definition 2, additionally: No doctor 
diagnosed asthma at S1 
o No shortness of breath of 
wheeze ever at S1  
o Exclude if at least 3/5 of the 
following symptoms at S1: 
wheeze and 
breathlessness, woken up 
with a feeling of chest 
tightness, attack of 
shortness of breath at rest, 
attack of shortness of 
breath after exercise, or 
woken by attack of 
shortness of breath  
 
Definition 3b 
 
combination of definition 2 and 3a, additionally 
excluding anyone reporting shortness of breath 
of wheeze ever at baseline 
 
 
Combination of definition 2 and 3a, 
additionally: 
o No sob wheeze ever at S1 
 
Definition 4: 
 
using asthma incidence definition from 
Jacquemin et al. (2014) (Jacquemin et al., 
2015) (which corresponds to definition 3b 
except the outcome is based on self-report and 
may reflect undiagnosed asthma) 
 
 
Definition 3b except the outcome is 
based on self-report  
 
Definition 5:   
 
definition 1, additionally excluding those 
reporting year of asthma onset at or before 
baseline  
 
 
Definition 1, additionally: 
o No asthma attack before or 
equal to 1991 
Gender Differences in Adult-Onset Asthma 
 
 
54 
 
 
 
 
 
  
Study population (N=5128)* Excluded but asthma free at 
SAPALIDA 1 in 1991  (N=3866)** 
P-Value*** 
 Male  Female  Male  Female  Male Female 
 N % N % N % N %   
OVERALL 2,500 48.8 2,628 51.3 1,915 49.5 1,951 50.5 0.46 
Age         <0.001 <0.001 
<30 565 22.6 520 19.8 399 20.8 368 18.9   
30-40 629 25.2 715 27.2 409 21.4 446   22.9   
40-50 754 30.2 759 28.9 533 27.8 555 28.5   
50-60 497 19.9 565 21.5 485 25.3 486 24.9   
60-70 55 2.2 69 2.6 89 4.7 96 4.9   
70+ - - - - - - - -   
Allergic 
sensitization  
849 34.0 777 29.6 552 36.6 372 27.3 0.09 0.13 
Smoking 
status 
        <0.001 <0.001 
Never-smoker 1,001 40.1 1,456 55.4 569 29.8 912 46.8   
Former-
smoker 
649 26.0 519 19.8 481 25.2 366 18.8   
Current-
smoker 
848 34.0 653 24.9 862 45.1 672 34.5   
BMI (mean) 
(SD) 
 
24.61 (3.12) 
 
22.77 (3.68) 
 
25.09 (3.63) 
 
23.56 (4.54) 
 
<0.001 
 
<0.001 
Parental 
asthma 
205 8.2 298 11.3 173    9.1 196 10.1 0.33 0.18 
Early-life 
respiratory 
infection 
146 5.8 215 8.2 100 5.2 144   7.4 0.39 0.35 
Occupational 
exposure 
1,005 40.2 530 20.2 849 44.5 459 23.8 0.01 0.00 
Education         <0.001 <0.001 
Low 223   8.9 404 15.4 391 20.5 493 25.4   
Intermediate 1,647 65.9 1,923 73.2 1,129 59.2 1,274 65.6   
High  630 25.2 300 11.4 388 20.3 174 9.0   
* Study population: reporting no doctor-diagnosed asthma at baseline, providing complete information on doctor diagnosed 
asthma in at least SAPALDIA 1 and 3 and having complete covariate information 
** Excluded but asthma free at s1: having incomplete asthma information in SAPALDIA1/SAPALDIA3, having missing covariate 
information, not participating in SAPALDIA 3, but being asthma free at SAPALDIA1 
***p-value: using t-test for variables sex, age and BMI and Fisher exact test for variables smoking, parental asthma, early-life 
respiratory infection, education, allergic sensitization  and occupational exposure  
Table 3.2: Main characteristics at baseline comparing those excluded from study 
population with those included, by sex 
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Table 3.3: Determinants of cumulative incidence of asthma using different definitions of asthma 
Variables Asthma incidence 
definition 1* 
OR (95% CI) 
( N=5128) 
Asthma incidence 
definition 2** 
OR (95% CI) 
(N=5056) 
Asthma incidence 
definition 3a*** 
OR (95% CI) 
(N=5009) 
Asthma incidence 
definition 3b**** 
OR (95% CI) 
(N= 4789) 
Asthma incidence 
definition 4**** 
OR (95% CI) 
(N=4932) 
Asthma incidence 
definition 5**** 
OR (95% CI) 
(N=4932) 
       
Female sex 1.99 (1.54 - 2.57) 2.07 (1.58 - 2.72) 1.92 (1.47 - 2.51) 2.08 (1.55 - 2.78) 1.82 (1.39 - 2.38) 1.90 (1.40 - 2.59) 
Age (yrs.) 0.98 (0.97 - 0.99) 0.98 (0.97 - 0.99) 0.98 (0.97 - 0.99) 0.98 (0.97 - 0.99) 0.98 (0.96 - 0.99) 0.98 (0.96 - 0.99) 
Allergic sensitization  3.04 (2.40 - 3.85) 2.85 (2.22 - 3.64) 3.09 (2.41 - 3.95) 2.86 (2.20 - 3.73) 2.80 (2.19 - 3.57) 2.49 (1.88 - 3.29) 
Never-smoker 
(reference) 
1 1 1 1 1 1 
Former-smoker 1.38 (1.06 - 1.78) 1.35 (1.03 - 1.76) 1.40 (1.07 - 1.83) 1.37 (1.02 - 1.83) 1.30 (0.99 - 1.69) 1.29 (0.95 - 1.75) 
Current-smoker 0.94 (0.67 - 1.32) 0.87 (0.61 - 1.25) 0.90 (0.63 - 1.28) 0.87 (0.59 - 1.29) 0.75 (0.52 - 1.08) 0.90 (0.60 - 1.33) 
BMI 1.05 (1.02 - 1.09) 1.06 (1.02 - 1.09) 1.06 (1.02 - 1.09) 1.05 (1.02 - 1.09) 1.03 (0.99 - 1.07) 1.03 (0.99 - 1.08) 
Parental asthma 1.87 (1.37 - 2.55) 1.74 (1.25 - 2.43) 1.98 (1.44 - 2.73) 1.95 (1.37 - 2.77) 1.71 (1.22 - 2.39) 1.47 (0.99 - 2.18) 
Early-life respiratory 
infection 
1.27 (0.83 - 1.94) 1.30 (0.84 - 2.03) 1.23 (0.79 - 1.93) 1.31 (0.81 - 2.12) 1.35 (0.87 - 2.11) 1.30 (0.78 - 2.17) 
Occupational exposure 1.26 (0.98 -1.63) 1.20 (0.92 - 1.58) 1.26 (0.96 - 1.66) 1.24 (0.93 - 1.67) 1.39 (1.06 - 1.82) 1.36 (1.01 - 1.85) 
Intermediate education 
(reference) 
1 1 1 1 1 1 
Low education 0.34 (0.17 - 0.67) 0.27 (0.13 - 0.60) 0.34 (0.16 - 0.71) 0.29 (0.12 - 0.67) 0.52 (0.27 - 0.98) 0.49 (0.23 - 1.03) 
Higher education 1.02 (0.78 - 1.34) 0.90 (0.68 - 1.20) 1.05 (0.79 - 1.38) 0.94 (0.70 - 1.28) 1.03 (0.78 - 1.37) 0.97 (0.70 - 1.34) 
       
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for female sex, age, allergic sensitization, cumulative 
smoking, BMI, parental asthma, early-life respiratory infection, occupational exposure, cumulative education and study area. Bold indicates significance at p ≤0.05. 
*Definition 1: final model also adjusting for study area, using asthma incidence definition 1- cumulative incidence of doctor-diagnosed asthma from SAPALDIA1-3  
**Definition 2: final model also adjusting for study area, using asthma incidence definition 2- same as definition 1 additionally adjusting for baseline self-report and close 
indicators of asthma  
***Definition 3a: final model also adjusting for study area, using asthma incidence definition 3a- same as definition 2, additionally adjusting for asthma symptoms 
****Definition 3b: final model also adjusting for study area, using asthma incidence definition 3b -  combination of definition 2 and 3a, additionally excluding at baseline anyone 
reporting shortness of breath of wheeze ever  
*****Definition 4: final model also adjusting for study area, using asthma incidence definition 4- Jacquemin et al. (2014) (Jacquemin et al., 2015)  
******Definition 5: final model also adjusting for study area, using asthma incidence definition 5-  same as definition 1, additionally excluding those reporting year of asthma 
onset at or before baseline 
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   Men Women 
Variables Overall Model 
OR (95% CI)  
N= 5128 
Never-Smokers 
OR (95% CI) 
N= 2243 
Overall 
OR (95% CI)  
N= 2500 
Never-Smokers 
OR (95% CI) 
N=1078 
 
Overall 
OR (95% CI) 
N= 2628 
Never-Smokers 
OR (95% CI) 
N=1621 
Female sex 1.99 (1.54 - 2.57) 1.78 (1.18 -  2.67) - - - - 
       
Age (yrs.) 0.98 (0.97 - 0.99) 0.98 (0.96 – 1.00) 0.99 (0.98 - 1.01) 1.01 (0.98 -  1.04) 0.98 (0.96 - 0.99) 0.97 (0.95 - 0.99) 
       
Allergic sensitization  3.04 (2.40 - 3.85) 3.54 ( 2.44 - 5.14) 4.90 (3.29 – 7.30) 6.42 (3.12 - 13.18) 2.28 (1.68 - 3.08) 2.80 (1.78 - 4.40) 
       
Never-smoker (reference) 1 - 1 - 1 - 
Former-smoker 1.38 (1.06 - 1.78) - 1.22 (0.80 -  1.85) - 1.45 (1.04 - 2.01) - 
Current-smoker 0.94 (0.67 - 1.32) - 0.68 (0.39 -  1.20) - 1.12 (0.73 - 1.72) - 
       
BMI 1.05 (1.02 - 1.09) 1.10 (1.04 - 1.16) 1.05 (0.98 - 1.11) 1.10 (0.98 - 1.23) 1.06 (1.02 - 1.10) 1.10 (1.04 - 1.17) 
       
Parental asthma 1.87 (1.37 - 2.55) 1.87 (1.12 - 3.11) 2.04 (1.22 - 3.40) 1.53 (0.54 - 4.29) 1.75 (1.19 - 2.59) 2.08 (1.14 - 3.77) 
       
Early-life respiratory infection 1.27 (0.83 - 1.94) 1.14 (0.55 - 2.36) 0.67 (0.26 - 1.70) omitted 1.60 (0.98 - 2.60) 1.67 (0.77 - 3.58) 
       
Occupational exposure 1.26 (0.98 - 1.63) 1.23 (0.82 - 1.86) 1.02 (0.69 - 1.52) 1.43 (0.72 - 2.83) 1.50 (1.07 - 2.11) 1.31 (0.77 - 2.22) 
       
Intermediate education 
(reference) 
1 1 1 1 1 1 
Low education  0.34 (0.17 - 0.67) 0.38 (0.14 - 1.01) 0.18 (0.02 - 1.38) omitted 0.38 (0.18 - 0.80) 0.50 (0.19 - 1.36) 
Higher education 1.02 (0.78 - 1.34) 1.00 (0 .65 - 1.53) 0.86 (0.57 - 1.27) 0.81 (0.41 - 1.60) 1.11 (0.77 - 1.59) 1.14 (0.65 - 2.01) 
 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for female sex, age, allergic sensitization, cumulative smoking, BMI, 
parental asthma, early-life respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 3.4: Determinants of asthma incidence stratified by sex, in the overall study population and in 
never-smokers 
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Table S 3.1: Cumulative incidence by sex using different asthma incidence definitions 
 
Asthma Incidence 
 
 Overall Male Female 
     
Definition (n)  (%)  (n) (%)  (n)  (%) 
       
Definition 1* 326/5128 6.4 128/2500 5.1 198/2628 7.5 
Definition 2** 292/5056 5.8 110/2464 4.5 182/2592 7.0 
Definition 3a*** 296/5009 5.9 120/2459 4.9  176/2,550 6.9 
Definition 3b**** 250/4789 5.2 95/2342 4.1 155/2447 6.3 
Definition 4***** 298/4789 6.2 121/2342 5.2 177/2447 7.2 
Definition 5****** 220/4932 4.5 86/2412 3.6 134/2520 5.3 
       
*Definition 1: cumulative incidence of doctor-diagnosed asthma from SAPALDIA1-3  
**Definition 2: definition 1, additionally adjusting for baseline self-report and close indicators of asthma 
***Definition 3a: definition 2, additionally adjusting for asthma symptoms 
****Definition 3b: combination of definition 2 and 3a, additionally excluding at baseline anyone reporting shortness of breath of wheeze 
ever 
*****Definition 4: using asthma incidence definition from Jacquemin et al. (2014)  which corresponds to definition 3b except the 
outcome is based on self-report and may reflect undiagnosed asthma  (Jacquemin et al., 2015) 
******Definition 5: definition 1, additionally excluding those reporting year of asthma onset at or before baseline  
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Table S 3.2: Determinants of cumulative asthma incidence, including interval exposure variables (smoking, BMI and occupational 
exposure) 
 
Variables Model 1* 
OR (95% CI) 
N= 5128 
Model 2** 
OR (95% CI) 
N= 5124 
Model 3*** 
OR (95% CI) 
N= 4235 
Model 4**** 
OR (95% CI) 
N= 4235 
     
Female sex 1.99 (1.54 - 2.57) 2.00 (1.54 - 2.58) 2.14 (1.61 - 2.84) 2.12 (1.60 - 2.83) 
Age (years) 0.98 (0.97 - 0.99) 0.98 (0.97 - 0.99) 0.98 (0.97 - 1.00) 0.98 (0.97 - 1.00) 
Atopy 3.04 (2.40 - 3.85) 3.06 (2.42 - 3.88) 3.35 (2.58 -  4.34) 3.35 (2.59 - 4.34) 
Never-smoker (reference) 1 1 1 1 
Former-smoker 1.38 (1.06 - 1.78) 1.46 (1.10 - 1.94) 1.57 (1.16 - 2.12) 1.58 (1.17 - 2.13) 
Current-smoker 0.94 (0.67 - 1.32) 1.16 (0.69 - 1.96) 1.32 (0.73 - 2.37) 1.33 (0.73 - 2.40) 
BMI 1.05 (1.02 - 1.09) 1.06 (1.02 - 1.09) 1.04 (1.01 - 1.09) 1.04 (1.00 - 1.09) 
Parental asthma 1.87 (1.37 - 2.55) 1.87 (1.38 - 2.55) 1.85 (1.32 - 2.60) 1.86 (1.33 - 2.61) 
Early-life respiratory infection 1.27 (0.83 - 1.94) 1.28  (0.84 -1.95) 1.43 (0.91 - 2.26) 1.44 (0.92 - 2.27) 
Occupational exposure 1.26 (0.97 - 1.63) 1.26 (0.98 - 1.63) 1.39 (1.05 - 1.84) 1.42 (1.06 - 1.91) 
Intermediate education (reference) 1 1 1 1 
Low education 0.34 (0.17 -  0.67) 0.34 (0.17 - 0.68) 0.31 (0.13 - 0.71) 0.30 (0.13 - 0.71) 
Higher education 1.02 (0.78 -  1.34) 1.02 (0.78 - 1.33) 1.13 (0.85 - 1.50) 1.13 (0.85 - 1.50) 
Smoking interval - 0.81 (0.54 - 1.22) 0.66 (0.42 - 1.03) 0.66 (0.42 - 1.03) 
BMI interval - - 1.04 (0.99 - 1.08) 1.04 (0.99 - 1.08) 
Occupational exposure interval - - - 0.93 (0.69 - 1.26) 
     
*Model 1: final model additionally adjusting for study area 
**Model 2: model 1, additionally adjusting for interval smoking  (never = consistent never smoker across all surveys, current = current smoker at SAPALDIA3, ex-smoker = 
smoker at SAPALDIA1 or SAPALDIA2 but not at SAPALDIA3) 
***Model 3: model 2, additionally adjusting for interval BMI  (0=no change, 1=change)  
****Model 4: model 3, additionally adjusting for interval occupational exposure (change in occupational exposure from SAPALDIA1-SAPALDIA3) 
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Abstract 
 
Several reproductive conditions and hormonal factors such as early menarche, irregular 
menses, early/surgical menopause or exogenous hormone intake have been found to be 
associated with respiratory health (Macsali et al., 2012). So far, these factors have been 
investigated separately and underlying mechanisms remain unclear. We investigated 
whether a history of reproductive pathologies across the reproductive life span has an impact 
on asthma incidence in adult women in Switzerland. 
 
2,977 asthma free women at baseline in 1991 (SAPALDIA 1), who participated in and 
provided information on asthma and reproductive histories at follow up in 2010/2011 
(SAPALDIA 3) were included in this study. New-onset of asthma was defined as the 20-year 
cumulative incidence of doctor-diagnosed asthma from SAPALDIA1-3 (S1-S3). Doctor-
diagnosed asthma was defined as a positive answer to the questions ‘have you ever had 
asthma?’ and ‘was this confirmed by a doctor?’ Reproductive pathologies included the self-
report of up to 10 conditions. Two different scores, one including all 10 conditions (score 1) 
and one including 7 of these conditions, having a stronger pathological similarity among 
themselves (score 2), were created and analyzed using multivariate logistic regression 
adjusting for relevant confounders and stratifying by age and atopic status at baseline. Our 
multivariate analysis was also run separately for each individual reproductive condition.  
 
218 women (7.3%) newly reported doctor diagnosed asthma. We found no significant 
association with the created scores and asthma incidence. The adjusted odds ratio for 
having 1 reproductive pathology using score 1 was 1.14 (95% CI 0.79 – 1.66) and 1.32 (95% 
CI 0.91 – 1.91) when having 2 or more reproductive pathologies. When using score 2, the 
adjusted odds ratio for having 1 reproductive pathology was 1.10 (95% CI 0. 76 - 1.58) and 
1.10 (95% CI 0.53 - 2.31) when having 2 or more reproductive pathologies. When stratifying 
by atopic status at baseline with score 1, non-atopics who had 1 reproductive pathology had 
an odds ratio of 1.12 (95% CI 0.67 - 1.88) and those having 2 or more reproductive 
pathologies had an odds ratio of 1.43 (95% CI 0.87 - 2.33). As for atopic women who had 1 
reproductive pathology the odds ratio was 1.23 (95% CI 0.71 - 2.12) and 1.20 (95% CI 0.67 - 
2.15) for those having 2 or more reproductive pathologies. For individual reproductive 
conditions, we saw a significant association with early menopause and asthma incidence, 
with an odds ratio of 1.73 (95% CI 1.21 - 2.49) which only remained significant in non-atopics 
when stratifying by atopy.  Furthermore, we saw a significant interaction of early menarche 
and irregular menses with BMI in the non-atopic women.  
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In conclusion we did not observe a significant association with new-onset of adult asthma 
and a combination of up to 10 reproductive pathologies in this Swiss cohort. We only found 
an association of early menopause and new-onset of asthma in non-atopic women, and 
interactions between early menarche and BMI as well as between irregular menses and BMI 
in non-atopic women.  
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4.1 Introduction 
Asthma is more common in boys than in girls during early childhood, but during adulthood 
asthma incidence, severity, healthcare utilization and impact on health-related quality of life 
have been found to be higher in women than in men (de Marco et al., 2005; De Marco et al., 
2002; Eagan et al., 2005; Hansen et al., 2015; Leynaert et al., 2012; Torén et al., 2011; Vink 
et al., 2010). Several mechanisms have been proposed to explain this differential life-course 
pattern, one of which is female sex hormones (Baibergenova et al., 2006; Forbes, 1999; 
Haggerty et al., 2003).  
 
Several reproductive conditions and hormonal factors such as early menarche, irregular 
menses, early/surgical menopause and exogenous hormone intake have been studied in 
association with respiratory health (Macsali et al., 2012).  
Findings that women with early menarche have more asthma and lower lung function has 
quite consistently been shown (Al-Sahab et al., 2011; Fida et al., 2012b; Lieberoth et al., 
2015; Macsali et al., 2012, 2011a; Salam et al., 2006a) except in a recent study Wei et al 
(Wei et al., 2015) where no significant association was shown between early menarche and 
asthma incidence.  
As for menstrual irregularity and polycystic ovarian syndrome, findings are conflicting 
(Macsali et al., 2012). Svanes et al, using the European Community Respiratory Health 
Survey found a significant association of irregular menses with asthma) OR=1.54, 95% CI; 
1.11-2.13. In the same study population, among 28-44 year old participants long menstrual 
cycles were significantly associated with frequent asthma symptoms (OR=1.76, 95%CI 1.29-
2.40) and allergic asthma (OR=2.49, 95%CI 1.43-4.23) (Gomez Real, 2008; Real et al., 
2007; Svanes et al., 2005). However, in the more recent Swedish Omega study, Fida, 
Williams and Enquobahrie (2014) found no association between menstrual irregularity or 
abnormal (short or long) cycle length with risk of adult onset asthma (Fida et al., 2012b). 
The relationship between menopause and the menopausal transition to lung health is still not 
very well understood. The reasons for this are several. There has been a great focus on HRT 
while the menopausal transition itself has been scarcely studied. In addition, study designs 
and populations have been heterogeneous (Macsali et al., 2012). The longitudinal analysis of 
the Nurses Health Study from the USA by Troisi et al showed that postmenopausal women 
who were never users of replacement hormones had a significantly lower age-adjusted risk 
of asthma than premenopausal women (relative risk: 0.65, 95%CI 0.46- 0.92) (R J Troisi et 
al., 1995). In the ECHRS, Real et al found that women not menstruating in the last 6 months 
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had significantly lower FEV, lower FVC values and more respiratory symptoms, especially in 
relation to allergy, than women of similar age menstruating regularly (Gomez Real, 2008). A 
systematic review and meta-analyses of available studies on the association between 
menopause and asthma showed no association overall but pointed to a higher risk in women 
who reported HRT intake (Zemp et al., 2012). 
Jarvis and Leynaert, in a cross-sectional analysis of data from the Health Survey for 
England, found that menstrual cessation due to surgery was associated with the reporting of 
wheeze (OR 1.55, 95% CI: 1.09-2.20) even if women denied ever using HRT (Jarvis and 
Leynaert, 2008).  
Concerning HRT intake, the literature shows puzzling results(Barr et al., 2004; Gomez Real, 
2008; Jarvis and Leynaert, 2008; Kos-Kudła et al., 2000, p.; Lange et al., 2001; R J Troisi et 
al., 1995): while studies dealing with asthma and respiratory symptoms report increased risks 
related to HRT, especially among nonsmokers and lean women (Real 2008), whereas those 
studying the impact of HRT intake on lung function indicate either a beneficial or at least a 
neutral association.  
So far, reproductive factors have only been investigated separately but underlying 
mechanisms remain unclear. Our hypothesis is that there may be pathological mechanisms 
leading to hormonal dysbalances underlying several reproductive conditions (such as 
irregular menses, PCOS, early menopause), or which may lead to higher cumulative 
estrogen or progesterone concentrations (as evidenced for early menarche (Apter et al., 
1989; Salam et al., 2006a) or the polycystic ovary syndrome [Shaw 2008]. There may also 
be other mechanisms playing a role as has been hypothesized from the findings that there is 
a higher role of obesity for asthma in women than in men (Appleton et al., 2006; Chinn et al., 
2006b). It is also derived from the findings that sex hormone levels vary according to 
metabolic situations (such as with obesity or with PCOS which is also a pathologic metabolic 
condition), and substantiated by findings on an interaction between HTR intake and obesity 
on asthma (F. G. Real et al., 2008). Also, evidence for a simultaneous role of obesity for 
hormonal states and for asthma stems for studies showing that obesity is more strongly 
related to non-allergic asthma than to allergic asthma (Leynaert et al., 2012). From these 
findings it can be derived that several reproductive conditions may be linked with hormonal or 
metabolic mechanisms which might underlie or contribute to their association with asthma. 
Therefore, studying not only the association of single but of a wider range of reproductive 
conditions over the reproductive life phase is of interest. A clearer understanding will facilitate 
preventive efforts to improve lung health among reproductive age women. 
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Making use of the on-going Swiss Cohort Study on Air Pollution and Lung and Heart 
Diseases in Adults (SAPALDIA), covering 20-years of longitudinal observation of a 
population aged 18-60 years at baseline, we tested the hypothesis that a history of 
reproductive pathologies across the reproductive life span has an impact on asthma 
incidence in women aged 18-60 years at baseline in Switzerland.  
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4.2 Methods 
4.2.1 Study design & population 
The “Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults” 
(SAPALDIA) (see appendix) was initiated in 1991 in eight geographically diverse areas in 
Switzerland (Aarau, Basel, Davos, Geneva, Lugano, Montana, Payerne, and Wald). A total of 
9,651 persons (51% female) aged 18-60, participated in the baseline study (SAPALDIA 1) 
after having been recruited through random population sampling. Re-assessments took 
place In 2002/2003 (SAPALDIA2, n= 8047) and in 2010/2011 (SAPALDIA 3, n=6088). 
Participants answered a detailed questionnaire and underwent health examinations including 
blood samples for serological tests and allergy skin testing. The protocol and participation 
rates have been described in further detail elsewhere (Ackermann-Liebrich et al., 
2005)(Martin et al., 1997). Starting in SAPALDIA 2 (S2) the Women's Health Questionnaire 
of the European Community Respiratory Health Study was introduced (The European 
Community Respiratory Health Survey II Steering, 2002) which included detailed questions 
on women’s reproductive histories.  
This analysis includes 2,977 women who reported no doctor-diagnosed asthma at baseline 
(S1), participated in and provided complete information on doctor-diagnosed asthma in the 
third follow up (S3) (Figure 1). Ethical approval was obtained from the Swiss Academy of 
Medical Sciences, the regional committees, and written informed consent was obtained from 
all participants.  
 
4.2.2 Definition of Asthma and Asthma Incidence 
The definition of asthma incidence used for this analysis was the 20-year cumulative 
incidence of doctor-diagnosed asthma from SAPALDIA1-3 (S1-S3) as used by (Hansen et 
al., 2015).  
4.2.3 Reproductive pathologies 
Up to 10 reproductive pathologies were investigated: early menarche, irregular menses, 
polycystic ovarian syndrome (PCOS), endometriosis, infertility, pregnancy complications, 
early menopause, surgical menopause, hysterectomy, and an indicator for pre-menstrual 
syndrome (PMS).  
Early menarche was defined based on self-reported age at menarche using the question 
‘how old were you when you had your first period?’ as asked in SAPALDIA 2 (2002/2003) or 
SAPALDIA 3 (2010/2011). Women who reported having their first period before the age of 12 
in either SAPALDIA 2 (S2) or SAPALDIA (S3) were considered as having early menarche. 
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Irregular menses was defined based on answers given to the question ‘Do you have regular 
periods?’ as asked in S2 and S3. Women who reported ‘No, my monthly period was never 
regular’ were considered as having irregular menses. 
PCOS was defined based on answers given to the question ‘Has a doctor or health 
professional ever told you have polycystic ovaries or polycystic ovarian syndrome (PCOS)?’ 
as asked in the S3 women’s health questionnaire. Women who answered ‘yes’ were 
considered as having PCOS. 
Endometriosis was defined primarily as a positive answer to the question in S3 ‘has a doctor 
or health professional ever told you have endometriosis?’ If women did not provide an 
answer to this question but reported endometriosis as reason for using oral contraceptives in 
S3 based on the question ‘which of the following reasons were the main reasons for taking 
the hormonal contraceptives’ were also considered as having endometriosis.  
Infertility was defined as a positive answer to the question asked in S3 ‘has a doctor or health 
professional ever treated you for infertility?  
Pregnancy complications were defined as having at least 1/5 of the following complications 
during pregnancy: hyperemesis, pre-eclampsia, glycosuria, gestational diabetes. Hypermesis 
was defined as a positive answer to the question asked in the S3 women’s module (for child 
1 - child 6): ‘Were you hospitalized because of nausea and /or vomiting (hyperemesis)?’ Pre-
eclampsia was defined as a positive answer to the following question (for child 1 - child 6): 
‘Did you have high blood pressure and/or protein in the urine (Pre-eclampsia)?’ Glycosuria 
(S3) was defined as a positive answer to the following question (for Child 1 - child 6): ‘Did 
you have sugar in urine (Glycosuria)?’ And finally, gestational diabetes was defined as a 
positive answer to the following question: Gestational diabetes (S3) (for child 1- child 6): ‘Did 
you develop diabetes in pregnancy?’ 
Early menopause was defined as either natural or surgical menopause at an age ≤ 45 years 
(Cao et al., 2015; Pikwer et al., 2012). Surgical menopause was defined based on the 
following two questions: S2 ‘How did your periods stop?’ and in S3 ‘What statement best 
describes the reason you have not had a period in the last 12 months?’. Those reporting 
‘surgery’ as an answer in S2 or reporting ‘hysterectomy (surgical removal of the uterus) or 
‘removal of the ovaries’ as a reason in S3 were considered as having had surgical 
menopause. 
Hysterectomy was defined primarily as a positive answer to the S3 question ‘Have you ever 
had a hysterectomy (your womb removed)?’ Women not giving an answer to this question 
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but giving hysterectomy as an answer to the following S3 question ‘What statement best 
describes the reason you have not had a period in the last 12 months?’ were also considered 
as having had a hysterectomy.  
PMS was defined based on Steiner et al.’s definition (2003), with the exception that we did 
not have information regarding severity of each symptom. Our definition was based on the 
following 6 symptoms: anger/irritability, anxiety or tension, tearfulness or increased sensitivity 
to rejections, feeling depressed or hopeless, difficulty with sleeping, abdominal pain and the 
following 3 interferences either at home or with work duties: interfered with work, sick from 
work, affected home duties. Our PMS indicator was defined as having at least 2/6 of 
symptoms & at least 1/3 interference with work or social role. 
4.2.4 Reproductive pathology scores 
From the above described reproductive pathologies we created two scores (Score 1 & Score 
2).  Score 1 included the following 10 reproductive pathologies: early menarche, irregular 
menses, PCOS, endometriosis, infertility, pregnancy complications, early menopause, 
surgical menopause, hysterectomy, and the PMS indicator. Score 1 was then categorized 
into three categories, never had any of the 10 reproductive pathologies, had 1 reproduvctive 
pathology, and having 2 or more pathologies. A second score was constructed  excluding 
menopause related variables as they occur at a later stage in a women’s life and might 
represent  processes differing from those occurring in the other reproductive conditions. 
Score 2 therefore comprised the following 7 pathologies: early menarche, irregular menses, 
PCOS, endometriosis, infertility, pregnancy complications, and the PMS indicator. Score 2 
was also categorized into three categories: having none of 7 reproductive pathologies, 
having had 1 reproductive pathology, and having had 2 or more pathologies.  
4.2.5 Age  
For the models, baseline age was used as a continuous variable (age in years). For the 
stratification by age, three different age categories were created: one with 3 categories 
approximately 15 years apart: ≤30 years, 31-45, >45-60, and two with 2 categories: 18-35 
and >35 (aiming at capturing the group where differences were largest with regard to atopic 
and non-atopic asthma), and 18-45 and >45 at baseline (aiming to capture women in their 
reproductive years). When creating the interaction terms, age was centered at the mean age 
of 41 years. This age centered variable was then used instead of the continuous age variable 
in the models using interaction terms.   
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4.2.6 Atopy 
Atopy was defined as a positive response to the skin prick test or Phadiatop test (Phadia, 
Uppsala, Sweden) at baseline. A positive skin prick test was indicated by an adjusted mean 
wheal diameter of ≥3mm to at least one of eight common allergens (grass, birch and 
Parietaria pollen, house dust mite, cat and dog epithelia and the moulds Alternaria and 
Cladosporium) (Martin et al., 1997)(Wüthrich et al., 1995). The Phadiatop test, an in vitro 
allergy screening test, detects the presence of specific serum IgE against 11 common aero-
allergens (Cladosporium, Dermatophagoides pteronyssinus., Dermatophagoides farinae, cat, 
dog, horse, birch, timothy grass [Phleum pratense], mugwort [Artemisia], olive, Parietaria 
judaica [spreading pellitory]. The percentage binding of the phadiatop was determined and 
results classified as positive or negative based on a cut-off of 0.35 kU/L (Merrett and Merrett, 
1987)(Wüthrich et al., 1995)(Martin et al., 1997). Atopic subjects with doctor-diagnosed 
asthma were considered as having allergic asthma.  
4.2.7 Further covariates 
Smoking status at baseline and S3 was categorized as never-smoker, former-smoker and 
current-smoker. Smoking status at S3 was defined in a cumulative way, never-smokers 
being consistent never smokers across all three surveys, current smokers being smokers at 
S3, and ex-smokers being people who were smokers at S1 and/or S2, but not at  S3. 
Education was categorized into primary education (low), secondary or middle school 
education (intermediate), and having a technical or university degree (high). For the 
descriptive tables, education at baseline was used. In the models, cumulative education, (the 
highest educational level reported at S1/S2), was used. Body mass index (BMI) at baseline 
was calculated as weight in kilograms, divided by the square of height in meters. For the 
interaction terms and models using interaction terms, BMI was centered at the mean of 23. 
Parental asthma was defined as a positive answer to the question ‘did one or both of your 
parents ever have asthma?’ Early life-respiratory infection was defined as a positive answer 
to the question ‘‘did you have a serious respiratory infection before the age of 5 years?’ 
Occupational exposure was defined as a positive answer to at least one of the items in the 
question ‘At your working place, are you currently exposed to dust, 
gas/smoke/aerosols/fumes/vapors?’ All of these covariates were selected based on literature 
findings. 
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4.2.8 Statistical analysis 
The 20-year cumulative incidence was calculated as the number of incident asthma cases at 
S2 or S3 in our sample divided by the size of the sample. The age-related probability of new 
onset of asthma was analyzed by logistic regression modeling, with the reproductive 
pathology scores as the exposure of main interest, and adjusting for BMI, parental asthma, 
early-life respiratory infection, occupational exposure and study area as reported at baseline, 
along with cumulative smoking and cumulative education as described above. We also ran 
our multivariate model using each of the 10 possible reproductive pathologies separately.  
We tested for the following interactions: In the model for early menarche, irregular menses 
and PCOS: early menarche and BMI, irregular menses and BMI, PCOS and BMI and early 
menopause and BMI using the centered BMI variable. For the models with score 2: score 2 x 
atopy, score 2 x age, score 2 x parity, score 2 x BMI>25, score 2 x BMI > 30.  
Analyses were also stratified by atopy and age in S1 to see whether the patterns of 
determinants differed in a similar way as was observed by Hansen et al (Hansen et al., 
2015).  
 
Furthermore, a sensitivity analysis was run using only SAPALDIA 3 (S3) variables to create 
the reproductive pathology variables and scores to see if estimates would change. 
All analyses were conducted using Stata V.12 (StataCorp LP, College Station, TX, USA). 
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4.3 Results 
4.3.1 Study Population 
Our study population consisted of 2,977 women who reported no doctor-diagnosed asthma 
at baseline (S1), provided complete information on doctor-diagnosed asthma and 
participated in the third follow up (S3) (Figure 4.1). The characteristics of the study 
population are given in table 4.1 and table 4.2.  
4.3.2 Cumulative asthma incidence 
Over 20 years of follow-up, 218 (7.3%) women newly reported doctor-diagnosed asthma.  
4.3.3 Reproductive pathology score 1 
The distribution of women reporting early menarche, irregular menses, PCOS, 
endometriosis, infertility, pregnancy complications, early menopause, surgical menopause, 
hysterectomy, and PMS (score 1) are presented in figure 4.2. A total of 1,710 (57.4%) 
women reported none of the above reproductive pathologies, 642 (21.6%) reported 1 of the 
above mentioned reproductive pathologies, and 625 (21%) women reported 2 or more of 
these reproductive pathologies (figure 4.2) 
The crude odds ratio (OR) for having 1 reproductive pathology using score 1 was 1.16 (95% 
CI 0.82 - 1.64) and 1.25 (95% CI 0.89 - 1.75) when having 2 or more reproductive 
pathologies. The adjusted OR for 1 reproductive pathology using score 1 was very similar, 
being 1.14 (95% CI 0.79 - 1.66) and 1.32 (95% CI 0.91 - 1.91) for 2 reproductive pathologies 
or more (table 4.3). In this model, age, atopy, former-smoker, BMI, parental asthma and 
occupational exposures were significant predictors of asthma incidence. The adjusted OR for 
age was 0.98 (95% CI (0.96 - 0.99). The adjusted OR for atopy was 2.28 (95% CI 1.69 - 
3.09). Former smokers had an OR of 1.45 (95% CI 1.05 - 2.02). The OR for BMI was 1.06 
(95% CI 1.02 - 1.10). The OR for parental asthma was 1.78 (95% CI 1.21 - 2.64) and finally 
the OR for occupational exposure was 1.52 (95% CI 1.08 - 2.14) (table 4.3) 
4.3.4 Reproductive pathology score 1 - stratified analysis 
 When stratifying by atopy, non-atopics having 1 reproductive pathology had an OR 1.12 
(95% CI 0.67 - 1.88) and those having 2 or more reproductive pathologies had an OR 1.43 
(95% CI 0 .87 - 2.33). Atopics on the other hand having 1 reproductive pathology had an OR 
1.23 (95% CI 0.71 - 2.12) and those having 2 or more reproductive pathologies had an OR of 
1.20 (95% CI 0.67 - 2.15). The only further covariate that remained significant in the model 
for non-atopics was BMI with an OR of 1.06 (95% CI 1.01 - 1.12).  The only further covariate 
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that remained significant in the model for atopics was parental asthma with an OR of 2.23 
(95% CI 1.29 - 3.87).  
 
When stratifying by age, those aged ≤30 years at baseline had a slightly higher odds ratio for 
asthma incidence than those aged 31-45 or >45 however insignificant across all models 
(table 4.3). Atopy remained a significant covariate in models for all three different age groups 
whereas current-smoker became significant in the model for ages 31-45, with an OR 2.17 
(95% CI 1.20 - 3.93) (table 4.3). Parental asthma only remained significant in the models for 
those aged above 30 (table 4.3). BMI only remained significant in the model for ages 31-45 
with an OR 1.09 (95% CI 1.03 - 1.16). Occupational exposure was no longer significant in the 
stratified models by age.  
4.3.5 Reproductive pathology score 2  
The distribution of women reporting early menarche, irregular menses, PCOS, 
endometriosis, infertility, pregnancy complications, and the PMS indicator (score 2) are 
presented in figure 6.3. A total of 2,320 (77.9%) women reported none of the above 
reproductive pathologies, 558 (18.7%) reported 1 of the above mentioned reproductive 
pathologies, and 99 (3.3%) women reported 2 or more of these reproductive pathologies 
(figure 4.3) 
As a sensitivity analysis we ran the same overall model and stratified by atopy and age but 
using score 2 (excluding menopause related variables). Results using score 2 remained 
insignificant and followed a similar pattern as when using score 1 (table 4.4). We also ran our 
model using score 2 with the following interaction terms: score*atopy, score*atopy in ages 
<45 and >45 at baseline, score2*age, score2*parity, score2*BMI>25, and score2*BMI>30, 
score2*BMI>30 in ages 45+ at baseline. None of these interaction terms were significant 
(data not shown). Furthermore we ran the adjusted analysis for score 1 and score 2 using 
SAPALDIA 3 variables only, which did not significantly change results (data not shown).  
4.3.6 Individual reproductive pathologies 
We furthermore ran our model using the individual 10 reproductive pathologies instead of the 
score (data not shown). None of the individual pathologies were significant except early 
menopause, showing an adjusted odds ratio of 1.73 (95% CI 1.21 - 2.49) (table 4.5).  
4.3.7 Individual reproductive pathologies - stratified analysis 
We also stratified these models by atopy and age. When stratifying by atopy, non-atopic 
women having early menopause had an adjusted OR of 2.13 (95% CI 1.33 - 3.42), whereas 
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the effect of early menopause in atopic women became insignificant, OR 1.29 (95% CI 0.72 - 
2.29). The univariate model for early menarche was OR 1.10 (95% CI 0.72 - 1.68) and in the 
adjusted model OR 0.89 (95% CI 0.55 - 1.46). The univariate model for irregular menses was 
1.06 (95% CI 0.55 - 2.06) and in the adjusted model OR 0.79 (95% CI 0.37 1.70). For early 
menopause the univariate model was an OR 1.59 (95% CI 1.15 - 2.21) and in the adjusted 
model OR 1.73 (1.21 - 2.49).  
4.3.8 Individual reproductive pathologies - interaction terms 
We also ran the individual model for early menarche and irregular menses using an 
interaction term for BMI. We found a significant interaction between BMI and early menarche 
(table 4.6) and BMI and irregular menses (table 4.7) in non-atopic women.  
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4.4 Discussion 
4.4.1 Main findings 
Over 20 years of follow-up, 218 (7.3%) women newly reported doctor-diagnosed asthma. 
Overall, 42.5% reported some kind of reproductive pathologies, 21% two or more conditions. 
We could not substantiate the hypothesis of an association between a history of reproductive 
pathologies and new onset of adult asthma: We found no significant association between our 
reproductive pathology score and development of new-onset of asthma in this female 
population aged 18-60 at baseline. However, when running our model with individual 
reproductive conditions, we found a significant association with early menopause and 
asthma incidence. We also found an interaction between early menarche and BMI, and 
between irregular menses and BMI in non-atopic women.  
4.4.2 Comparison with other studies 
Other studies have found a significant association with cumulative reproductive histories and 
cardiovascular health (Cao et al., 2015; de Kleijn et al., 1999, 1999), however to the best of 
our knowledge, this is the first study to investigate the association of cumulative reproductive 
histories and asthma incidence in adulthood. When combining up to 10 reproductive 
pathologies (score 1), we found a slightly higher risk of asthma incidence in women with ≥ 2 
pathologies, especially in the non-atopics and those aged ≤30, but results did not reach 
statistical significance. Although these findings did not reach statistical significance, the 
trends are what we would expect - that women’s risk of asthma would increase with 
increasing reproductive pathologies.  Furthermore, the stronger association of reproductive 
pathologies in those with non-allergic asthma is consistent with our previous study showing 
that women are more likely than men to have new-onset of asthma that is non-allergic in 
adulthood (Hansen et al., 2015). Perhaps new-onset of non-allergic asthma in women is 
partly explained by reproductive pathologies such as early menopause. The trend that the 
reproductive pathology score was strongest in those aged ≤30 when stratifying by age could 
indicate a certain amount of recall bias or potentially a cohort affect.   
When investigating individual reproductive factors, we found no significant association 
between early menarche and asthma incidence, OR 0.89 (95% CI 0.55 - 1.46). This is in 
contrast to other studies who have found a strong association between early menarche and 
asthma (Fida et al., 2012b; Lieberoth et al., 2015, 2012; Macsali et al., 2012, 2011a; Salam 
et al., 2006b; Varraso et al., 2005b). However our findings are somewhat in line with 
(Burgess et al., 2007; Wei et al., 2015). One possible reason that we may not find a 
significant association is that our study population was older (18-60 at baseline) than those in 
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other studies (Al-Sahab et al., 2011; Fida et al., 2012a; Lieberoth et al., 2015; Salam et al., 
2006a), implying a longer recall period for  the age of menarche. Another possible 
explanation might be that early menarche might be associated with an increased asthma risk 
for some limited years following menarche but not later on. We did however see a significant 
interaction between early menarche and BMI in non-atopic women. This is the first study to 
our knowledge which has investigated this interaction stratifying by atopy.  
Similarly we found no significant association between irregular menstruation and asthma 
incidence, OR 0.79 (95% CI 0.37 - 1.70). Previous studies by Real et al (2007) and Svanes 
et al (2005) found that women with irregular menstruation had an increased risk of new-onset 
of asthma (Svanes et al., 2005), decreased lung function, asthma symptoms, and current 
asthma (Real et al., 2007). However, in the study by Svanes et al (2005) the association was 
only significant in women 25-42 years (OR 1.58, 95% CI  1.03 – 2.42). In the age group 43-
54 years, the association was not significant (OR 0.62, 95% CI 0.32 – 1.18).  Women in our 
study were aged 28-70 years at S2 and 38-80 years at S3- the two time points where we 
gathered information about irregular menstruation.  When looking only at the older age 
group, our results are similar to those in the study by Svanes et al (Svanes et al., 2005).. 
Another potential explanation is that Real et al (2007) used the outcome of current asthma as 
defined by having an asthma attack in the last 12 months or currently taking asthma 
medication. They furthermore investigated asthma symptoms and lung function. In our study 
we looked at new onset of doctor-diagnosed asthma. It could be that irregular menstruation 
has more of an effect on current asthma than new-onset of asthma. Similarly, our definition 
of irregular menstruation slightly differed to that used by Real et al (2007). We categorized as 
having irregular menstruation if women said ‘no, my monthly period was never regular’ 
whereas Real et al (2007) also included women who reported ‘no, they have been irregular 
for a few months’ or women reporting intervals of more than 32 days. This more inclusive 
definition is also reflected in the percentage of women reporting irregular menstruation which 
was much higher in their study, ranging from 7.1% to 28%, whereas we only found 5%.  
As for early menopause, we found a significant association with asthma incidence, (OR 1.73, 
95% CI 1.21 - 2.49), which was most likely driven by the strong association in non-atopics, 
OR 2.13 (95% CI 1.33 - 3.42). Many previous studies have investigated the association 
between hormonal replacement therapy and asthma but only a few with the menopausal 
transition itself (Triebner et al., 2015; Zemp et al., 2012). In their systematic review and meta-
analysis, Zemp et al (2012) found no significant association with menopause and asthma 
prevalence or incidence except in women reporting use of menopausal hormone therapy 
(MHT). However this was based on a small number of studies, only 1 of which was a large 
cohort with incidence rates for pre-menopausal and post-menopausal women. In the more 
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recent longitudinal study by Triebner et al (2015), using data from the Respiratory Health in 
Northern Europe Survey, women who were in transitional, early postmenopausal, and late 
postmenopausal stages had an increased risk of new-onset asthma compared to non-
menopausal women. To the best of our knowledge, no studies have investigated the role of 
age at menopause and asthma incidence, nor have previous studies stratified by atopy. We 
found a significant association between early menopause and asthma incidence, which when 
stratified by atopy, remained significant only in the non-atopics which is in line with our 
previous study (Hansen et al., 2015) and studies which report total IgE to be lower in 
menopausal women (Siroux et al., 2004).  
4.4.3 Strengths and limitations 
The strengths of this study is its large database representing the general Swiss population 
from urban, rural and mountainous areas with different environmental exposure 
characteristics, with standardized health assessment  and a women’s health questionnaire 
that was developed alongside the ECHRS (Ackermann-Liebrich et al., 2005; The European 
Community Respiratory Health Survey II Steering, 2002).  
One limitation of this study is that while creating a reproductive pathology score including 
events over a women’s life time, it is not possible to have a homogenous study population. 
For example, in the study by Real et al (2007) on irregular menstruation and asthma, they 
excluded women older than 45 because menstrual irregularity in the perimenopausal 
transition. We could not do this in our study because our primary focus was the reproductive 
score over the whole reproductive life span including the menopausal transition. Real et al 
(2007) furthermore had excluded women using hormonal replacement therapy since the start 
of the survey, currently using oral contraceptives, pregnant women, or women having given 
birth in the past 6 months because these factors could influence the patterns of bleeding. 
Again we could not exclude these women. We can also not be sure that asthma cases 
always occurred after the exposure since the exposure included time points throughout 
women’s lives, from menarche to menopause. This may have blurred our association. It is 
also possible that with age reproductive pathologies are increasingly underreported, in which 
case we may have lost power to detect an association with asthma. This might indeed 
explain our null-finding which is in contrast to the findings in the younger ECRHS (and 
RHINE-9) population.  
Another potential limitation may be that our variables are a combination of questions asked 
at two different follow-up points- SAPALDIA 2 (2002/2003) and SAPALDIA 3 (2010/2011) 
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which could have led to a differential recall bias. However in our sensitivity analysis using 
only SAPALIDA 3 variables we did not observe a significant change in any of the OR.  
4.5 Conclusion 
Overall, we found no significant association between the number of reported reproductive 
pathologies and new-onset of asthma in this female population aged 18-60 at baseline. We 
did, however, find a significant association of early menopause and asthma incidence as well 
as a significant interaction between early menarche and irregular menses with BMI among 
non-atopic women. The role of hormonal factors for the etiology of asthma seems to differ for 
atopic and non-atopic women. The impact of early menarche and irregular menses appear to 
be modified by BMI. Further knowledge of respiratory health in women holds interesting 
potential for intervention. Further research should investigate the role of BMI and the 
interaction between BMI and hormonal factors in non-atopic women.  
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Figure 4.1: Study Population 
Diagram of initial population, the reasons for exclusion and the population included in 
the analysis 
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Table 4.1: General characteristics of study population 
 
(N=2977) 
 
 N % 
Age   
≤30  595 19.99 
31-45 1,244 41.79 
46-60 1,138 38.23 
   
   
Atopy 794 29.76 
   
Smoking   
Never-smoker 1,509 50.98 
Former-smoker 951 32.13 
Current-smoker 500 16.89 
   
BMI (mean) (SD) 22.81 (3.83) 
   
Parental asthma 332 11.16 
   
Early-life respiratory 
infection  
254 8.54 
    
Occupational exposure 600 20.26 
   
Education   
Low 459 15.45 
Intermediate 2,170 73.04 
High 342 11.51 
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Table 4.2: Reproductive characteristics of study population  
 
(N=2977) 
 
 N % 
   
Early menarche 333 12.26 
    
Irregular menses 123 4.93 
   
PCOS   26 1.88 
   
Endometriosis 41 2.99 
   
Infertility 52 3.63 
   
Pregnancy complication 146    9.62 
   
Early menopause 518 20.00 
   
Surgical menopause 537 27.40 
   
Hysterectomy 488 30.27 
   
PMS indicator 42 2.13 
   
   
History of Reproductive Pathologies and Adult-Onset of Asthma 
 
 
78 
 
Figure 4.2: Distribution of reproductive pathologies among women using score 1* 
 
 
 
 
 
 
 
 
 
 
 
 
*Score 1: having none of, 1 of or ≥2 of the following: early menarche, irregular menses, PCOS, endometriosis, infertility, 
pregnancy complications, early menopause, surgical menopause, hysterectomy, and the PMS indicator 
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Figure 4.2: distribution of reproductive pathologies among women using score 2* 
 
 
 
 
 
 
 
 
 
 
Score 2*: having none of, 1 of or ≥2 of the following early menarche, irregular menses, PCOS, endometriosis, infertility, 
pregnancy complications, and the PMS indicator 
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Variables Overall Model 
OR (95% CI)  
N=  2,629 
Non-Atopic 
OR (95% CI) 
N=  1,852 
Atopic 
OR (95% CI)  
N=777 
 Age ≤30 
OR (95% CI) 
N=520 
 
Age 31-45 
OR (95% CI) 
N=1,105 
Age 46+ 
OR (95% CI) 
N=1,004 
Score 1       
No pathology (reference) - - - - - - 
1 pathology 1.14 (0.79 - 1.66) 1.12 (0.67 - 1.88) 1.23 (0.71 - 2.12) 1.72 (0.89 - 3.29) 0.99 (0.54 - 1.83) 1.04 (0.50 - 2.19) 
2+ pathologies 1.32 ( 0.91 - 1.91) 1.43 (0 .87 - 2.33) 1.20 (0.67 - 2.15) 1.83 (0.79 - 4.25) 1.26 (0.70 - 2.27) 1.24 (0.66 - 2.33) 
       
Age (yrs.) 0.98  (0.96 - 0.99)   0.98 (0.96 - 1.00) 0.97 (0.95 - 0.99) 0.95 (0.87 - 1.03) 1.00 (0.94 - 1.05) 0.97 (0.91 - 1.03) 
       
Atopy 2.28 (1.69 - 3.09) - - 2.37 (1.34 - 4.21) 2.19 (1.34 - 3.56) 2.12 (1.20 - 3.74) 
       
Never-smoker (reference) - - - - - - 
Former-smoker 1.45 (1.05 - 2.02) 1.57 (0.99 - 2.48) 1.32 (0.81 - 2.16) 1.36 (0.72 -  2.57) 1.26 (0.71 - 2.23) 1.72 (0 .98 - 3.02) 
Current-smoker 1.14 (0.75 - 1.75) 1.71 (0.98 - 2.96) 0.67 (0.33 - 1.32) 0.53 (0.21 -  1.31) 2.17 (1.20 - 3.93) 0.41 (0.09 - 1.80) 
       
BMI 1.06 (1.02 - 1.10) 1.06 (1.01 - 1.12)  1.05 (0.98 - 1.12) 1.01 (0.92 - 1.11) 1.09 (1.03 - 1.16) 1.03 (0.95 - 1.11) 
       
Parental asthma 1.78 (1.21 - 2.64) 1.50 (0.84 - 2.68) 2.23 (1.29 - 3.87) 0.87 (0.34 - 2.22) 2.34 (1.31 -  4.18) 2.10 (1.05 - 4.23) 
       
Early-life respiratory infection 1.04 (0.81 - 1.33) 1.12 (0.78 - 1.60) 0.97 (0.68 - 1.38) 0.93 (0.50 - 1.75) 1.28 (0.81 - 2.00) 0.84 (0.59 - 1.19) 
       
Occupational exposure 1.52 (1.08 - 2.14) 1.56 (0.98 - 2.48) 1.45 (0.87 - 2.42) 1.56 (0.82 - 2.95) 1.38 (0.80 - 2.39) 1.46 (0.77 -  2.79)  
       
Intermediate education 
(reference) 
- - - - - - 
Low education  0.37 (0.17 - 0.79) 0.37 (0.13 - 1.04) 0.39 (0.13 - 1.16) 0.50 (0.06 - 4.14) 0.30 (0.07 - 1.35) 0.41 (0.15 - 1.12)   
Higher education 1.13 (0.78 - 1.62) 1.29 (0.77 - 2.14) 0.96 (0.56 - 1.63) 0.75 (0.37 - 1.52) 1.34 (0.77 - 2.34) 1.32 (0.64 - 2.73) 
 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting forage, atopy, cumulative smoking, BMI, parental asthma, early-life 
respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 4.3: Determinants of asthma incidence in women using score 1 stratified by atopic status and age at baseline 
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Variables Overall Model 
OR (95% CI)  
N=  2,629 
Non-Atopic 
OR (95% CI) 
N=  1,852 
Atopic 
OR (95% CI)  
N=777 
 Age ≤30 
OR (95% CI) 
N=520 
 
Age 31-45 
OR (95% CI) 
N=1,105 
Age 46+ 
OR (95% CI) 
N=1,004 
Score 2       
No pathology (reference) - - - - - - 
1 pathology 1.10 (0.76 - 1.58) 0.96 (0.57 - 1.64) 1.27 (0.75 - 2.15) 1.16 (0.60 - 2.25) 1.15 (0.65 - 2.04) 0.97 (0.45 - 2.09) 
2+ pathologies 1.10 (0.53 - 2.31) 1.24 (0.47 - 3.29) 1.08 (0.34 - 3.43) 1.36 (0.42 - 4.38) 1.39 (0.45 - 4.32) 0.41 (0.05 - 3.56)    
       
Age (yrs.) 0.98 (0.96 - 0.99) 0.98 (0.96 - 1.00) 0.97 (0.95 - 0.99) 0.95 (0.88 - 1.03) 1.00 (0.94 - 1.06) 0.97 (0.91 - 1.03) 
       
Atopy  2.27 (1.68 - 3.07) - - 2.40 (1.36 - 4.25) 2.17 (1.33 - 3.53) 2.15 (1.22 - 3.80) 
       
Never-smoker (reference) - - - - - - 
Former-smoker 1.45 (1.05 - 2.02) 1.55 (0.98 - 2.46) 1.33 (0.82 - 2.17) 1.38 (0.73 - 2.61) 1.27 (0.72 - 2.26) 1.73 (0.98 - 3.05) 
Current-smoker 1.15 (0.75 - 1.75) 1.69 (0.97 -  2.94) 0.68 (0.34 - 1.34) 0.59 (0.24 - 1.45) 2.18 (1.20 - 3.94) 0.41 (0.09 - 1.80) 
       
BMI 1.06 (1.02 - 1.10) 1.07 (1.01 - 1.12) 1.05 (0.98 - 1.12) 1.01 (0.92 - 1.11) 1.09 (1.03 - 1.16) 1.03 (0.96 - 1.12) 
       
Parental asthma 1.79 (1.21 - 2.64) 1.49 (0.83 - 2.66) 2.23 (1.29 - 3.87) 0.88 (0.35 - 2.24) 2.34 (1.31 - 4.18) 2.20 (1.09 - 4.43) 
       
Early-life respiratory infection 1.04 (0.81 - 1.34) 1.11 (0.78 - 1.59) 0.97 (0.68 - 1.37) 0.92 (0.50 - 1.70)   1.28 (0.82 - 2.02) 0.85 (0.60 - 1.21)   
       
Occupational exposure 1.54 (1.09 - 2.16) 1.58 (0.99 - 2.52) 1.46 (0.87 - 2.43) 1.63 (0.86 - 3.07) 1.37 (0.79 - 2.37) 1.48 (0.78 - 2.82) 
       
Intermediate education 
(reference) 
- - - - - - 
Low education  0.37 (0.17 - 0.78) 0.36 (0.13 - 1.03) 0.39 (0.13 - 1.17) 0.47 (0.06 - 3.88) 0.30 (0.07 - 1.34) 0.41 (0.15 -1.10) 
Higher education 1.12 (0.78 - 1.61) 1.27 (0.77 - 2.12) 0.96 (0.57 - 1.64) 0.75 (0.37 - 1.51) 1.34 (0.77 - 2.34) 1.36 (0.66 - 2.81) 
 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, atopy, cumulative smoking, BMI, parental asthma, early-life 
respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 4.4: Determinants of asthma incidence in women using score 2 stratified by atopic status and age at baseline 
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Variables Overall Model 
OR (95% CI)  
N=  2,310 
Overall Model with 
Interaction Term 
OR (95% CI) 
N= 2,310 
 
Non-Atopic 
OR (95% CI) 
N=  1,620 
Atopic 
OR (95% CI)  
N=690 
Non-Atopic with 
Interaction Term 
OR (95% CI) 
N= 1,620 
Atopic with Interaction 
Term 
OR (95% CI) 
N= 690 
Early menopause 1.73 (1.21 - 2.49) 1.73 (1.20 - 2.50) 2.13 (1.33 - 3.42) 1.29 (0.72 - 2.29) 2.12 (1.31 - 3.42) 1.29 (0.72 - 2.31) 
       
Age (yrs.) 0.98 (0.96 - 0.99) 0.98 (0.96 - 0.99) 0.99 (0.97 - 1.01) 0.97 (0.95 - 0.99) 0.99 (0.97 - 1.01) 0.97 (0.95 - 0.99) 
       
Atopy  2.53 (1.84 - 3.47) 2.55 (1.86 - 3.50) - - - - 
       
Never-smoker (reference) - - - -   
Former-smoker 1.38 (0.98 - 1.94) 1.37 (0.97 - 1.93) 1.62 (0.99 - 2.63) 1.16 (0.70 -1.91) 1.62 (1.00 - 2.64) 1.14 (0.69 - 1.89) 
Current-smoker 0.98 (0.62 - 1.55) 0.97 (0.61 - 1.53) 1.42 (0.77 - 2.62) 0.61 (0.30 - 1.24) 1.40 (0.76 - 2.58) 0.60 (0.29 - 1.23) 
       
BMI 1.04 (0.99 - 1.08) 1.03 (0.97 - 1.09) 1.02 (0.96 - 1.08) 1.05 (0.99 -1.13) 1.00 (0.92 - 1.09) 1.05 (0.98 - 1.14) 
       
Parental asthma 1.75 (1.16 - 2.64) 1.69 (1.12 - 2.55) 1.50 (0.81 - 2.80) 2.18 (1.24 - 3.83) 1.45 (0.78 - 2.72) 2.13 (1.20 - 3.76) 
       
Early-life respiratory infection 1.03 (0.80 - 1.34) 1.77 (1.07 - 2.93) 1.12 (0.76 - 1.63) 0.98 (0.68 - 1.40) 2.18 (1.14 - 4.16) 1.31 (0.58 - 2.95) 
       
Occupational exposure 1.59 (1.11 - 2.26) 1.54 (1.08 - 2.21) 1.73 (1.06 - 2.84) 1.47 (0.87 - 2.47) 1.68 (1.02 - 2.77) 1.44 (0.85 - 2.44) 
       
Intermediate education 
(reference) 
- - - - -  
Low education  0.40 (0.18 - 0.89) 0.41 (0.18 - 0.91) 0.33 (0.10 - 1.12) 0.46 (0.15 - 1.40) 0.35 (0.10 -1.17) 0.46 (0.15 - 1.41) 
Higher education 1.16 (0.80 - 1.70) 1.15 (0.79 - 1.68) 1.29 (0.75 - 2.21) 1.05 (0.61 - 1.81) 1.25 (0.73 - 2.15) 1.04 (0.61 - 1.80) 
       
Early menopause*BMI - 1.02 (0.94 - 1.11) - - 1.04 (0.93 - 1.17) 1.00 (0.88 - 1.14) 
       
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for, age, atopy, cumulative smoking, BMI, 
parental asthma, early-life respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 4.5: Determinants of asthma incidence in women with early menopause stratified by atopic status at baseline with interaction 
term for BMI 
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Variables Overall Model 
OR (95% CI)  
N=  2,419 
Non-Atopic 
OR (95% CI) 
N= 1,705  
Atopic 
OR (95% CI)  
N=714 
 Age ≤30 
OR (95% CI) 
N=476 
 
Age 31-45 
OR (95% CI) 
N=1,017 
Age 46+ 
OR (95% CI) 
N=926 
Early menarche 0.89 (0.55 - 1.46) 0.60 (0.26 - 1.37) 1.20 (0.63 - 2.25)   1.20 (0.54 - 2.69) 0.59 (0.26 -1.34) 1.19 (0.50 - 2.87) 
       
Age (yrs.) 0.98 (0.96 - 0.99) 0.99 (0.97 - 1.01) 0.97 (0.95 - 0.99) 0.98 (0.90 - 1.06) 0.98 (0.93 - 1.04) 0.96 (0.90 - 1.03) 
       
Atopy  2.48 (1.81 - 3.39) - - 2.93 (1.60 - 5.36) 2.26 (1.37 - 3.74) 2.50 (1.39 - 4.48) 
       
Never-smoker (reference) - - - - - - 
Former-smoker 1.39 (0.99 - 1.96) 1.61 (0.99 - 2.62) 1.18 (0.71 - 1.94) 1.45 (0.74 - 2.81) 1.26 (0.70 - 2.26) 1.47 (0.82 - 2.66) 
Current-smoker 1.14 (0.74 - 1.77) 1.78 (0.99 - 3.19) 0.66 (0.33 - 1.33)   0.48 (0.18 - 1.28)   2.26 (1.23 - 4.15) 0.43 (0.10 - 1.90)   
       
BMI 1.03 (0.97 - 1.08) 1.00 (0.93 - 1.07) 1.05 (0.97 - 1.13) 0.98 (0.88 - 1.09) 1.11 (1.05 - 1.18) 0.10 (0.92 - 1.08) 
       
Parental asthma 1.71 (1.14 - 2.58) 1.47 (0.79 - 2.72) 2.18 (1.23 - 3.85) 1.02 (0.39 - 2.63) 2.11 (1.15 - 3.88) 2.04 (0.98 - 4.24) 
       
Early-life respiratory infection 1.04 (0.81 - 1.34) 1.09 (0.75 - 1.58) 0.99 (0.70 - 1.42) 0.96 (0.50 - 1.83) 1.28 (0.81 - 2.02) 0.82 (0.57 - 1.18) 
       
Occupational exposure 1.60 (1.13 - 2.28) 1.74 (1.07 - 2.83)    1.48 (0.88 - 2.49) 1.71 (0.88 - 3.31) 1.45 (0.82 - 2.55) 1.45 (0.74 - 2.85) 
       
Intermediate education 
(reference) 
- - - - - - 
Low education  0.40 (0.18 - 0.91) 0.36 (0.11 - 1.20) 0.45 (0.15 - 1.37) 0.90 (0.10 - 8.35) 0.32 (0.07 - 1.49)  0.39 (0.13 - 1.16) 
Higher education 1.12 (0.77 - 1.62) 1.23 (0.72 - 2.09) 1.01 (0.59 - 1.73) 0.71 (0.34 - 1.49)   1.45 (0.82 - 2.56) 1.27 (0.61 -  2.66) 
       
Early menarche*BMI 1.07 (0.98 - 1.18) 1.15 (1.01 - 1.31) 1.01 (0.87 - 1.16) - - - 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, atopy, cumulative smoking, BMI, parental asthma, early-life 
respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 4.6: Determinants of asthma incidence in women using early menarche stratified by atopic status and age at baseline with 
interaction term for BMI 
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Variables Overall Model 
OR (95% CI)  
N=  2,237 
Non-Atopic 
OR (95% CI) 
N= 1,564 
Atopic 
OR (95% CI)  
N=673 
 Age ≤30 
OR (95% CI) 
N=474 
 
Age 31-45 
OR (95% CI) 
N=966 
Age 46+ 
OR (95% CI) 
N=797 
Irregular menses 0.79 (0.37 - 1.70)  0.63 (0.19 - 2.14) 0.99 (0.35 - 2.82) 0.89 (0.29 - 2.79) 0.91 (0.31 - 2.73) 0.80 (0.08 - 7.88) 
       
Age (yrs.) 0.98 (0.97 -  1.00) 0.99 (0.97 - 1.02) 0.97 (0.95 - 0.99) 0.98 (0.90 - 1.06) 0.98 (0.92 - 1.04) 0.97 (0.90 - 1.04) 
       
Atopy  2.51 (1.82 -  3.46) - - 2.97 (1.62 - 5.44) 2.38 (1.42 - 3.99) 2.36 (1.28 - 4.36) 
       
Never-smoker (reference) - - - - - - 
Former-smoker 1.40 (0.99 - 1.99) 1.66 (1.01 - 2.74) 1.22 (0.73 - 2.03) 1.41 (0.72 - 2.74) 1.34 (0.74 - 2.43) 1.47 (0.79 - 2.71) 
Current-smoker 1.06 (0.67 - 1.68) 1.64 (0.89 - 3.03) 0.61 (0.30 - 1.26) 0.47 (0.18 - 1.26) 2.00 (1.06 - 3.78) 0.43 (0.10 - 1.91) 
        
BMI 1.03 (0.98 - 1.08) 1.00 (0.94 - 1.07) 1.06 (0.99 - 1.13) 0.98 (0.88 - 1.09)    1.09 (1.02 - 1.15) 0.98 (0.91 - 1.08) 
       
Parental asthma 1.60 (1.05 - 2.45) 1.26 (0.65 - 2.44) 2.20 (1.23 - 3.94) 0.99 (0.38 - 2.57) 1.90 (1.01 - 3.60) 1.98 (0.93 - 4.25) 
       
Early-life respiratory infection 1.08 (0.82 - 1.43) 1.11 (0.75 - 1.63) 1.10 (0.74 - 1.63) 0.96 (0.50 - 1.82) 1.28 (0.79 - 2.07) 0.92 (0.61 - 1.38) 
       
Occupational exposure 1.66 (1.16 - 2.38) 1.82 (1.10 - 2.99) 1.56 (0.92 - 2.64) 1.72 (0.89 - 3.32) 1.61 (0.91 - 2.87) 1.62 (0.81 - 3.22) 
       
Intermediate education 
(reference) 
- - - - - - 
Low education  0.35 (0.14 - 0.84) 0.19 (0.04 - 0.95) 0.49 (0.16 -1.51)   0.86 (0.10 - 7.73) 0.19 (0.02 - 1.50) 0.44 (0.15 -1.35) 
Higher education 1.13 (0.77 - 1.65) 1.32 (0.77 - 2.25) 0.95 (0.55 - 1.66) 0.71 (0.34 - 1.48) 1.47 (0.82 - 2.61) 1.33 (0.62 -2.89) 
       
Irregular menses*BMI 1.13 (0.97 - 1.31) 1.26 (1.06 - 1.51) 0.90 (0.67 - 1.21) - - - 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, atopy, cumulative smoking, BMI, parental 
asthma, early-life respiratory infection, occupational exposure, cumulative education and study area.  Bold indicates significance at p ≤0.05. 
Table 4.7: Determinants of asthma incidence in women using irregular menses stratified by atopic status and age at baseline with 
interaction term for BMI 
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Abstract  
The association between early menarche and new-onset of asthma warrants further 
investigation in those aged > 30 years.  
Using data from the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in 
Adults (SAPALDIA), we investigated whether early menarche was associated with new-onset 
of asthma in women aged 18-60 years at baseline. 
Our analysis included 2,492 women with information on age at menarche and doctor-
diagnosed asthma, who were asthma free at time of menarche and had complete covariate 
information. New-onset of asthma was defined as newly reported doctor-diagnosed asthma 
which occurred at least one year after menarche. Asthma incidence and its association with 
early menarche was analysed using logistic regression adjusting for age, atopy, smoking, 
BMI, parental asthma, urbanity, education and study area, and additionally stratifying by 
atopy and BMI.  
After adjustment of relevant confounders, women with early menarche did not have a 
significantly higher risk of asthma-onset than women without early menarche (OR 1.23, 95% 
CI 0.85 - 1.80). Young atopic women with early menarche appeared to have an increased 
risk of asthma-onset compared to non-atopic women (OR 2.21, 95% CI 0.90 - 5.43); however 
our results did not reach statistical significance. 
We could not substantiate an association of early menarche with new-onset of asthma in this 
Swiss population-based cohort aged 18-60 years at baseline. Future studies may need to 
prospectively assess age of menarche to investigate the association with new-onset of 
asthma in those aged > 30 years. 
Keywords:  menarche, incidence, asthma, Switzerland  
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5.1 Introduction  
The gender-related life-course pattern of asthma is characterised by higher incident rates in 
boys than girls, followed by a female preponderance in early and middle-adulthood (Eagan et 
al., 2005; Hansen et al., 2015). Because this switch takes place around puberty, hormonal 
factors have been suggested as one possible explanatory pathway. Observations of 
increasing asthma incidence and decreasing age at menarche, have led investigators to 
hypothesize potential associations of age at menarche with incident asthma.  
Studies have consistently found an association between early menarche and new-onset of 
asthma (Lieberoth et al., 2014), at least in young adulthood. The cause for the observed 
association between early menarche and asthma is poorly understood. Some suggest that it 
could reflect  genetic and early life environment as the timing of both events are affected by 
early life factors, or that menarche itself might induce immunological and hormonal changes 
as well as changes in airway function (Lieberoth et al., 2015). Higher levels of leptin and 
increased insulin resistance in women with early menarche may influence inflammation and 
innate immunity, potentially contributing to higher risk of asthma (Bouloumie et al., 1999; 
Jartti et al., 2009). Animal studies have provided evidence that estrogen and progesterone 
have effects on humoral and cellular immunity and smooth muscle function (Wei et al., 
2015). Therefore, hormonal factors might be expected to be associated with the clinical 
occurrence of asthma in humans.  
What remains unclear is whether the observed association between early menarche and 
asthma, also holds for older adulthood. With the exception of five studies (Fida et al., 2012a; 
Gnatiuc et al., 2013; Jartti et al., 2009; Lieberoth et al., 2015; Macsali et al., 2011a), the 
association between early menarche and asthma incidence has not been investigated in 
adults > 30 years. Lieberoth et al (2015)(Lieberoth et al., 2015) found a significant 
association in women aged 12-41 years, Macsali et al. (2011)(Macsali et al., 2011a) in 
women aged 27-57 years, and Fida et al (2012)(Fida et al., 2012a) in women aged 18-35 
years. However, in the study by Gnatiuc et al (2013) (Gnatiuc et al., 2013) they did not find a 
significant association between early menarche and asthma at age 33 and neither did Jartti 
et al (2009) (Jartti et al., 2009) in women at ages 24-39 years. The association between early 
menarche and new-onset of asthma warrants further investigation in those aged > 30 years.  
 
Making use of the on-going Swiss Cohort Study on Air Pollution and Lung and Heart 
Diseases in Adults (SAPALDIA), (Ackermann-Liebrich et al., 2005; Martin et al., 1997), we 
investigated whether early menarche was associated with new-onset of asthma in women 
aged 18-60 at baseline.  
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5.2 Methods 
5.2.1 Study design & population 
The “Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults” 
(SAPALDIA) (see appendix 1) was initiated in 1991 (SAPALDIA 1 [S1]) in eight 
geographically diverse areas in Switzerland, recruiting 9,651 participants (51% female) aged 
18-60 at baseline through random population sampling. Re-assessments took place in 
2002/2003 (SAPALDIA2 [S2], n=8047) and in 2010/2011 (SAPALDIA3 [S3], n=6088). The 
protocol and participation rates have been described elsewhere (Ackermann-Liebrich et al., 
2005)(Martin et al., 1997). Starting in SAPALDIA 2, the Women's Health Questionnaire of the 
European Community Respiratory Health Study was introduced (The European Community 
Respiratory Health Survey II Steering, 2002) which included detailed questions on women’s 
reproductive histories. This analysis includes 2,492 women who provided retrospective 
information on age at menarche in either S2 or S3, provided information on doctor-diagnosed 
asthma in at least S1, S2 or S3, reported asthma-onset after menarche, and had complete 
covariate information (Figure 5.1). Ethical approval was obtained from the Swiss Academy of 
Medical Sciences, the regional committees, and written informed consent was obtained from 
all participants. 
 
5.2.2 Definition of Asthma and Asthma Incidence 
New-onset of adult asthma was defined as newly reported doctor-diagnosed asthma at 
baseline or follow-up which occurred at least one year after reported age at menarche. 
Doctor diagnosed asthma was defined as a positive answer to both questions ‘have you ever 
had asthma?’ and ‘was this confirmed by a doctor?’ For the purpose of sensitivity analyses, 
two additional definitions of asthma were created: a) self-report only and b) doctor-diagnosed 
asthma with current medication. 
5.2.3 Definition Early Menarche 
The primary definition of early menarche used for our analysis, as also defined in other 
studies (Gnatiuc et al., 2013; Lieberoth et al., 2015; Salam et al., 2006a), was menarche < 12 
years. If age of menarche was reported < 12 years in S2 or S3, then the individual was 
considered as having early menarche. For the purpose of  sensitivity analyses, three further 
definitions were created based on other literature findings (Table 5.1): age at menarche 1 
standard deviation (SD) less than the mean (Al-Sahab et al., 2011; Fida et al., 2012a; Wei et 
al., 2015), age at menarche 2 SD less than the mean (Burgess et al., 2007; Varraso et al., 
2005a), and finally age at menarche 1 SD less than the language region specific mean 
(German, French and Italian), based on findings by Dratva et al (2007) that age at menarche 
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differs in these three Swiss language regions (Dratva et al., 2007). Additionally, we grouped 
early menarche into a categorical variable of whole years and compared the risk of new-
onset of asthma in women with menarche at 10 years to women with menarche at the mean 
age of menarche, as done by Macsali et al (2011)(Macsali et al., 2011b). 
5.2.4 Atopy & BMI 
Atopy was defined as a positive response to the skin prick test or Phadiatop test (Phadia, 
Uppsala, Sweden) at baseline. Allergically sensitised subjects with doctor-diagnosed asthma 
were considered as having allergic asthma. Body mass index (BMI) at baseline was 
calculated as weight in kilograms, divided by the square of height in meters. For the 
descriptive tables and stratification by BMI, 3 categories were created according to the WHO 
cut off points (47) for underweight (BMI <18.50), normal weight (BMI 18.50-24.99), and 
overweight/obese (BMI >=25.00).  
5.2.5 Further covariates 
Smoking status at baseline and S3 were categorized as never-smoker, former-smoker and 
current-smoker. Smoking status at S3 was defined in a cumulative way, never-smokers 
being consistent never smokers across all three surveys, current smokers being smokers at 
S3, and ex-smokers being people who were smokers at S1 and/or S2, but not at  S3. 
Education was categorized into primary education (low), secondary or middle school 
education (intermediate), and having a technical or university degree (high). For the 
descriptive tables and models, cumulative education, (the highest educational level reported 
at S1/S2), was used. Parental asthma was defined as a positive answer to the question ‘did 
one or both of your parents ever have asthma?’ Urbanity was defined as residing in the 
following study areas: Basel, Lugano, Aarau or Geneva. All of these covariates were 
selected based on literature findings. 
 
5.2.6 Statistical analysis 
Asthma incidence and its association with early menarche was analysed using logistic 
regression adjusting for age (S1), atopy (S1), cumulative smoking (S1-S3), BMI (S1), 
parental asthma (S1), urbanity (S1), cumulative education (S1-S3) and study area (S1) as 
described above. Based on a priori reasons (Castro-Rodriguez, 2016; Gemelli et al., n.d.; 
Gnatiuc et al., 2013; Hansen et al., 2015; Hong et al., 2014; Varraso et al., 2005b) we 
additionally stratified our analysis by atopy and BMI to see whether the patterns of 
determinants differed.  
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We conducted several sensitivity analyses. Firstly, to make our results comparable to other 
studies, we ran our analysis using three different early menarche definitions (table 5.1) and in 
addition, grouped early menarche into a categorical variable of whole years as done by 
Macsali et al (2011)(Macsali et al., 2011b). 
Secondly, to assess whether early menarche might be associated with an increased asthma 
risk only for some limited years following menarche, we split occurrence of asthma into 3 
groups: asthma occurring a) 1-3 years after menarche b) 4-10 years after menarche and c) 
more than 10 years after menarche.  
Thirdly, to address the validity of recalled age of menarche, we restricted our analysis to 
those aged ≤30 years at baseline and also ran our analysis using information on age at 
menarche from S2 only- the earliest time point at which participants gave information on age 
at menarche. Furthermore, we analysed whether report of age at menarche differed with 
increasing time since menarche, calculating the Kappa statistic for agreement between 
reported age at menarche in S2 and S3 overall, as well as between the three created age 
groups at baseline (≤30, 31-45, 46-60).  
Fourthly, to address potential inconsistent reporting in age at menarche between the two 
surveys, we ran our analysis excluding women reporting early menarche only in one follow-
up, as well as running our analysis excluding women who reported a difference in age of 
menarche in the two follow-ups of ≥1 year and ≥2 years. 
Finally, to account for potential bias due to loss to follow up, models were furthermore run 
with inverse probability weighting and in addition, excluding covariates with the largest 
amount of missing information 
All analyses were conducted using Stata V.12 (StataCorp LP, College Station, TX, USA). 
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5.3 Results 
5.3.1 Study Population 
Our study population consisted of 2,492 women who provided information on age at 
menarche and doctor-diagnosed asthma, reported onset of asthma after menarche, and had 
complete covariate information (Figure 5.1). The characteristics of the study population as 
well as of women excluded from the analyses are given by age at menarche in table 5.2. In 
our study population women with early menarche tended to be younger, atopic, and live in an 
urban environment. Women with early menarche who were excluded from our study, tended 
to be living in an urban environment, but did not significantly differ on other covariates.  
5.3.2 Age at menarche & new-onset of asthma  
The mean age at menarche was 13.5 years overall, varying from 13.1 years in the Italian 
language region, to 13.3 years in the French and 13.7 years in the German language region. 
300 (12.0%) women reported age at menarche < 12 years at either S2 or S3. The 
percentage of women defined as having early menarche was considerably lower for the 
definition of <2SD of mean age (2.3%). The highest percentage was seen when using 1SD 
below language region specific mean (19.1%). The percentage of women presenting new-
onset of asthma at least 1 year after menarche was 10.0%.  
5.3.3 Determinants of asthma incidence 
The crude odds ratio (OR) for asthma incidence in women with menarche <12 years 
compared to women with menarche ≥12 years was 1.50 (95% CI 1.05 - 2.15). In the fully 
adjusted analysis, the OR for early menarche was 1.23 (95% CI 0.85 - 1.80) (table 5.3). To 
examine why our crude OR became statistically insignificant in our fully adjusted model, we 
added our covariates in a stepwise manner (table S5.3a/S5.3b), selecting the order of 
variables for a priori reasons. The addition of urbanity, study area, BMI and atopy into our 
model decreased the odds ratio and the OR became statistically non-significant when 
entering study area. 
5.3.4 Stratified Analysis 
When stratifying by atopy (figure 5.2), non-atopic women with menarche <12 years had an 
OR for new-onset of asthma of 1.11 (95% CI 0.63 - 1.95), whereas atopic women had a OR 
of 1.36 (0.81 - 2.27).  
When stratifying by BMI categories (figure 5.2), estimates for asthma-onset in 
overweight/obese women with early menarche were slightly higher (OR 1.51, 95% CI 0.76 – 
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3.00) than in normal weight women (OR 1.27, 95% CI 0.80 - 2.02), though CI’s were 
overlapping. Underweight women had an OR 0.45 (95% CI 0.32 - 6.27), however the wide 
and overlapping CI’s indicate a lack in power.  
5.3.5 Sensitivity Analysis 
Running analyses with varying definitions of asthma did not change results (data not shown). 
When running the overall model using varying definitions of early menarche, the OR for 
asthma incidence in those having early menarche did not change much, varying from 1.23 
(95% CI 0.85 - 1.80) to 1.25 (95% CI 0.90 - 1.73) (table 5.3). When grouping early menarche 
into a categorical variable of whole years and comparing the risk of new-onset of asthma in 
women with menarche at 10 years to women with menarche at the mean age of menarche, 
as done by Macsali et al (2011b), did not change results (data not shown).  
When splitting occurrence of asthma into 3 groups: results did not change nor reach 
statistical significance. The OR for asthma-onset occurring 1-3 years after menarche was 
1.61 (95% CI 0.52 - 4.99) and 1.22 (95% CI 0.81 - 1.85) 10 years after menarche. 
When restricting our analysis to those ≤30 years at baseline, we found a higher OR for 
asthma incidence in those with early menarche, especially in the area specific definition (OR 
1.63 (95% CI 0.84 - 3.15) (table S5.1). When running our stratified analysis by atopy and BMI 
in those age <30 years at baseline we saw an increase in the OR for asthma incidence in 
young atopic women (OR 2.21, 95% CI 0.90 - 5.43) (table 5.4). When defining early 
menarche using S2 information only, we found a slightly lower OR (1.13 (95% CI 0.75 - 1.72) 
for asthma incidence in those with early menarche compared to our definition using S2 or S3 
information (table S5.2). 
The kappa statistic for agreement between reported age at menarche at S2 and S3 overall 
was 0.46. In those ages ≤30 years at baseline the kappa statistic for agreement for reported 
age at menarche between S2 and S3 was 0.49, and 0.46 in those aged 31-45 years, and 
0.46 in those aged 46-60 years at baseline. Results did not differ (data not shown) when 
excluding women reporting early menarche only in S2 or S3 (N=107), nor when running our 
analysis excluding women who reported a difference in age of menarche in the two follow-
ups of ≥1 year (N=374) or ≥2 years (N=85). 
To account for potential bias in loss to follow up inverse probability weighting was done 
which yielded largely the same results (data not shown). In addition, when excluding 
covariates with the most amount of missing information (smoking N=559, education N=547, 
atopy N=335), associations stayed similar (data not shown). 
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5.4 Discussion 
5.4.1 Main findings 
In our population-based cohort, 250 (10.0%) women newly reported doctor-diagnosed 
asthma at least one year after menarche. In our fully adjusted analysis, we could not 
substantiate an association between early menarche and new-onset of asthma in women 
aged 18-60 years at baseline. Young atopic women with early menarche appeared to have 
an increased risk of asthma-onset (OR 2.21, 95% CI 0.90 - 5.43) (table 5.4), although the 
association was not statistically significant.  
This study is among the few to investigate the impact of early menarche on on asthma 
incidence in women in later adulthood.  
5.4.2 Comparison with other studies 
Most recently in the review by Lieberoth et al. (2014), they found a pooled OR of 1.37 (95% 
CI 1.15 - 1.64) for new-onset of asthma among women with menarche before the age of 12.  
However, the majority of studies included in this review who found a significant association of 
early menarche with asthma incidence, only followed-up women to the age of 30 years (Al-
Sahab et al., 2011; Herrera-Trujillo et al., 2005; Salam et al., 2006a; Xu et al., 2000). With 
the exception of five studies (Fida et al., 2012a; Gnatiuc et al., 2013; Jartti et al., 2009; 
Lieberoth et al., 2015; Macsali et al., 2011b), early menarche and asthma incidence has not 
been investigated in adults > 30 years. From these five studies, three found a significant 
association of early menarche with asthma (Fida et al., 2012a; Lieberoth et al., 2015; Macsali 
et al., 2011b) whereas two did not (Gnatiuc et al., 2013; Jartti et al., 2009). , Lieberoth et al 
(2015), in ages 12-41 years,  found the eight-year cumulative incidence of asthma was 
higher in girls with early menarche compared to girls without early menarche, (OR 1.53 (95% 
CI 1.15 - 2.04)). In the Omega study, Fida et al (2012a), in ages 18-35 years, found that 
women who had early menarche (<12 years old) had a 60% higher risk of being diagnosed 
with adult asthma as compared with women who did not have early menarche  (aRR 1.59, 
95% CI 1.19 - 2.13). Macsali et al (2011b), in ages 27-57 years, found that women with early 
menarche had lower lung function and more asthma in adulthood. In contrast, Jartii et al 
(2009) did not find early menarche to be associated with asthma at ages 24-39 years, and 
neither did Gnatiuc et al (2013) at age 33. 
Similar to Jartti et al (2009) and Gnatuic et al  (2013), we did not see a significant association 
between early menarche and new-onset of asthma in our study population aged 18-60 at 
baseline. Jartii et al (2009), who also had a slightly older study population (24-39 years) 
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reported that age at menarche was not associated with prevalent asthma among 
participants, so possibly older age partly explains our findings. One possible reason that we 
may not find a significant association is that our study population was older (18-60 at 
baseline), implying a longer recall period for the age of menarche. However, when restricting 
our analysis to those aged ≤30 years at baseline, although the OR for asthma incidence in 
women with early menarche slightly increased, it still did not reach statistical significance 
(table S1 in online supplement). To try to account for potential recall bias we also restricted 
our analysis to using S2 information only (the earliest time point when participants gave 
information on menarche). However, the OR for asthma incidence in women with early 
menarche actually slightly decreased (table S5.2).  
 
We saw a tendency  among young atopic women with early menarche to have increased risk 
of asthma-onset, which is consistent with, and may partly explain, our previous findings 
(Hansen et al., 2015) that young atopic women have the highest risk of newly developing 
asthma after the age of 18 (OR 3.21, 95% CI 2.12 – 4.85).  To the best of our knowledge, 
other studies have not taken atopy into account when investigating the association with early 
menarche and asthma incidence. If atopy was more prevalent in other study populations, we 
cannot exclude that this might have increased their probability to find an association. 
Furthermore, if atopic women are aware of their asthma risk, and they are also more 
overweight (associated with earlier age at menarche); they may have more complaints when 
asthma develops and may tend to visit the doctor earlier. 
 
5.4.3 Strengths and limitations 
The strengths of this study is its large database representing the general Swiss population 
from urban, rural and mountainous areas with different environmental exposure 
characteristics, with standardised health assessment  and a women’s health questionnaire 
that was developed alongside the ECHRS (Ackermann-Liebrich et al., 2005; The European 
Community Respiratory Health Survey II Steering, 2002). .  
A limitation of this study is that women were 18-60 years at baseline and therefore had to 
recall their age at menarche and age of first asthma attack retrospectively. This may have 
introduced some recall bias (Must et al., 2002) as possibly reflected in the insignificant odds 
ratios and moderate agreement between reported age at menarche in the two surveys (S1 & 
S2). We observed that 107 (14%) women reported early menarche only once in the two 
follow-up periods. Although analyses excluding these women did not change our results, we 
believe that this non-differential misclassification may have biased our associations towards 
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the null. This is also consistent with our finding that we had a higher kappa statistic for 
agreement and slightly higher odds ratios in those ages ≤30 years at baseline. Although 
studies looking at recall of early menarche have generally found a quite good correlation 
between recoded and recalled menarche in women both close to and distant from the event 
(Casey et al., 1991; Must et al., 2002), future studies may need to prospectively follow girls 
from the time of their transition into puberty up to adulthood to really assess whether early 
menarche is also a risk factor for asthma developing in later adulthood. Another limitation is 
that BMI at baseline was used which does not take into account BMI at menarche nor 
adiposity.  
5.4.4 Conclusion 
In this Swiss population-based cohort we could not substantiate an association between 
early menarche and asthma-onset in women aged 18-60 years at baseline. Future studies 
may need to prospectively assess the age of menarche and - besides assessing BMI or 
more appropriate measures of adiposity - take into account atopic status.  
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Figure 5.1: Study Population 
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Figure 5.2: Associations of early menarche and asthma incidence in analyses stratified 
by atopy and BMI 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI) for early menarche (age at menarche <12 years of age as 
reported in SAPALDIA 2 or SAPALDIA 3).  
Stratified models for non- atopic/ atopic: based on logistic regression adjusting for age, cumulative smoking, BMI, parental asthma,, 
urbanity, cumulative education and study area 
Stratified models for underweight/normal weight/overweight/obese: based on logistic regression adjusting for age, atopy, cumulative 
smoking, parental asthma,, urbanity, cumulative education and study area 
Underweight (BMI < 18.5), normal weight (BMI 18.50 – 24.99), overweight/obese (BMI ≥25 ) 
Interaction models: based on logistic regression adjusting for age, atopy, cumulative smoking, parental asthma, urbanity, cumulative 
education and study area. Results of the interaction terms early menarche x atopy and early menarche x BMI are displayed 
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Table 5.1: Definitions of Early Menarche 
 
 
  
Short Name Definition Literature with same definition 
Early menarche < 12 years Lieberoth et al (2014) 
Gnatiuc et al 2013 (2013) 
Salam et al (2006a)  
Early menarche 1SD 1 SD < mean Wei et al (2015) 
Fida et al (2012a) 
Al-Sahab (2011)  
 
Early menarche 2SD 2 SD < mean Varraso et al (2005a)  
Burgess et al (2007)  
Early menarche 1SD 
area 
1 SD < language region 
specific mean (German, 
French, Italian) 
Dratva et al (2007) 
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Table 5.2: General characteristics of study population and those excluded by age at menarche  
 
 
 Study Population* 
(N=2,492) 
Women excluded† 
(N=2,414) 
 
Adult 
Characteristics 
Total Menarche 
< 12 yrs. 
Menarche 
≥12 yrs. 
P-
Value 
Total Menarche 
< 12 yrs. 
Menarche 
≥12 yrs. 
P-
Value‡ 
 
 N % N % N %  N % N % N %  
               
Overall 2,492 100 300 12 2,192 88.0 - 2,414 100 119 12.2 853 87.8 - 
               
Age       <0.01       0.11 
≤30  488 19.6 70 23.3 418 19.1  465 19.3 21 17.7 156 18.3  
31-45 1,036 41.6 134 44.7 902 41.2  920 38.1 57 47.9 311 36.5  
46-60 968 38.8 96 32.0 872 39.8  1,029 42.6 41 34.5 386 45.3  
               
Atopy 752 30.2 107 35.7 645 29.4 0.03 588 32.7 23 32.9 205 36.8 0.60 
               
Smoking §       0.82       0.59 
Never-smoker 1,287 51.7 150 50.0 1,137 51.9  318 46.8 27 45.8 163 47.4  
Former-smoker 813 32.6 102 34.0 711 32.4  222 32.7 18 30.5 118 34.3  
Current-smoker 392 15.7 48 16.0 344 15.7  140 20.6 14 23.7 63 18.3  
               
BMI        1.00       1.00 
Underweight  144 5.8 12 4.0 132 6.0  153 6.5 9 7.9 57 6.8  
Normal weight 1,802 72.3 205 68.3 1,597 72.9  1,513 64.5 62 54.4 570 67.9  
Overweight/obese 546 21.9 83 27.7 436 21.1  679 30.0 43 37.7 212 25.3  
               
Parental asthma 286 11.5 38 12.7 248 11.3 0.50 271 11.2 16 13.6 108 12.7 0.77 
               
Urban 1,208 48.5 168 56.0 1,040 47.5 <0.01 1,391 57.6 81 68.1 470 55.1 0.01 
               
Education ll       0.34       0.15 
Low 215 8.6 26 8.7 189 8.6  87 12.5 7 11.5 24 6.8  
Intermediate 1,789 71.8 206 68.7 1,583 72.2  482 69.1 37 60.7 255 71.8  
High 488 19.6 68 22.7 420 19.2  129 18.5 17 27.9 76 21.4  
               
*Study Population: women who provided information on age at menarche in either SAPALDIA 2 (S2) or SAPALDIA 3 (S3), provided 
information on doctor-diagnosed asthma in at least SAPALDIA 1 (S1), S2 or S3, reported onset of asthma at least one year after 
menarche, and had complete covariate information  
†Women excluded: women having no information on age at menarche (N=1442), having asthma onset before menarche (N=81), or having 
missing covariate information (N=891) 
‡Using t-test for variables early menarche, age and BMI, and Fischer exact test for variables smoking, parental asthma, early-life 
respiratory infection, education, atopy and urbanity.   
§Smoking:  cumulative smoking at SAPALDIA 3 (S3), never-smokers being consistent never smokers across all three surveys, current 
smokers being smokers at S3, and ex-smokers being people who were smokers at S1 and/or S2, but not at  S3 
ll Education: cumulative education at SAPALDIA 3 (S3) (the highest educational level reported at S1/S2). 
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Table 5.3: Determinants of new-onset asthma using different definitions of early 
menarche 
 
Overall Study Population 
 
Variables Early Menarche 
<12* 
 
OR (95% CI) 
( N= 2,492) 
Early Menarche 
1SD† 
 
OR (95% CI) 
(N= 2,492) 
Early Menarche 2 
SD‡ 
 
OR (95% CI) 
(N= 2,492) 
Early Menarche 
Area§ 
 
OR (95% CI) 
(N= 2,492) 
     
Early menarche 1.23 (0.85 - 1.80) 1.23 (0.85 - 1.80) 1.12 (0.51 - 2.46) 1.25 (0.90 - 1.73) 
Age (yrs.) 0.99 (0.98 - 1.00) 0.99 (0.98 - 1.00) 0.99 (0.98 - 1.00) 0.99 (0.98 - 1.00) 
Atopy 2.75 (2.10 - 3.62) 2.75 (2.10 - 3.62) 2.77 (2.11 - 3.63) 2.75 (2.10 - 3.61) 
Never-smoker 
(reference) 
1 1 1 1 
Former-smoker 1.45 (1.08 - 1.94) 1.45 (1.08 - 1.94) 1.45 (1.08 - 1.94) 1.45 (1.08 - 1.94) 
Current-smoker 1.01 (0.67 - 1.51) 1.01 (0.67 - 1.51) 1.01 (0.67 - 1.51) 1.01 (0.67 - 1.52) 
BMI 1.06 (1.03 - 1.10) 1.06 (1.03 - 1.10) 1.07 (1.03 - 1.10) 1.06 (1.02 - 1.10) 
Parental asthma 1.66 (1.15 - 2.37) 1.66 (1.15 - 2.37) 1.66 (1.16 - 2.38) 1.66 (1.11 - 2.30) 
Urban 1.05 (0.64 - 1.71) 1.05 (0.64 - 1.71) 1.34 (0.63 - 1.70) 1.02 (0.62 - 1.67) 
Intermediate 
education 
(reference) 
1 1 1 1 
Low education 0.73 (0.43 - 1.26) 0.73 (0.43 - 1.26) 0.73 (0.43 - 1.26) 0.74 (0.43 - 1.26) 
Higher education 1.02 (0.72 - 1.43) 1.02 (0.72 - 1.43) 1.02 (0.73 - 1.43) 1.01 (0.72 - 1.42) 
     
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, 
atopy, cumulative smoking, BMI, parental asthma, urbanity, cumulative education and study area 
*Definition early menarche <12: age of menarche reported as <12 years of age at either in SAPALDIA 2 or SAPALDIA 3  
†Definition early menarche <1SD:  age at menarche  reported as < 1 standard deviation of mean age at menarche at either 
SAPALDIA 2 or SAPALDIA 3  
‡Definition early menarche <2SD:  age at menarche reported as < 2 standard deviation of mean age at menarche at either 
SAPALDIA 2 or SAPALDIA 3 
§Definition early menarche area:  age at menarche reported as <1SD below language region specific mean (German, French, 
Italian) at either SAPALIDA 2 or SAPALDIA 3  
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Table 5.4: Determinants of new-onset asthma stratified by atopy and BMI 
Restricted to those aged <30 at baseline  
 
Variables Early Menarche <12*, OR (95% CI)  
 Non-Atopic 
(N=261) 
Atopic 
(N=180) 
Underweight†  
(Omitted) 
Normal Weight† 
(N=393) 
Overweight/Obese† 
(N=  48 ) 
 
Early menarche 0.23 (0.28 - 1.95)  2.21 (0.90 - 5.43) - 1.28 (0.57 - 2.87) 1.77 (0.04 - 69.79) 
Age (yrs.) 1.09 (0.93 - 1.27) 1.05 (0.94 - 1.16) - 1.03 (0.94 - 1.12) 1.08 (0.81 - 1.45) 
Atopy - - - 3.75 (1.98 - 7.12) 6.26 (0.29 - 136.25) 
Never-smoker 
(reference) 
1 1 1 1 1 
Former-smoker 1.93 (0.66 - 5.60) 2.06 (0.89 - 4.78) - 2.87 (1.41 - 5.86) 0.10 (0.00 - 4.33) 
Current-smoker 1.00 (0.28 - 3.60) 0.64 (0.21 - 1.95) - 1.23 (0.51 - 2.98) 0.35 (0.01 - 12.56) 
BMI 1.02 (0.86 - 1.22) 0.97 (0.85 - 1.12) - - - 
Parental asthma 1 (omitted) 1.18 (0.35 - 3.97) - 0.54 (0.17 - 1.69) 1.22 (0.06 - 25.85) 
Urban 2.11 (0.42 - 10.55) 1.71 (0.48 -  6.09) - 1.94 (0.68 - 5.48) 4.22 ( 0.03 -  550.02) 
Intermediate education 
(reference) 
1 1 1 1 1 
Low education 1 (omitted) 1.82 (0.24 - 13.57) - 1.37 (0.13 - 13.96) 3.19 (0.21 -  47.94) 
Higher education 0.68 (0.22 - 2.12) 0.63 (0.25 - 1.57) - 0.68 (0.32 - 1.44)   0.41 (0.00 -  34.38) 
      
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, atopy, cumulative smoking, BMI, parental asthma, urbanity, cumulative 
education and study area.  
*Definition early menarche <12: age of menarche reported as <12 years of age at either in SAPALDIA 2 or SAPALDIA 3 
†Underweight (BMI < 18.5), normal weight (BMI 18.50 – 24.99), overweight/obese (BMI ≥25 ) 
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Table S 5.1: Determinants of new-onset asthma using different definitions of early menarche 
 
Restricted to those aged <30 at baseline 
 
Variables Early Menarche <12* 
OR (95% CI) 
(N=488) 
Early Menarche 1SD† 
OR (95% CI) 
(N=488) 
Early Menarche 2 SD‡ 
OR (95% CI) 
(N=488) 
Early Menarche Area§ 
OR (95% CI) 
(N=488) 
     
Early menarche 1.42 (0.68 – 2.97) 1.42 (0.68 - 2.97) 0.79 (0.16 - 3.91) 1.63 (0.84 - 3.15) 
Age (yrs.) 1.05 (0.96 - 1.14) 1.05 (0.96 - 1.14) 1.05 (0.96 - 1.14) 1.05 (0.96 - 1.14) 
Atopy 3.77 (2.10 - 7.01) 3.77 (2.10 - 7.01) 3.80 (2.12 - 6.83) 3.75 (2.08 - 6.74) 
Never-smoker (reference) 1 1 1 1 
Former-smoker 1.94 (1.03 - 3.66) 1.94 (1.03 - 3.66) 1.98 (1.04 - 3.75) 1.94 (1.03 - 3.67) 
Current-smoker 0.79 (0.34 - 1.80) 0.79 (0.34 - 1.80) 0.78 (0.34 - 1.78) 0.81 (0.35 - 1.85) 
BMI 0.98 (0.90 - 1.09) 0.98 (0.90 - 1.09) 0.99 (0.89 - 1.10) 0.98 (0.88 - 1.09) 
Parental asthma 0.60 (0.21 - 1.68) 0.60 (0.21 - 1.68) 0.59 (0.21 - 1.67) 0.59 (0.21 - 1.67) 
Urban 1.88 (0.71 - 4.95) 1.88 (0.71 - 4.95) 1.83 (0.70 - 4.79) 1.81 (0.69 - 4.75) 
Intermediate education (reference) 1 1 1 1 
Low education 1.74 (0.31 - 9.65) 1.74 (0.31 - 9.65) 1.83 (0.34 - 9.98) 1.73 (0.31 - 9.75) 
Higher education 0.66 (0.33 - 1.32) 0.66 (0.33 - 1.32) 0.65 (0.32 - 1.30) 0.67 (0.33 - 1.34) 
     
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic regression adjusting for age, atopy, cumulative smoking, BMI, parental asthma, urbanity, cumulative 
education and study area 
*Definition early menarche <12: age of menarche reported as <12 years of age at either in SAPALDIA 2 or SAPALDIA 3 
†Definition early menarche <1SD:  age at menarche  reported as < 1 standard deviation of mean age at menarche at either SAPALDIA 2 or SAPALDIA 3 
‡Definition early menarche <2SD:  age at menarche reported as < 2 standard deviation of mean age at menarche at either SAPALDIA 2 or SAPALDIA 3 
§Definition early menarche area:  age at menarche reported as <1SD below language region specific mean (German, French, Italian) at either SAPALIDA 2 or SAPALDIA 3  
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Table S 5.2: Determinants of new-onset asthma  
 (SAPALDIA 2 information only)* 
 
Variables OR (95% CI) 
(N=2,492) 
  
Early menarche* 1.13 (0.75 - 1.72) 
Age (yrs.) 0.99 (0.98 - 1.00) 
Atopy 2.76 (2.10 - 3.63) 
Never-smoker (reference) 1 
Former-smoker 1.45 (1.08 - 1.94) 
Current-smoker 1.01 (0.67 - 1.51) 
BMI 1.06 (1.03 - 1.10) 
Parental asthma 1.66 (1.16 - 2.38) 
Urban 1.04 (0.63 - 1.70) 
Intermediate education (reference) 1 
Low education 0.73 (0.43 - 1.26) 
Higher education 1.02 (0.73 - 1.43) 
  
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Based on logistic 
regression adjusting for age, atopy, cumulative smoking, BMI, parental asthma, urbanity, cumulative 
education and study area 
*Definition early menarche <12: age of menarche reported as <12 years of age  in SAPALDIA 2  
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Table S5.3a: Step-Wise Selection of Variables for Early Menarche Model  
Variables Crude model 
OR (95% CI) 
(N= 2,492) 
Model 1† 
OR (95% CI) 
(N= 2,492) 
age 
Model 2‡ 
OR (95% CI) 
(N= 2,492) 
education 
Model 3§ 
OR (95% CI) 
(N= 2,492) 
smoking 
Model 4 ll 
OR (95% CI) 
(N= 2,492) 
Parental asthma 
      
Early 
menarche 
<12* 
 
1.50 (1.05 - 
2.15) 
1.47 (1.02 -  2.10) 1.46 (1.02 - 2.10) 1.45 (1.01 - 2.09) 1.44 (1.01 - 2.07) 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Bold indicated significance at p≤0.05.  
*Definition early menarche <12: age of menarche reported as <12 years of age at either in SAPALDIA 2 or SAPALDIA 3 
†Model 1: based on logistic regression  adjusting for age  
‡Model 2:  based on logistic regression  adjusting for age  and cumulative education  
§Model 3:  based on logistic regression  adjusting for age, cumulative education and cumulative smoking  
ll Model 4:  based on logistic regression  adjusting for age, cumulative education, cumulative smoking and parental asthma 
Table S5.3b: Step-Wise Selection of Variables for Early Menarche Model 
 
Variables Model 5†† 
OR (95% CI) 
(N= 2,492) 
urban 
Model 6‡‡ 
OR (95% CI) 
(N= 2,492) 
area 
Model 7§§ 
OR (95% CI) 
(N= 2,492) 
atopy 
Model 8 llll 
OR (95% CI) 
(N= 2,492) 
BMI 
Model 9*** 
OR (95% CI) 
(N= 2,492) 
Full 
      
Early 
menarche 
<12** 
 
1.41 (0.98 - 2.03) 1.40 (0 .97 -   2.01) 1.34 (0.92 - 1.94) 1.29 (0.89 - 1.87) 1.23 (0.85 - 1.80) 
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Bold indicated significance at p≤0.05.  
**Definition early menarche <12: age of menarche reported as <12 years of age at either in SAPALDIA 2 or SAPALDIA 3 
††Model 5:  based on logistic regression  adjusting for age, cumulative education, cumulative smoking, parental asthma, and urbanity 
‡‡Model 6:  based on logistic regression  adjusting for age, cumulative education, cumulative smoking, parental asthma, urbanity, and study area 
§§Model 7:  based on logistic regression  adjusting for age, cumulative education, cumulative smoking, parental asthma, urbanity, study area and atopy 
llll Model 8:  based on logistic regression  adjusting for age, cumulative education, cumulative smoking, parental asthma, urbanity, study area and BMI  
***Model 9: based on logistic regression adjusting for  age, cumulative education, cumulative smoking, parental asthma, urbanity, study area, BMI and atopy 
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Abstract  
The association of obesity and asthma has been described in children and adults. However, 
whether a different life course of weight in men and women may explain gender differences 
in asthma incidence, has not been addressed. 
Using data from the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in 
Adults, we investigated the role of overweight/obesity as measured by body silhouettes at 
different life stages in men and women for asthma incidence. 
Our analysis included 5,417 subjects who were asthma free at age 8, followed up to 2011, 
and had complete covariate information. The main predictor of interest was self-reported 
body silhouettes at age 8, menarche, 30, 45, menopause, and 60, and additionally changes 
in body silhouette number across these different time points. Asthma incidence was defined 
as newly reported doctor-diagnosed asthma after the body silhouette time point. Asthma 
incidence and its association with body silhouettes was analysed using sex stratified logistic 
regression, adjusting for age, atopy, smoking, parental asthma, education and study area. 
Men at age 60 had an increased risk of asthma incidence per unit increase in body silhouette 
number (OR 1.93, 95% CI 1.13 - 3.30). This association was stronger in women at age 60 
(OR 2.78, 95% CI 1.49 - 5.18) and observed also at menopause (OR 1.35, 95% CI 1.03 -
1.78), as well as per unit change in body silhouette number between age 45 – menopause 
(OR 1.74, 95% CI 1.15 -2.63).  
In this longitudinal study, the risk of new-onset asthma increased in men and women with a 
larger body silhouette in late adulthood. In women, this risk appeared present between age 
45 and menopause and was most pronounced at age 60. The age-related increase of 
obesity may underlie new-onset of asthma at higher ages, especially in women. 
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6.1 Introduction  
The incidence of asthma almost doubles in those who are obese (Rönmark et al., 2005). 
Although studies have shown a steady dose-response relationship between incident asthma 
and increasing BMI, only few have evaluated the interaction of sex and overweight/obesity 
on incident asthma (David A. Beuther and Sutherland, 2007; Brumpton et al., 2013; Chen et 
al., 2005, 2002, 2013; Egan et al., 2014). Among those studies, many demonstrate the effect 
to be stronger in women than in men (Beckett et al., 2001; Camargo et al., 1999; Chen et al., 
2002; Ford et al., 2004; Gunnbjörnsdóttir et al., 2004; HUOVINEN et al., 2003), however, the 
difference in point estimates between men and women is usually small, and other studies 
have shown conflicting results (Beuther et al., 2006; Egan et al., 2014; Jeong et al., 2017; 
Nystad et al., 2004).  
Furthermore, to the best of our knowledge, no study has addressed the association of life 
history of body weight and asthma in women and men even though the course of overweight 
across life is known to differ between men and women. This is well documented for the 
Swiss population by the Swiss Health Survey (“Schweizerische Gesundheitsbefragung 2012 
Übersicht,” 2013), with a male preponderance of overweight between the ages 20-50 years. 
In Europe, differences in overweight and obesity across countries are larger in men (ranging 
between 51% and 69%) than in women (37.0% and 50.7%) (Organisation for Economic Co-
operation and Development [OECD], 2014). There is a more rapid increase of overweight 
and obesity in the early adult years in men as compared to women, the assumption being 
that active boys become inactive adults without change to their eating behaviour (European 
Commission [EC], 2011). Post-menopausal women, however, have twice the levels of 
visceral fat compared to pre-menopausal women (Rexrode et al., 1998 see table 1) and are 
at a higher risk of cardiovascular disease.  
Given the gendered life-course pattern of asthma (Eagan et al., 2005; Hansen et al., 2015), 
and the differential course of overweight across life between men and women (European 
Commission [EC], 2011; Organisation for Economic Co-operation and Development [OECD], 
2014; “Schweizerische Gesundheitsbefragung 2012 Übersicht,” 2013), it would be beneficial 
to investigate the life-course of overweight/obesity and asthma incidence in men and women. 
Romieu et al (2003) (2003b) found that an increase in body silhouette between menarche 
and adulthood relates to the incidence of asthma in later life in women from the French E3N 
cohort study (Romieu et al., 2003b). A high BMI was significantly associated with the risk of 
asthma incidence, as was a change in body silhouette over time (Romieu et al., 2003b). 
However, no such study exists in a general population sample including men and women in 
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order to investigate the role of overweight/obesity at different life stages for asthma 
incidence. 
Making use of the on-going Swiss Cohort Study on Air Pollution and Lung and Heart 
Diseases in Adults (SAPALDIA), now covering 20-years of longitudinal observation of a 
general population sample aged 18-60 years in 1991, we investigated the association of 
body silhouettes and asthma incidence in men and women, taking into account the history of 
body silhouettes at different life stages as well as changes in body silhouettes over time.   
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6.2 Methods 
6.2.1 Study Design and Population 
The SAPALDIA study (see appendix 1) was initiated in 1991 in eight geographically diverse 
areas in Switzerland. A total of 9651 persons (51% female) aged 18-60 years participated in 
the baseline study (SAPALDIA 1 (S1)) after having been recruited through random 
population sampling.  Re-assessments took place In 2002/2003 (SAPALDIA2 (S2), n= 8047) 
and in 2010/2011 (SAPALDIA 3 (S3), n=6088). In S3 participants were asked to assess their 
body silhouettes retrospectively from age 8 to current age (see figure 6.1a and 6.1b). The 
protocol and participation rates have been described in further detail elsewhere (Ackermann-
Liebrich et al., 2005; Martin et al., 1997). This analysis includes 5,417 subjects who were 
asthma free at age 8, participated in S3 and had complete covariate information (see figure 
S6.1 in supplementary material). Ethical approval was obtained from the Swiss Academy of 
Medical Sciences, the regional ethics committees, and written informed consent was 
obtained from all participants.  
 
6.2.2 Definition of Asthma and Asthma Incidence 
Doctor-diagnosed asthma was defined as a positive answer to the questions ‘Have you ever 
had asthma?’ and ‘Was this confirmed by a doctor?’ Asthma incidence was defined as 
reported asthma having been diagnosed by a doctor after age 8. We additionally 
distinguished different incidence periods defined by the ages for which body silhouettes were 
assessed, i.e. age 8, menarche, age 30, age 45, menopause, and age 60.  Asthma incidence 
was defined at these six different time points so that new-onset of asthma occurring after the 
age of reported body silhouettes could be investigated. In our statistical analysis, when 
investigating reported body silhouette at age 8, our outcome was new-onset of asthma 
occurring after age 8. When investigating change in body silhouette from age period 8-30, 
then our outcome was asthma occurring after age 30 and so on.  
  
Gender Differences in Body Silhouettes and Asthma Incidence  
 
 
110 
 
6.2.3 Body Silhouettes 
The main predictor of interest was self-report of body silhouette number at specific ages, and 
additionally, the number of body silhouette changes in men and women over time. 
Participants were asked to report their body silhouette at age 8, menarche, age 30, age 45, 
menopause, and age 60 (see figure 6.1a and 6.1b). The body silhouette images are based 
on those created by Stunkard et al. (1983) and range from 1 (very lean) to 9 (very obese). If 
participants were unsure of their exact body silhouette, they could select two adjacent body 
silhouettes.  For our analysis, we reported body silhouette as a continuous variable, using 
the average of the two selected body silhouettes when participants selected two silhouettes. 
Based on findings by Bulik et al. (2001) we categorized participants who chose a body 
silhouette of 6 or more as being overweight and used this dichotomous variable in our 
sensitivity analysis. 
Additionally, in order to assess the association between change in body silhouettes over time 
and asthma incidence, we created the following variables indicating the changes in silhouette 
score in men between ages 8-30, 30-45, 45-60, and in women between ages 8-menarche, 
menarche-30, 30-45, 45-menpause, menopause-60 in.  For the descriptive table (table 6.2), 
we grouped the number of changes into a score of the following four categories ≤0, 0, 1, 2+ 
following the example of Romeieu et al (2003a). For our statistical analysis, the number of 
changes in body silhouettes was used as a continuous variable.  
6.2.4 Further covariates  
Smoking status was categorized as never-smoker, former-smoker and current-smoker at S1, 
S2 and S3. Additionally, we created a smoking status variable indicating the smoking status 
of subjects corresponding to the time period of the reported body silhouettes, namely 
smoking status at ages 30-45, 45-60 and at age 60.  
Baseline age was categorized into 3 groups roughly 15 years apart (<30, 31-45, 46-60) for 
the descriptive table (table 6.1). For the models, baseline age was used as a continuous 
variable (age in years). Allergic sensitization was defined as a positive response to the skin 
prick test or Phadiatop test (Phadia, Uppsala, Sweden) at baseline. Allergically sensitized 
subjects with doctor-diagnosed asthma were considered as having allergic asthma.  
Education was categorized into primary education (low), secondary or middle school 
education (intermediate), or having a technical or university degree (high). For the descriptive 
tables and models, education at baseline was used. Parental asthma was defined as a 
positive answer to the question ‘did one or both of your parents ever have asthma?’ Early 
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life-respiratory infection was defined as a positive answer to the question ‘'Did you have a 
severe respiratory infection before the age of 5 years?’  All of these covariates were selected 
based on literature findings for an association with asthma. 
6.2.5 Statistical Analysis 
Asthma incidence and its association with selected body silhouettes and the number of 
changes in body silhouette over time was analyzed using logistic regression adjusting for age 
(S1), atopy (S1), smoking (S1-S3), parental asthma (S1), education (S1) and study area (S1) 
as described above. Models were stratified by sex and run separately for the given body 
silhouette time points (including, for women, menarche and menopause) with asthma 
incidence occurring after that given time point. Analyses were additionally stratified by atopy.  
We conducted several sensitivity analyses. Firstly, in order to address potential bias in loss 
to follow up, inverse probability weighting was considered. Secondly, we ran our model using 
our dichotomous overweight variable, comparing those who were overweight (body 
silhouette ≥6) to those who were not (body silhouette <6). Thirdly, we ran our analysis 
additionally adjusting for physical activity since studies have shown physical activity may be 
a protective factor against new asthma development (Eijkemans et al., 2012) and obesity 
(Lakka and Bouchard, 2005). Physical activity was categorized into a binary variable 
comparing those reporting 150min/week of moderate physical activity or 60min/week of 
vigorous physical activity (sufficiently active) those who were reporting less than this 
(insufficiently active).  
All analyses were conducted using Stata V.12 (StataCorp LP, College Station, TX, USA). 
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6.3 Results 
6.3.1 Study Population 
Our study population consisted of 5,417 subjects who were asthma free at age 8, 
participated in S3 and had complete covariate information (see figure S6.1). The 
characteristics of our study population, and of those excluded from our analyses, are 
presented in table 6.1. Those excluded from our study population were more likely to be 
men, older, and smokers. Excluded men were also more likely to be atopic, report parental 
asthma, low education and early respiratory infections. However, when conducting inverse 
probability weighting for non-participation, results remained largely unchanged (data not 
shown). 
In our study population, men were more likely to be atopic than women, more likely to be 
former or current smokers at all ages, and more likely to have a higher educational level, 
whereas women tended to report more parental asthma than men.  
6.3.2 Body Silhouettes 
The reported body silhouettes in men and women at different ages are shown in figures 6.2a 
and 6.2b. Overall, higher proportions of lower body silhouettes were reported at younger than 
older ages. Irrespective of age of body silhouette, we observed considerable gender 
differences in the distributions of body silhouette. As for the number of changes in body 
silhouettes over the time, these are presented by sex in table 6.2. More men than women 
reported an increase of body silhouette of 1 or more at all ages than did women. 
6.3.3 Asthma Incidence 
New-onset of asthma occurring after each body silhouette time point is presented in table 
S6.1. New-onset of asthma was persistently higher among women than among men, 
particularly up to age 30. 
 
6.3.4 Determinants of Asthma incidence 
When adjusting for relevant confounders, the risk of new-onset of asthma associated with a 1 
unit increase in body silhouette for men and women is presented for men and women 
separately in table 6.3. In men and women, the association become statistically significant at 
age 60 (men OR 1.93, 95% CI 1.13 – 3.30), (women OR 2.78, 95% CI 1.49 – 5.18) and 
additionally, in women after menopause (OR 1.35, 95% CI 1.03 – 1.78).  
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Women also had an increased risk of asthma incidence per 1 unit change in body silhouette 
between the age 45-menopause (OR 1.74, 95% CI 1.15 – 2.63) (table 6.4). In women, the 
risk of new-onset of asthma with each unit of increasing body silhouette from menopause to 
age 60 was borderline significant (OR 1.97, 95% CI 1.00 - 3.90). We saw no association 
between change in body silhouette and asthma incidence in men.  
6.3.5 Sensitivity Analysis 
When stratifying by atopic status, there was a tendency, albeit low statistical power, for a 
stronger body silhouette-asthma onset associations after age 60 in non-atopic men (OR 
2.34, 95% CI 1.09 - 5.05) and non-atopic women (OR 4.14, 95% CI 1.39 - 12.38) (table 6.3). 
In women the OR for new-onset of asthma after menarche was stronger in atopic women 
with each unit of increase in body silhouette at menarche (OR 1.19, 95% CI 1.02 - 1.38) 
(table 6.3) whereas it was stronger in non-atopic women when looking at changes in body 
silhouette from menarche – age 30 (OR 1.25, 95% CI 1.01 - 1.55). 
When running our analysis with our dichotomous body silhouette variable comparing those 
with a body silhouette of ≥6 to those with a body silhouette of <6, the ORs increased in all 
age groups for both body silhouettes at a specific age (table 6.3) and also increase in body 
silhouette changes over time (table 6.4).  
We ran our analysis additionally adjusting for physical activity (table S6.2 and S6.3 
supplementary material). The results did not significantly change. However, the OR for men 
with a higher body silhouette at age 60 became slightly larger (OR 1.83, 95% CI 1.09 - 3.07), 
as did the OR for new-onset of asthma after age 60 in women (OR 2.69, 95% CI 1.44 - 5.02) 
(table S6.2 supplementary material).  When additionally adjusting for physical activity when 
looking at the association between in change of body silhouettes and new-onset of asthma, 
the association with 1 unit increase in body silhouette score in women between age 45 and 
menopause became significant (OR 1.67, 95% CI 1.09 - 2.58) (table S6.3 supplementary 
material). 
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6.4 Discussion 
6.4.1 Main findings 
A larger body silhouette later in life, but not at young ages, increases the risk of new-onset of 
asthma in men, and even more so in women. In men, each unit increase in body silhouette at 
age 60 doubled the risk for asthma after age 60. The risk increase for new asthma in women 
was 1.5 fold for the body silhouette at menopause and 3 fold for age 60. Change in body 
silhouette number over time was only significantly associated with the risk of new-onset of 
asthma in women between age 45- menopause, with an almost twofold risk. Despite low 
numbers, atopic status seemed to be a modifying effect in women at menarche and 
menopause, and in men at age 60. The results point to an important effect of weight on 
asthma at older ages and in postmenopausal women.  
6.4.2 Comparison with other studies 
Only a few studies have evaluated the interaction of sex and overweight/obesity on newly 
acquired asthma, which is important given the sex effect observed in previous studies on 
obesity and asthma (Beuther et al., 2006; Egan et al., 2013). Brumpton et al (2013) 
prospectively explored the association of BMI and waist circumference on asthma incidence 
in a Norwegian study population aged 19-65 years old. They found that BMI-derived general 
overweight and obesity was a risk factor for incident asthma for males and females, and, in 
addition, that waist circumference derived abdominal obesity was a risk factor for incident 
asthma only in females. Egan et al (2014) have also used measures in addition to BMI to 
assess the risk for asthma incidence but in a slightly younger Norwegian study population 
(12-30 years old). Egan et al (2014) found that baseline general overweight and abdominal 
obesity were significantly associated with an increased risk of newly acquired asthma, 
however when stratified by sex, this association remained significant only in men. This is in 
contrast to previous findings which found BMI to be associated with new onset of asthma in 
adolescent and young females, but not in males (Chen et al., 2013; Egan et al., 2013). 
However, this effect has been inconsistent among children, possibly due to the differences in 
body fat accumulation and distribution around timing of puberty, particularly among females. 
Egan et al (2014) could not adjust for duration and intensity of physical activity, nor could 
they differentiate between allergic and non-allergic asthma. However, Beckett et al (2001)  
found that gain in BMI is associated with new asthma diagnosis in young female adults even 
when adjusting for changes in physical activity.  
In order to assess the life history of body weight, the use of body silhouette images 
(Sørensen et al., 1983; Stunkard et al., 1983), offers a practical method when asking elderly 
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subjects to recall the distant past and childhood build (Dratva et al., 2016; Koprowski et al., 
2001; Muñoz et al., 1996; Must et al., 1993; Nagasaka et al., 2008) or when measured and 
self-reported BMI are not available (Lo et al., 2012). The use of body silhouettes has been 
validated (Dratva et al., 2016; Muñoz-Cachón et al., 2009; Nagasaka et al., 2008) and used 
in studies assessing incident diabetes (de Lauzon-Guillain et al., 2010) and asthma 
incidence in women (Romieu et al., 2003b).  Romieu et al (2003a) found a higher BMI to be 
significantly associated with the risk of asthma incidence, and also, that an increase in body 
silhouette between menarche and adulthood related to the incidence of asthma in later life. 
Women who gained two or more silhouette points (approximately ≥10 kg) after menarche 
had a 66 percent increased risk of asthma when compared with women who did not change 
silhouette, after adjustment for relevant confounders (multivariate RR = 1.66, 95% CI 1.18, 
2.23, test for trend: p < 0.001). Similarly, an 89% increased risk of asthma was observed for 
women who gained two or more silhouettes after the age of 20 years (multivariate RR= 1.89, 
95% CI 1.37, 2.60, test for trend: p< 0.001). When Romieu et al (2003a) restricted the 
analysis to women who had a BMI of 20-24 (“normal”) at menarche or around 20 years of 
age, results remained similar, suggesting that estimates were not driven by women with high 
BMIs who gained additional weight. The observed association between an increase in body 
silhouette after menarche and adult onset of asthma in the study by Romieu et al (2003a) 
somewhat contradicts our findings. In our study, body silhouette at menopause and later was 
a significant predictor for asthma incidence in women. A change of body silhouette as of age 
45 was only borderline significant in our study. But when stratifying by atopy, atopic women 
with a larger body silhouette at menarche were more likely than other women at the same 
age to newly develop asthma after menarche (OR 1.19, 95% CI 1.02 - 1.38). Perhaps this 
partly accounts for the highest asthma incidence seen in young atopic women in the study by 
Hansen et al (2015).  
To the best of our knowledge, no study has addressed the association of life history of body 
silhouettes and asthma in men, even though the course of overweight across life is known to 
differ between men and women (“Schweizerische Gesundheitsbefragung 2012 Übersicht,” 
2013), as is the fat distribution (Veilleux and Tchernof, 2012). In our previous study, women 
were twice as likely as men to newly develop asthma (Hansen et al., 2015). This association 
was modified by age and atopy: the highest risk of new onset of asthma being in young 
atopic women.  Gender differences were most pronounced in non-atopic subjects and 
decreased with increasing age (Hansen et al., 2015). In our current study, atopic women at 
menarche with a larger body silhouette number were at increased risk for new-onset of 
asthma, which could potentially explain the high incidence of asthma in young atopic women 
which we observed previously. At age 60, both men and women were at higher risk of 
Gender Differences in Body Silhouettes and Asthma Incidence  
 
 
116 
 
asthma incidence per unit increase in body silhouette, the risk being more pronounced in 
women. These findings are consistent with and support the life course pattern on new-onset 
of asthma we observed previously (Hansen et al., 2015 see figure 2a and 2b). The 
associations of larger body silhouettes with asthma incidence in our current study may help 
explain gender differences in asthma incidence.   
6.4.3 Strengths and limitations 
The Swiss Cohort on Lung and Heart Disease in Adults (SAPALDIA) offers the unique 
opportunity to investigate the role of body silhouettes from a life course perspective for men 
and women. In addition, with the extensive SAPALDIA data, a number of further factors can 
be taken into account, such as allergic and non-allergic asthma, as well as duration and 
intensity of physical activity. And finally, strength lies in SAPALDIA’s large data base 
representing the general population of Switzerland across urban, rural and mountainous 
areas with different environmental exposure characteristics and building on standardized 
measurements and a health questionnaire which was developed along with the European 
Community Respiratory Health Survey (ECHRS) (Burney et al., 1994; Martin et al., 1997). 
In studies prospectively investigating the association between obesity and asthma,  reported 
sex-related differences are inconsistent (David A Beuther and Sutherland, 2007). It has been 
argued that BMI cannot distinguish between fat mass and muscle mass (Ness-Abramof and 
Apovian, 2008). Most notably, BMI has limitations in predicting abdominal fat deposition, 
which is associated with reduced pulmonary function, metabolic syndrome and 
cardiovascular complications (Arner, 1998; Chen et al., 2007; Janssen et al., 2004).  BMI 
may inadequately reflect fat distribution and may under- or overestimate obesity as wide 
variations in body fat distribution can occur within the same BMI percentile group (Musaad et 
al., 2009). BMI does not differentiate between fat and lean body mass, and for a given BMI, 
females generally have a higher proportion of body fat than males (Ellis et al., 1999). This is 
where the use of body silhouettes is important and beneficial. Abdominal obesity may better 
reflect metabolic differences in subcutaneous and visceral fat deposits known to influence 
systemic inflammation.  
A possible limitation of this study is the remote recall of body silhouettes as well as the 
accuracy of self-reported body silhouettes. Worse recall of body silhouette at younger ages 
may have biased associations with asthma onset during earlier years towards null. However, 
Must et al. (Must et al., 1993) found good correlations between body silhouettes and 
measured BMI for females, even when using adult silhouettes to represent their body sizes 
at age 10 and 15 years. Troy et al. (Troy et al., 1995) reported correlation of 0.66 between 
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BMI at age 18 years and silhouettes compared with a correlation of 0.84 for actual and 
recalled BMI at 18 years whereas Munoz et al (Muñoz et al., 1996) obtained correlations of 
0.75 for BMI and silhouettes compared with 0.89 for actual and recalled BMI. As for 
Koprowski et al (Koprowski et al., 2001) they found that recall of body shape at menarche 
was considered to be a less precise measure than asking about weight and height, but use 
of body silhouettes may offer a more practical method for obtaining information for the past. 
And finally, Bulik et al (2002) found that  figural stimuli are effective in classifying individuals 
as obese or thin (Bulik et al., 2001). 
6.4.4 Conclusion  
According to this longitudinal study, body silhouettes matter most for asthma onset at older 
ages in men and women. Additionally, increasing in body silhouette number from age 45 - 
menopause significantly increases the risk of new-onset of asthma in women. Despite low 
numbers, atopic status seems to be a modifying effect in women at menarche and 
menopause, but not in men. The increasing prevalence of obesity may therefore lead to 
more asthma at higher ages in adults and particularly in postmenopausal women. Pooling 
data or having future studies with an even larger study population with an older age range 
may help to better understand the role of body silhouettes in gender differences in asthma, 
especially the potential modification by atopy. 
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Figure 6.1a: Questionnaire Body Silhouettes Women  
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Figure 6.1b : Questionnaire Body Silhouette Men 
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Table 6.1: Main characteristics at baseline comparing those excluded from study 
population with those included, by sex 
Study population (N= 5417)* Excluded (N= 4,234)** P-Value*** 
 Male  Female  Male  Female  Male Female 
 N % N % N % N %   
OVERALL 2,614 48.3 2,803 51.7 2,131 50.3 2,103 49.6 0.98 
Age         <0.01 <0.01 
≤ 30 591 22.6 551 19.7 451 21.2 402 19.1   
30-40 1,029 39.4 1,173 41.9 745 35.0 783    37.2   
45-60 994 38.0 1,079 38.5 935   43.9 918 43.7   
Smoking 
status age 
30-45 
 
        <0.01 <0.01 
Never-
smoker 
1,018 39.1 1,512 54.2 545 28.0 929 47.4   
Former-
smoker 
760 29.2 631 22.6 549 28.2 406 20.7   
Current-
smoker 
 
825 31.7 648 23.2 852 43.7 626 31.9   
Smoking 
status age 
45-60 
        <0.01 <0.01 
Never-
smoker 
867 38.5 1,375 54.7 370 27.5 708 50.0   
Former-
smoker 
898 39.8 682 27.1 498 37.0 343 24.2   
Current-
smoker 
 
489 21.7 456 18.2 478 35.5 364 25.7   
Smoking 
status age 60 
        <0.01 0.03 
Never-
smoker 
504 38.4 892 62.1 151 28.7 365 60.1   
Former-
smoker 
622 47.4 378 26.3  233 44.2 146 24.1   
Current-
smoker 
 
187 14.2 167 11.6 143 27.1 96 15.8   
Atopy 931 35.6 875 31.2 697 40.8 465 31.2 <0.01 1.00 
Parental 
asthma 
 
221 8.5 326 11.6 219    10.3 231 11.0 0.03 0.50 
Early-life 
respiratory 
infection 
 
155 5.9 244 8.7 155 7.3 186 8.9 0.07 0.88 
Education         <0.01 <0.01 
Low 95 3.6 263 9.4 17 6.0 39 10.1   
Intermediate 1,553 59.4 2,004 71.5 156 55.3 267   69.0   
High  966 37.0 536 19.1 109 38.7 81 20.9   
* Study population:  asthma free at age 8, participated in S3 and had complete covariate information  
** Excluded: having asthma ≤age 8 or having missing covariate information 
***p-value: comparing distribution of characteristics within men and women separately. Using t-test for variable sex and age, 
and Fisher exact test for variables smoking, parental asthma, early-life respiratory infection, education, and atopy   
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Figure 6.2a: Selected Body Silhouette in Men 
Figure 6.2b: Selected Body Silhouette in Women  
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Table 6.2: Changes in body silhouette score at different age periods stratified by sex 
 
Men  Women 
Age Number of changes*  Age Number of changes* 
 ≤ 0 0 1 2+   ≤ 0 0 1 2+ 
 n % n % n % n %   n % n % n % n % 
 - - - - - - - -  8 - menarche 116 5.2 1,019 45.9 816 36.7 270 12.2 
 - - - - - - - -  Menarche – 30 294 13.4 746 33.9 862 39.2 296 13.5 
8 - 30 135 6.1 311 14.1 728 33.1 1,026 46.6  8 - 30 212 9.6 443 20.0 750 33.9 807 36.5 
30 - 45 62 3.3 647 34.3 827 43.9 349 18.5  30 – 45 91 4.8 875 46.4 724 38.4 196 10.4 
 - - - - - - - -  45 – menopause 82 5.7 767 53.4 489 34.0 99 6.9 
 - - - - - - - -  Menopause - 60 69 7.5 473 51.1 316 34.1 68 7.3 
45 - 60 63 6.0 277 26.5 455 43.6 249 23.9  45 - 60 63 6.3 316   31.8 409 41.2 205 20.6 
 
*number of changes in body silhouette from one age to the next 
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Table 6.3: Association of body silhouettes at different ages and reproductive time 
points with new-onset of asthma,  stratified by sex, atopic status & overweight 
 
Models OR Body Silhouette Men
*
 
 
OR Body Silhouette Women
*
 
  
 N OR (95% CI) 
 
N OR (95% CI) 
 
Age 8
†
     
Overall model
‡
 2,208 1.01 (0.90 - 1.13) 2,245 1.04 (0.94 - 1.14) 
Dichotomous overweight model
§
 2,208 1.31 (0.62 - 2.77) 2,245 1.50 (0.65 - 3.49) 
Stratified atopic model
ll
 781 1.03 (0.90 - 1.18) 703 1.10 (0.96 -  1.26) 
Stratified non-atopic model
ll
 1,427 0.95 (0.76  - 1.20) 1,542 0.98 (0.85 - 1.13) 
     
Menarche
**
     
Overall model
‡
 - - 2,191 1.05 (0.94 - 1.16) 
Dichotomous overweight model
§
 - - 2,191 1.25 (0.58 - 2.69) 
Stratified atopic model
ll
 - - 684 1.19 (1.02 - 1.38) 
Stratified non-atopic model
ll
 - - 1,507 0.93 (0.79 - 1.08) 
     
Age 30
††
     
Overall model
‡
 2,136 1.13 (0.96 - 1.33) 2,125 1.12 (0.98 - 1.29) 
Dichotomous overweight model
§
 2,136 1.70 (0.82 - 3.57) 2,125 1.52 (0.71 - 3.27) 
Stratified atopic model
ll
 711 1.22 (0.99 - 1.52) 622 1.21 (0.97 - 1.51) 
Stratified non-atopic model
ll
 1,425 0.98 (0.75 - 1.28) 1,503 1.06 (0.88 - 1.27) 
     
Age 45
‡‡
     
Overall model
‡
 1,776 1.12 (0.90 - 1.39) 1,752 1.12 (0.90 - 1.39) 
Dichotomous overweight model
§
 613 4.66 (1.06 -  20.45) 1,752 2.20 (0.95 -  5.13) 
Stratified atopic model
ll
 541 1.11 (0.80 -1.53) 440 1.17 (0.82 -  1.69) 
Stratified non-atopic model
ll
 1,235 1.12 ( 0.81- 1.53) 1,265 1.09 (0.82 – 1.43) 
     
Menopause
§§
     
Overall model
‡
 - - 1,136 1.35 (1.03 - 1.78) 
Dichotomous overweight model
§
 - - 1,136 2.22 (0.96 - 5.15) 
Stratified atopic model
ll
 - - 275 1.48 (0.92 - 2.38) 
Stratified non-atopic model
ll
 - - 700 1.23 (0.85 - 1.76) 
     
Age 60
llll
     
Overall model
‡
 613 1.93 (1.13 - 3.30) 877 2.78 (1.49 - 5.18) 
Dichotomous overweight model
§ 
 613 4.66 (1.06 - 20.46) 877 6.17 (1.68 -  22.69) 
Stratified atopic model
ll
 130 1.40 (0.58 - 3.41) 124 3.27 (0.88 - 12.21) 
Stratified non-atopic model
ll
 312 2.34 (1.09 - 5.05) 274 4.14 (1.39 -  12.38) 
     
Data are presented as odds ratios (OR) representing the relative risk increase per 1 unit increase in body silhouette number at 
given age or reproductive time point, and 95% confidence intervals (CI). Bold indicates significance at p≤0.05.  
*
Body silhouettes men and women: selected body silhouette (1-9) (see figure S1a and S1b) 
‡
Overall model: logistic regression stratified by sex, adjusting for body silhouette as a continuous variable, age, atopy, smoking 
at the corresponding interval of the body silhouette, parental asthma, education and study area. 
§
Dichotomous
 
overweight model: overall model but using body silhouette as a dichotomous variable comparing those reporting a 
body silhouette ≥6 (overweight) to those reporting body silhouette <6 (not overweight) 
ll
Atopic/non-atopic model: overall model stratified by atopic status at baseline 
†
Age 8: overall model using body silhouette reported at age 8 and its association with asthma occurring after 8 years age 
**
Menarche:  overall model investigating body silhouette reported at menarche and its association with asthma occurring after 
menarche 
††
Age 30: overall model investigating body silhouette reported at age 30 and its association with asthma occurring after age 30  
‡‡
Age 45: overall model investigating body silhouette reported at age 45 and its association with asthma occurring after age 45  
§§
Menopause: overall model investigating body silhouette reported at menopause and its association with asthma occurring after 
menopause 
llll
Age 60: overall model investigating body silhouette reported at age 60 and its association with asthma occurring after age 60  
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Table 6.4: Association of change in body silhouette across different age periods with 
new-onset of asthma,  stratified by sex, atopic status & overweight 
Models OR Change Body Silhouette 
Men* 
 
OR Change Body Silhouette 
Women** 
  
 N OR (95% CI) 
 
N OR (95% CI) 
 
Age 8-menarche
†
     
Overall model
‡
 - - 2,156 0.98 (0.83 - 1.14) 
Stratified atopic model
§
 - - 675 1.08 (0.87 - 1.35) 
Stratified non-atopic model
§
 - - 1,481 0.87 (0.69 - 1.10) 
     
Menarche- age 30
ll
     
Overall model
‡
 - - 2,066 1.15 (0.98 - 1.34) 
Stratified atopic model
§
 - - 616 1.02 (0.81 - 1.30) 
Stratified non-atopic model
§
 - - 1,450 1.25 (1.01 - 1.55) 
     
Age 8 - age 30
**
     
Overall model
‡
 2,081 1.02 (0.87 - 1.21) - - 
Stratified atopic model
§
 697 1.06 (0.85 - 1.32) - - 
Stratified non-atopic model
§
 1,384 0.98 (0.76 - 1.26) - - 
     
Age 30 - age 45
††
     
Overall model
‡
 1,757 1.18 (0.87 - 1.59) 1,722 0.92 (0.66 - 1.30) 
Stratified atopic model
§
 535 1.01 (0.64 - 1.57) 432 0.70 (0.37 - 1.34) 
Stratified non-atopic model
§
 1,222 1.34 (0.90 - 1.99) 1,243 1.06 (0.69 - 1.61) 
     
Age 45 - menopause
‡‡
     
Overall model
‡
 - - 1,086 1.74 (1.15 -  2.63) 
Stratified atopic model
§
 - - 266 1.64 (0.82 -  3.29) 
Stratified non-atopic model
§
 - - 658 1.83 (1.07 -  3.12) 
     
Age 45 - age 60
§§
     
Overall model
‡
 498 1.38 (0.69 - 2.75) - - 
Stratified atopic model
§
 101 0.48 (0.17 - 1.35) - - 
Stratified non-atopic model
§
 218 2.07 (0.88 -  4.87) - - 
     
Menopause – age 60
llll
 - -   
Overall model
‡
 - - 527 1.97 (1.00 -  3.90) 
Stratified atopic model
§
 - - 52 329.9 (0.33 - 334797.9) 
Stratified non-atopic model
§
 - - 192 1.37 (0.51 -  3.71) 
     
Data are presented as odds ratios (OR) representing the relative risk increase per 1 unit change in silhouette number across the 
given age period, and 95% confidence intervals (CI).  
*
Change body silhouettes men and women: change in selected body silhouette score (1-9) (see figure S1a and S1b)  
‡
Overall model: logistic regression stratified by sex, adjusting for change in body silhouette as a continuous variable, age, atopy, 
smoking at the corresponding interval of the body silhouette, parental asthma, education and study area
 
§
Atopic/non-atopic model: overall model stratified by atopic status at baseline 
†
Age 8-menarche: overall model using changes in body silhouette score between age 8 and menarche as a continuous variable 
and asthma incidence occurring after menarche 
**
Age 8 - age 30
 
: overall model using changes in body silhouette score between age 8 and age 30 as a continuous variable and 
asthma incidence occurring after age 30 
††
Age 30 - age 45: overall model using number changes in body silhouette score between age 30 and age 45 as a continuous 
variable and asthma incidence occurring after age 45 
‡‡
Age 45 - menopause: overall model using changes in body silhouette score between age 45 and menopause as a continuous 
variable and asthma incidence occurring after menopause 
§§
Age 45 - age 60: overall model using changes in body silhouette score between age 45 and age 60 as a continuous variable 
and asthma incidence occurring after age 60 
llll
Menopause – age 60:  overall model using changes in body silhouette score between menopause and age 60 as a continuous 
variable and asthma incidence occurring after age 60 
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Figure S6.1: Study Population 
(diagram of initial population, the reason for exclusion and the population included in the analysis) 
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Table S 6.1: Number of new asthma diagnosis according to age group and sex 
 
 Asthma Incidence 
 Men Women 
 n % n % 
After age 8 211 8.2 289 10.5 
After Menarche - - 251 9.2 
After age 30 100 4.0 171 6.5 
After age 45 48 2.3 71 3.1 
After Menopause - - 46 2.1 
After age 60 13 1.1 12 0.9 
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Table S 6.2: Association of body silhouette at different ages with new-onset of asthma,  
additionally adjusting for physical activity 
 
Models OR Body Silhouette Men* 
 
OR Body Silhouette Women* 
  
 N OR (95% CI) 
 
N OR (95% CI) 
 
Age 8
†
     
Overall model
‡
 2,208 1.01 (0.90 - 1.13) 2,245 1.04 (0.94 - 1.14) 
Physical activity model
§
 1,987 1.00 (0.89 - 1.13) 2,009 1.03 (0.93 - 1.15) 
     
Menarche
ll
     
Overall model
‡
 - - 2,191 1.05 (0.94 - 1.16) 
Physical activity model
§
 - - 1,962 1.04 (0.93 - 1.16) 
     
Age 30
**
     
Overall model
‡
 2,136 1.13 (0.96 - 1.33) 2,125 1.12 (0.98 - 1.29) 
Physical activity model
§
 1,918 1.14 (0.96 - 1.35) 1,912 1.13 (0.98 - 1.31) 
     
Age 45
††
     
Overall model
‡
 1,776 1.12 (0.90 - 1.39) 1,752 1.12 (0.90 - 1.39) 
Physical activity model
§
 1,623 1.13 (0.90 - 1.41) 1,578 1.16 (0.92 - 1.46)   
     
Menopause
‡‡
     
Overall model
‡
 - - 1,136 1.35 (1.03 - 1.78) 
Physical activity model
§
 - - 1,051 1.31 (0.98 - 1.76) 
     
Age 60
§§
     
Overall model
‡
 613 1.93 (1.13 - 3.30) 877 2.78 (1.49 - 5.18) 
Physical activity model
§
 615 1.83 (1.09 - 3.07) 796 2.69 (1.44 - 5.02) 
     
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Bold indicated significance at p≤0.05. The OR 
represents the relative risk increase per 1 unit increase in silhouette number at given age. 
*Body silhouettes men and women: selected body silhouette (1-9) (see figures 1a and 1b). Used as a continuous variable. 
‡
Overall model: logistic regression stratified by sex, adjusting  age, atopy, smoking at the corresponding interval of the body 
silhouette, parental asthma, education and study area 
§
Physical activity model: overall model as described above, additionally adjusting for physical activity  
†
Age 8: overall model run stratified by sex using body silhouette reported at age 8 and asthma incidence occurring after 8 years 
age  
ll
Menarche: overall model run in women using body silhouette reported at menarche and asthma incidence occurring after 
menarche 
**
Age 30: overall model run stratified by sex using body silhouette reported at age 30 and asthma incidence occurring after 30 
years age 
††
Age 45: overall model run stratified by sex using body silhouette reported at age 45 and asthma incidence occurring after 45 
years age 
‡‡
Menopause: overall  model run in women using body silhouette reported at menopause and asthma incidence occurring after 
menopause 
§§
Age 60: overall model run stratified by sex using body silhouette reported at age 60 and asthma incidence occurring after 60 
years age 
Gender Differences in Body Silhouettes and Asthma Incidence  
 
 
128 
 
 
 
Table S 6.3: Association of change in body silhouette number across different age 
periods with new-onset of asthma, additionally adjusting for physical activity  
Models OR Change Body Silhouette 
Men
*
 
 
OR Change Body Silhouette 
Women
*
 
  
 N OR (95% CI) 
 
N OR (95% CI) 
 
Age 8-menarche
†
     
Overall model
‡
 - - 2,156 0.98 (0.83 - 1.14) 
Physical activity model
§
 - - 1,933 0.99 (0.84 - 1.16) 
     
Menarche- age 30
ll
     
Overall model
‡
 - - 2,066 1.15 (0.98 - 1.34) 
Physical activity model
§ 
 - - 1,854 1.14 (0.96 - 1.34) 
     
Age 8 - age 30
** 
     
Overall model
‡
 2,081 1.02 (0.87 - 1.21) - - 
Physical activity model
§
 1,869 0.99 (0.83 -  1.18) - - 
     
Age 30 - age 45
††
     
Overall model
‡
 1,757 1.18 (0.87 - 1.59) 1,722 0.92 (0.66 - 1.30) 
Physical activity model
§
 1,605 1.19 (0.88 - 1.61) 1,554 0.97 (0.68 - 1.37) 
     
Age 45 - menopause
‡‡
     
Overall model
‡
 - - 1,086 1.74 (1.15 -  2.63) 
Physical activity model
§
 - - 998 1.67 (1.08 -  2.57) 
     
Age 45 - age 60
§§
     
Overall model
‡
 498 1.38 (0.69 - 2.75) - - 
Physical activity model
§
 473 1.48 (0.72 - 3.04) - - 
     
Menopause – age 60
llll
 - -   
Overall model
‡
 - - 527 1.97 (1.00 -  3.90) 
Physical activity model
§
 - - 485 1.88 (0.95 - 3.70) 
     
Data are presented as odds ratios (OR) and 95% confidence intervals (CI). Bold indicated significance at p≤0.05. The OR 
represents the relative risk increase per 1 unit change in silhouette number across given time period. 
*
Body silhouettes men and women: selected body silhouette (1-9) (see figures 1a and 1b). Used as a continuous variable 
‡
Overall model:  based on logistic regression adjusting for body silhouette, age, atopy, smoking at the corresponding interval 
of the body silhouette, parental asthma, education and study area 
§
Physical activity model: overall model as described above, additionally adjusting for physical activity  
†
Age 8-menarche: overall model run in women using number of changes in body silhouette between age 8 and menarche as 
a continuous variable and asthma incidence occurring after menarche 
ll
Menarche – age 30: overall model run in women using number of changes in body silhouette between menarche and age 
30 as a continuous variable and asthma incidence occurring after age 30 
**
Age 8 - age 30
 
: overall model run in men using number of changes in body silhouette between age 8 and age 30 as a 
continuous variable and asthma incidence occurring after age 30 
††
Age 30 - age 45: overall model stratified by sex using number of changes in body silhouette between age 30 and age 45 
as a continuous variable and asthma incidence occurring after age 45 
‡‡
Age 45 - menopause: overall model run in women using number of changes in body silhouette between age 45 and 
menopause as a continuous variable and asthma incidence occurring after menopause 
§§
Age 45 - age 60: overall model run in men using number of changes in body silhouette between age 45 and age 60 as a 
continuous variable and asthma incidence occurring after age 60 
llll
Menopause – age 60: overall model run in women using number of changes in body silhouette between menopause and 
age 60 as a continuous variable and asthma incidence occurring after age 60 
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7. Discussion 
The aim of this PhD project was to determine the incidence of asthma for men and women 
across the entire adult life span in the Swiss Cohort Study on Air Pollution and Lung and 
Heart Disease in Adults (SAPALDIA), and to address two sex/gender related pathways: i) 
reproductive pathologies (pathway 1) and ii) lifetime history of overweight/obesity as 
measured by body silhouettes (pathway 2). The results to these research questions are 
presented in more detail in chapters 3-6. The discussion and implications of these results 
and the overall PhD project are presented in the sections hereafter.  
 
7.1 Main findings 
Over 20 years of follow-up, 5% of men and 7% of women aged 18-60 years at baseline 
newly reported doctor diagnosed asthma in this population-based cohort. When adjusting for 
relevant confounders, women were twice as likely as men to newly develop asthma. The 
association between sex/gender and asthma incidence was modified by atopy and age. A 
higher asthma incidence was seen among atopic persons, particularly in younger women. 
Gender differences in asthma incidence were most pronounced in non-atopic subjects. A 
clear age-related decline of asthma incidence and a differential pattern of this decline 
between atopic and non-atopic subjects were significant only in women, which needs further 
investigation. This study is among the few to report the cumulative incidence of adult-onset 
asthma by sex/gender in a population-based study with a high proportion of people aged >50 
years of age. The more pronounced decrease of incidence by age among atopic compared 
to non-atopic women, and the decreasing sex differences with age are novel findings. 
7.1.1 Role of reproductive pathologies and early menarche 
Many have postulated the role of hormones as a possible reason for gender differences in 
asthma- given that a switch in asthma incidence takes place around puberty (Leynaert et al., 
2012; Schatz and Camargo, 2003; The ENFUMOSA Study Group, 2003). Several 
hormonally important time points and their association with asthma have been investigated 
individually (Macsali et al., 2012). Reproductive risk factors developing in different stages 
throughout a women’s life are seldom singular experiences and their cumulative risk has 
been investigated with regard to cardiovascular health (Cao et al., 2015). To the best of our 
knowledge, this is the first study to consider the association of a cumulative effect of 
reproductive pathologies occurring in an individual’s history and asthma incidence in 
adulthood. We hypothesized that a history of reproductive pathologies may represent 
underlying hormonal dysbalances or they may be exposures or insults that gradually 
accumulate and cause asthma.  
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Up to 10 reproductive pathologies were investigated through the creation of a score 
including: early menarche, irregular menses, polycystic ovarian syndrome (PCOS), 
endometriosis, infertility, pregnancy complications, early menopause, surgical menopause, 
hysterectomy, and an indicator for pre-menstrual syndrome (PMS). Two scores were 
investigated: score 1 including any of the above mentioned pathologies and score 2 
excluding pathologies related to menopause. We could not substantiate our hypothesis of an 
association between a cumulation of reproductive pathologies and new-onset of adult 
asthma, as we found no significant association between our reproductive pathology scores 
and incident doctor-diagnosed asthma in the female study population of SAPALDIA aged 18-
60 years at baseline. However, the prevalence of multiple pathologies, i.e. a score of 2 or 
more pathologies, was 21% for score 1 and only 3.3% for score 2, revealing that a history of 
multiple pathologies in our study population was mainly driven by menopause-related 
pathologies. We cannot rule out that reporting of reproductive pathologies occurring in the 
earlier reproductive life phase were underreported in our cohort aged 38 – 80 years in S3, 
the time of retrospective assessment of reproductive pathologies. Also, the inclusion of 
women of the whole reproductive life span leads to a heterogeneous study population which 
may actually blur associations of reproductive pathologies and new-onset of asthma. When 
running our model with individual reproductive conditions, we found a significant association 
with early menopause and asthma incidence, which when stratified by atopy, remained 
significant only in non-atopic women. To the best of our knowledge, no studies have 
investigated the role of age at menopause and asthma incidence, nor have previous studies 
stratified by atopy. We also found that BMI modified the effect of early menarche on asthma 
incidence among non-atopic women. Among non-atopic women, those with early menarche 
and high BMI as well as those with irregular menses and high BMI had an increased risk of 
new-onset of asthma. This modification by BMI points towards the importance of 
overweight/obesity in asthma incidence in women, something which we investigated further 
in men and women in chapter 6.  
When investigating the role of early menarche on asthma incidence in more detail and in a 
more well-defined study population, we saw a trend that women reporting menarche <12 
years had a higher risk of newly developing asthma than women who had menarche ≥12 
years, although our results did not reach statistical significance (chapter 5). The association 
was stronger among atopic women (figure 5.2) and strongest among young atopic women 
(table 5.4). To the best of our knowledge, this study is the first to investigate the association 
of early menarche and new-onset of asthma in the Swiss population. It is also among the first 
studies to investigate the impact of early menarche with prospective assessment of asthma 
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incidence in women in later adulthood. Similar to other studies (Al-Sahab et al., 2011; Fida et 
al., 2012a, 2012b; Lieberoth et al., 2014, n.d.; Macsali et al., 2011a; Salam et al., 2006a; 
Varraso et al., 2005a), we find a trend towards an increased risk of new-onset of asthma in 
women who experience early menarche; however, like Wei et al (2015), our results did not 
reach statistical significance. It is unlikely that the number of women in our study population, 
the percentage of women having early menarche, or the percentage of women having new-
onset of asthma would explain why our results did not reach a conventional level of statistical 
significance, since our numbers are quite comparable to other studies who did find a 
significant association (table 7.1). The fact that we saw the strongest association of early 
menarche and asthma incidence in young atopic women is consistent with our previous 
findings (Hansen et al., 2015) that young atopic women have the highest risk of newly 
developing asthma after the age of 18 (figure 3.1b). The trend of increasing risk of new-onset 
of asthma in overweight/obese women with early menarche is also consistent with other 
studies (Castro-Rodríguez et al., 2001; Herrera-Trujillo et al., 2005; Varraso et al., 2005c) 
who have found overweight/obese females with early menarche to have increased asthma 
severity (Varraso et al., 2005c), wheeze (Herrera-Trujillo et al., 2005), and asthma-like 
symptoms (Castro-Rodríguez et al., 2001). These findings point towards the importance of 
further investigating the role of overweight/obesity for asthma incidence in adulthood. 
 
7.1.2 Role of obesity as measured by body silhouettes 
There is a growing trend to view asthma as a condition related to systemic inflammation 
rather than a condition affecting exclusively the lungs (Bjermer, 2007). In studies 
prospectively investigating the association between obesity and asthma,  reported sex-
related differences are inconsistent (David A Beuther and Sutherland, 2007). It has been 
argued that BMI cannot distinguish between fat mass and muscle mass (Ness-Abramof and 
Apovian, 2008). Most notably, BMI has limitations in predicting abdominal fat deposition, 
which is associated with reduced pulmonary function, metabolic syndrome and 
cardiovascular complications (Arner, 1998; Chen et al., 2007; Janssen et al., 2004).  BMI 
may inadequately reflect fat distribution and may under- or overestimate obesity as wide 
variations in body fat distribution can occur within the same BMI percentile group (Musaad et 
al., 2009). BMI does not differentiate between fat and lean body mass, and for a given BMI, 
females generally have a higher proportion of body fat than males (Ellis et al., 1999).  Use of 
further measures is needed to investigate the association between adiposity and asthma in a 
sex-stratified approach. This is why, in order to assess the association between lifetime 
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history of overweight/obesity and incidence of asthma in men and women (chapter 6), we 
used body silhouettes as our weight measurement. 
We found that a larger body silhouette later in life, but not at young ages, increases the risk 
of new-onset of asthma in men, and even more so in women (chapter 6). In men, each unit 
increase in body silhouette at age 60 doubled the risk for asthma-onset after age 60. The risk 
increase for new onset of asthma in women was 1.5 fold for the body silhouette at 
menopause and 3 fold for the body silhouette at age 60. Change in body silhouette number 
over time was only significantly associated with the risk of new-onset of asthma in women 
between age 45- menopause, with an almost twofold risk. Despite low numbers, atopic 
status seems to be a modifying effect in women at menarche and menopause, but not in 
men. The results point to an important effect of overweight/obesity on asthma at older ages 
and in postmenopausal women. An age-related increase of weight may underlie new-onset 
of asthma at higher ages, especially in women.  
Our study is the first to assess the role of overweight/obesity as measured by body 
silhouettes for asthma incidence in men and women.  Romieu et al (2003a) found  that an 
increase in body silhouette between menarche and adulthood relates to the incidence of 
asthma later in life, however their study was conducted among women only. Our findings 
suggest that it is also crucial to recognize that overweight/obese males are at increased risk 
of asthma onset after age 60.  Authors who describe the phenotype of obesity-induced 
asthma note that it is characterized by lack of atopy, female predominance and late onset 
(Farzan, 2013; Koczulla et al., 2016). While our findings substantiate a relatively higher risk 
of late-onset asthma in overweight/obese women when compared to men, men who are 
overweight/obese at age 60 also have an increased risk of new-onset of asthma which needs 
to be recognized.  
As for the role of atopy, larger studies or pooled data are needed to substantiate our findings. 
Despite low numbers, when stratifying by atopy, we found a differential role of atopy in men 
and women over their lifespan. Only atopic women at menarche were at increased risk for 
new-onset of asthma with each unit increase in body silhouette. This finding could partly 
explain the pattern we observed previously (chapter 3) that young atopic women are at the 
highest risk of new-onset of asthma (Hansen et al., 2015 see figure 3a and 3b). In chapter 5 
when we investigated the role of early menarche for new-onset of asthma, our interaction 
term for early menarche and BMI did not reach statistical significance, however it could be 
because we used BMI at baseline and not body silhouette at menarche. Our study population 
was also not large enough to run the interaction term for early menarche and BMI in stratified 
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models by atopy.  Further research on this, in larger study populations would be beneficial. 
As for the role of atopy at age 60, we found that non-atopic men and women were at higher 
risk of asthma incidence per unit increase in body silhouette, the risk being more pronounced 
in women. These findings are consistent with and support the life course pattern on new-
onset of asthma we observed previously (Hansen et al., 2015 see figures 3a and 3b) with 
non-sensitised women more likely to newly develop asthma than non-sensitised men, a 
difference which decreased with increasing age.  
Because asthma in obese patients is difficult to treat (Koczulla et al., 2016) and adults who 
are obese are more likely to have higher asthma-related emergency room visits than their 
non-obese counterparts (Becerra, 2016), we must recognize the important effect of weight on 
asthma at older ages and in postmenopausal women. The associations of larger body 
silhouettes with asthma incidence in our study may help explain sex/gender differences in 
asthma incidence, however further research on the interaction of atopy on overweight/obesity 
and sex/gender differences in adult-onset asthma are needed. 
7.1.3 Piecing together the puzzle- asthma onset in adulthood  
In contrast to childhood-onset asthma, less is known about the prevalence and factors 
associated with adult-onset asthma. Studies have shown that it mainly affects women 
(Eagan et al., 2005), has a low remission rate (De Marco et al., 2002) and is less often 
associated with allergy and atopic diseases (Leynaert et al., 2012; Shaaban et al., 2008). It is 
also not clear to what extent the incidence of asthma among adults is age-dependent—
though some studies indicate a flat rate or even increase in the age groups 20-50 years 
(Eagan et al., 2005). In their review, Eagan et al (2005) call for more prospective studies in 
populations with a wide age span, to settle the issue of the true incidence of asthma in the 
middle aged and beyond, and whether the incidence is also higher in women in this age 
group (Eagan et al., 2005) 
In this PhD project, new-onset of adult-asthma has been explored from a life course 
perspective with an analytical focus on sex/gender related pathways.  We have confirmed 
that there is a female preponderance of asthma incidence in adulthood. Little was known on 
what happens with these sex/gender differences in adulthood (beyond the age >50 years). 
Even though severe asthma occurs more often in older adult patients (Zein et al., 2015), few 
studies of a prospective nature and with a representative population sample have been able 
to study asthma incidence in this age group. What we found was a decreasing trend of new 
asthma onset with age which is in contrast to the findings of the review by Eagan et al. 
(2005). However, in their review, the age course seemed less consistent in women for the 
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two studies reporting sex-specific rates (Lundbäck et al., 2001; Rönmark et al., 1997). 
Furthermore, the age trend disappeared in one of the studies when subjects with chronic 
bronchitis at baseline were excluded (Lundbäck et al., 2001), suggesting confounding of 
asthma incidence by chronic bronchitis in men. Our findings expand on earlier SAPALDIA 
findings showing lower prevalence rates of asthma in men and women compared with below 
age 60 years  (Wüthrich et al., 2013) and are in line with a recent Swedish study (Torén et 
al., 2011), showing a decrease of asthma incidence across an age range of 16-75 years in 
men and women overall, and in never-smokers. In our study, the negative association with 
age was much more pronounced among women than men. It remained significant also when 
restricting the analysis to never-smokers and when excluding subjects with COPD. The 
overlap of asthma and COPD would need to be studied in more detail, also on the 
background of reported diagnostic bias in relation to asthma and COPD (Chapman et al., 
2001b; Watson et al., 2004; Zemp et al., 2014). 
From this PhD work it also becomes clear that atopy and overweight/obesity are important 
sex/gender related pathways that may help explain the gendered life course pattern of adult-
onset asthma. In young adults, atopic women are in the highest risk group for new-onset of 
asthma. Previous studies have characterized late-onset of asthma as predominantly female 
and non-allergic. Whereas we did indeed see a female preponderance of adult-onset asthma 
and the largest sex/gender differences in non-allergic asthma, it is also important to 
recognize that young atopic females are at the highest risk of asthma as of age 18. We are 
also the first study to investigate the role of overweight/obesity as measured by body 
silhouettes and found that a larger body silhouette later in life, but not at young ages, 
increases the risk of new-onset of asthma in men, and even more so in women. Because 
asthma in obese patients is difficult to treat (Koczulla et al., 2016) and adults who are obese 
are more likely to have higher asthma-related emergency room visits than their non-obese 
counterparts (Becerra, 2016), we must recognize that women with a larger body silhouette at 
menopause and age 60, and men with a larger body silhouette at age 60 are at increased 
risk of new-onset of asthma. This adds to and underscores previous findings that women 
have more difficulty controlling symptoms and show more adverse effects to drugs (Choi, 
2011). Severe complications from asthma are more common in women than in men, leading 
to more frequent or longer hospitalization and higher death rates (European Institute of 
Women’s Health, 2014; Office on Women’s Health, 2006). Moreover, many patients with 
adult-onset asthma have a poor prognosis (De Marco et al., 2002), with a faster decline in 
lung function and have compromised lung function even if they have asthma of short duration 
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(Jenkins et al., 2003). Clearly further research into sex/gender related pathways in asthma 
incidence remains crucial.  
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Table 7.1: Summary Literature Early Menarche & Asthma 
 Author (year) Study Participants/Studies Included Definition Early Menarche Adjusted OR (95% CI) 
Hansen et al 
(2016)* 
SAPALDIA
†
 N= 2,492 18-60 years < 12 years = 10.0%
‡
 
1 SD < mean = 12.0%
‡
 
2 SD < mean = 2.3%
‡
 
1 SD < language region specific mean = 19.1%
‡
 
1.23 (0.85 - 1.80) 
1.23 (0.85 - 1.80) 
1.12 (0.51 - 2.46) 
1.25 (0.90 - 1.73) 
Lieberoth et al. 
(2014) 
Systematic 
Review & 
Meta-
Analysis 
N= 7 studies Xu (2000)  
Herrera-Truijillo 
(2005) 
Salam (2006) 
Macsali (2011) 
Al-Sahab (2011) 
Fida (2012) 
Gnatiuc (2013) 
< 12 yrs. 1.37 (1.15- 1.64)
§
 
Macsali  
et al. (2012) 
Literature 
Review 
- - - Early menarche ↑ asthma & 
asthma symptoms 
Wei et al. (2015) ISAAC
ll
  
(Germany)  
N=992 9-11 yrs. Early (<mean 1SD)  = 
19%
‡
 
Normal (mean ± 1 SD) 
Late (>mean + 1 SD) = 
23%
‡
 
Self report or 
doctor diagnosed asthma 
≥ 1 yr. menarche 
= 3%
‡
 
1.87 (0.79 - 4.40) 
Lieberoth et al. 
(2015)  
Danish Twin 
Registry 
(Denmark) 
N= 10,648 12-41 yrs. <12 yrs 9.3%
‡
 Doctor diagnosed 
asthma at follow-up 
= 4.8%
‡
 
1.53 (1.15-2.04) 
Burgess et al. 
(2007)** 
TAS** 
(Tasmania) 
N= 753 7-21 yrs. ≤ 11 yrs 16.8%
‡
 Asthma onset >21 yrs. = 
5.4%
‡
 
1.79 (0.68 – 4.72) 
*Studies marked in red did not find a significant association between early menarche and new-onset of asthma, 
†
Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in 
Adults, 
‡
Blue indicates the percentage with that condition reported in the study, 
§ 
random effects odds ratio and 95% confidence interval, 
ll
Subset of the cohort enrolled in Munich and 
Dresden in 1995 and 1996 as part of The International Study of Asthma and Allergens in Childhood Phase II Study, **Tasmanian Health Study 
Discussion 
 
 
137 
 
7.2 Strengths and Limitations 
 
7.2.1 Overall Strengths  
The primary strength of this study is its large database representing the general Swiss 
population from urban, rural and mountainous areas with different environmental exposure 
characteristics (figure 2.1), standardised health assessments and a women’s health 
questionnaire that was developed alongside the European Community Respiratory Health 
Survey (ECHRS) (appendices 3-6). Given the great breadth and depth of The Swiss Cohort 
Study on Lung and Heart Disease in Adults (SAPALDIA), we were able to investigate 
sex/gender differences in adult-onset asthma in the general population aged 18-60 at 
baseline in 1990 and take into account reproductive pathologies, BMI/body silhouettes, age, 
atopy, parental asthma, early-life respiratory infection, occupational exposure, smoking, 
educational status and urbanity. This PhD project is important because there are very few 
studies on adult-onset asthma that ascertain incident, rather than prevalent, asthma cases 
(Torén and Hermansson, 1999). As Eisner (2002) correctly points out, studies focusing on 
risk factors for prevalent asthma cannot distinguish whether an exposure causes new cases 
of asthma or adversely affects persons with pre-existing disease, resulting  in a longer 
duration of symptoms.  As such, the present study makes a significant contribution to the 
literature. 
A further strength of this study and the SAPALDIA database is the opportunity to investigate 
the cumulative impact of reproductive pathologies and asthma incidence in women. 
Reproductive risk factors developing in different stages throughout a women’s life are seldom 
singular experiences (Cao et al., 2015). Taking a life-course approach, we investigated the 
role of cumulative reproductive pathologies in relation to asthma incidenc, hypothesizing that 
these reproductive histories may represent underlying hormonal dysbalances or that they 
may be exposures or insults that gradually accumulate and cause asthma (section 2.4.1). 
Although we could not substantiate our hypothesis of an increased risk of new-onset of 
asthma with an increased number of reproductive pathologies, it would be beneficial for 
future studies to take such an approach, with prospective data assessment and perhaps 
using a survival model approach. 
A final strength of this study lies in the body silhouette questionnaire (figure 6.1a and figure 
6.2b) which was introduced in the third follow-up of SAPALDIA in 2010/2011, allowing the 
assessment of body silhouettes from age 8 to age 60 and older in men and women. One 
benefit of using body silhouettes as a weight measure is that it may better capture the 
difference between fat mass and muscle mass than BMI. This is important because females 
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generally tend to have a higher proportion of body fat than males (Ellis et al., 1999).  BMI 
also has limitations in predicting abdominal fat deposition, which is associated with reduced 
pulmonary function, metabolic syndrome and cardiovascular complications (Arner, 1998; 
Chen et al., 2007; Janssen et al., 2004). Therefore BMI may inadequately reflect fat 
distribution and may under- or overestimate obesity as wide variations in body fat distribution 
can occur within the same BMI percentile group (Musaad et al., 2009). Another benefit of the 
body silhouette questionnaire is that it offers the opportunity to study overweight/obesity from 
a lifecourse perspective, allowing us to investigate the impact of overweight/obesity at what 
may be critical periods, but also, the cumulative impact of overweight/obesity or even the 
impact of changes body composition at different life stages.  
7.2.2 Added benefit of life course perspective 
As mentioned in section 2.3.1, a life course approach takes into account the temporal and 
social perspective, investigating the individual’s experiences and their current and past 
patterns of health and disease, taking socio-cultural, environmental and economic context 
into account (WHO, 2000). Different stages in life are addressed: early life, childhood, 
adolescence, young adulthood, and the different phases in adulthood from reproductive to 
occupational life phase as well as old age. Each life stage affects health and disease 
development, thereby impacting on the chances of healthy aging. 
By taking a life course perspective we were able to reveal some important sex/gender related 
differences in adult-onset asthma: asthma incidence was higher in women than in men but 
this difference decreased with increasing age. The female predominance was considerably 
stronger in non-sensitised adults compared with those with allergic sensitisation.  We also 
found that a larger body silhouette later in life, but not at young ages, increases the risk of 
new-onset of asthma in men, and even more so in women.  
Taking a lifecourse perspective on sex/gender differences in adult-onset asthma is also 
important because the particular time points at which exposures occur (critical or sensitive 
periods), or the sequence in which exposures occur (exposure trajectory), or the utter 
intensity of the exposure of time (accumulation), are important for understanding outcomes 
later in life (Lynch, 2003). Through using the SAPALDIA cohort study and taking such a 
lifecourse approach we were able to investigate sex/gender related pathways in adult-onset 
of asthma while adjusting for relevant confounders occurring at all stages in life, from early 
childhood to late adultood. As Lynch (2003, p. 1122) emphasizes, “time matters in regard to 
better understanding health and inequalities”. The ability to assess new-onset of asthma over 
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the adult life-course and in those aged >50 provided important insights. The added benefit of 
taking a sex and gender sensitive approach over the life-course by investigating asthma 
incidence in a sex-stratified approach, important differences with regard to atopy and the role 
of overweight/obesity became evident.   
7.2.3 Added benefit of sex/gender perspective  
Understanding sex and gender differences in asthma is important to provide effective 
education and personalized management plans for asthmatics across the life course  (Zein 
and Erzurum, 2015). When reflecting on the proposed analytical framework for studying  sex 
and gender (section 1.1.2), the strength of this study is that we followed these guidelines and 
reported  the sex of our participants, recognized differences within groups of females and 
males such as differences by age and atopy, collected information on factors intersecting 
with sex such as education, smoking, ageing, atopy, occupational exposure, and finally, we 
tried to report results as clearly as possible, following standards in literature, so that our 
results could be used for potential future meta-analyses.  
Our results clearly reflect a mixture of sex and gender related pathways which have an 
impact on asthma. This gives rise to a unique view on asthma incidence and pathways in 
which gender might produce differences. We were also able to investigate sex/gender 
differences in asthma in later adulthood where very little data exists. SAPALDIA offered the 
unique opportunity to investigate gender differences in asthma incidence from a life-course 
perspective. Perhaps this work will also inspire others to take such an approach. As 
epidemiologist Lesley Doyal states (2003, p. 578) “In the coming decades, some of the most 
exciting work in health research will be interdisciplinary in approach, and epidemiologists are 
especially well placed to contribute to these developments. The growing interest in the links 
between the biological and the social offers unique opportunities for epidemiologists to work 
with colleagues across those disciplinary boundaries. With their history of using biomedical 
techniques in a social context, I believe they can play a central role in mainstreaming sex 
and gender in health research”. 
7.2.4 Limitations  
As the SAPALDIA study is of a prospective nature, recall bias is unlikely. However, early 
menarche, some reproductive pathologies, and some body silhouettes were reported 
retrospectively. When investigating the role of early menarche and and asthma-onset  
(chapter 5), women in our study population were 18-60 years at baseline and therefore had 
to recall their age at menarche and age of first asthma attack retrospectively up to around 40 
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years back. This may have introduced some recall bias (Must et al., 2002), which may have 
possibly led to the insignificant odds ratios and moderate agreement between reported age 
at menarche in the two surveys (S1 & S2). Such inconsistencies have also been found in 
regards to reported age of first asthma attack by Künzli et al (2009). This is to some extent 
also consistent with the higher kappa statistic we found for agreement and slightly higher 
odds ratios in those aged ≤30 years at baseline. However, studies looking at recall of early 
menarche generally have found a quite good correlation between recoded and recalled 
menarche in women both close to and distant from the event (Casey et al., 1991; Must et al., 
2002).  
When investigating the life history of body silhouettes a possible limitation is the remote 
recall of body silhouettes as well as the accuracy of self-reported body silhouettes. Worse 
recall of body silhouette at younger ages may have biased associations with asthma onset 
during earlier years towards null. However, a few studies have also looked at the validity of 
remote recall of body silhouettes (Koprowski et al., 2001; Muñoz et al., 1996; Must et al., 
1993; Troy et al., 1995). Must et al. (1993) found high correlations between body silhouettes 
and measured BMI for females at several ages (correlation coefficient of 0.65 at 10 years of 
age, 0.75 at 15 years, 0.66 at 20 years and 0.75 for current age), even when using adult 
silhouettes to represent their body sizes at age 10 and 15 years. Troy et al. (1995) reported 
correlation of 0.66 between BMI at age 18 years and silhouettes compared with a correlation 
of 0.84 for actual and recalled BMI at 18 years. Munoz et al (1996) obtained correlations of 
0.75 for BMI and silhouettes compared with 0.89 for actual and recalled BMI. As for 
Koprowski et al (2001) they found that recall of body shape at menarche was considered to 
be a less precise measure than asking about weight and height, but use of body silhouettes 
may offer a more practical method for obtaining information for the past. And finally, Bulik et 
al (2001) found that  figural stimuli are effective in classifying individuals as obese or thin.  
Even though asthma incidence was reported prospectively, there could be a differential 
reporting of asthma in men and women in higher age groups as suggested by Torèn et al. 
(2011). We can only speculate that this might have had an impact on the low probability of 
incident asthma in the oldest ages and the decreasing sex/gender differences with age. 
Furthermore, in older ages, it is well-known that there may be misdiagnosis of asthma with 
COPD (Braman, 2003) or patients may even have asthma-COPD overlap syndrome (ACOS) 
(GINA, 2015; Wheaton et al., 2016) . There may also be sex/gender differences in diagnosis 
and reporting of asthma and COPD  (Chapman et al., 2001a; Wheaton et al., 2016).  
Although our results in chapter 3 did not differ when additionally adjusting for COPD, it would 
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be interesting for future research to investigate whether there is diagnostic bias for asthma in 
the SAPALDIA cohort population.  
Since there exists no gold standard for defining asthma, any definition will have its 
limitations. In our study we used doctor-diagnosed asthma which has been found to have 
high specificity and low sensitivity (Torén et al., 2004)- sensitivity being the proportion of 
subjects with ‘true’ asthma and specificity being the proportion of subjects without asthma 
who are correctly identified. When estimating risk factors for asthma it has been argued that 
specificity is often the most important validity measure (Torén et al., 1993). Although clinical 
diagnosis of asthma is difficult (section 1.2), agreement between physicians seems to be 
fairly good (de Marco et al., 1998).  It would be interesting for future research to investigate 
whether the sensitivity and specificity of doctor-diagnosed asthma differs by sex/gender and 
could help to explain some differences observed between men and women.  
Finally, when reflecting on our sex/gender analytical approach, one limitation of this PhD 
project may have been that we did not pay enough explicit attention to our own assumptions 
and behaviors as these relate to the proposed research, as outlined in section 1.1.4. By 
focusing primarily on sex/gender related pathways, we may have overlooked other important 
aspects of adult-onset asthma. One such aspect, for which the gendered innovations project 
has also been criticized, is its lack of attention to race and ethnicity. Asthma has been shown 
to differ according to ethnicity (Forno and Celedón, 2009; Koebnick et al., 2016; Zein et al., 
2016). However detailed information on race/ethnicity is not available in SAPALDIA, only 
whether participants were of non-European descent. In general the SAPALDIA study may 
miss information on health in non-swiss residents such as migrants or temporary residents 
as it was a requirement to take part in the SAPALDIA survey to speak German, French or 
Italian, and the study was restricted to the ‘stable population’, requiring at least 3 years of 
residence in the respective study areas. Therefore, those living in Switzerland and not 
speaking one of these three languages, as well as the migrant population, were excluded. 
This may be an interesting aspect for future research on asthma in Switzerland.  And finally, 
as Springer et al (2012a) emphasized- sex and gender are entangled (Springer et al., 2012a) 
and it is not easy to separate the influence of sex and gender (Regitz-Zagrosek, 2012), and 
unmeasured aspects of gender may be present in this work as well. 
7.3 Implications for research 
The decreasing trend of new asthma onset with age is in contrast to the findings of the 
review by Eagan et al. (2005), which showed an increase of risk with greater age for studies 
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with a wide age span and adjusted risk estimates. Their observed age course, however, 
seemed less consistent in women for the two studies reporting sex-specific rates (Lundbäck 
et al., 2001; Rönmark et al., 1997). Furthermore, the age trend disappeared in one of the 
studies when subjects with chronic bronchitis at baseline were excluded (Lundbäck et al., 
2001), suggesting confounding of asthma incidence on chronic bronchitis in men. Our 
findings expand earlier SAPALDIA findings showing lower prevalence rates of asthma in men 
and women compared with below age 60 years  (Wüthrich et al., 2013) and are in line with a 
recent Swedish study (Torén et al., 2011), showing a decrease of asthma incidence across 
an age range of 16-75 years in men and women overall, and in never-smokers. The negative 
association with age we found was much more pronounced among women than men. It 
remained significant also when restricting the analysis to never-smokers (table 3.4) and 
when excluding subjects with COPD. Future studies should further investigate whether there 
is a decrease in asthma incidence across this age range and whether this differs between 
men and women. 
We were not able to substantiate a role of reproductive histories on asthma incidence. Future 
studies may need to be prospective, following girls from the time of their transition into 
puberty, but also follow them up to adulthood to prevent recall bias blurring the association 
between early menarche and adult-onset asthma. The association of body silhouettes with 
asthma incidence seems to be modified by atopy but our study population was not large 
enough to confirm these results. Pooled data analysis with ALEC or ECHRS would allow to 
further study the association of body silhouette with asthma incidence stratified by atopy.  
To the best of our knowledge, no research on gender differences on asthma incidence has 
been conducted in low-middle income countries. Previous studies have shown that low-
middle income countries have a great burden of disease but also that non-allergic asthma is 
more common in low-middle income countries. Since the greatest gender differences are 
observed in those with non-allergic asthma (Hansen et al., 2014; Leynaert et al., 2012), 
research into gender differences in low-middle income countries could lead to a better 
understanding of reported increases of asthma prevalence in low-middle income countries. 
 Future studies should address possibly gendered pathways in disease perception and 
diagnosis. Gender-based differences in reporting of some respiratory symptoms are known, 
such as more frequent reporting of phlegm by men, or shortness of breath by women, which 
often are attributed to socio-cultural factors but may actually arise from interaction of socio-
cultural and biological factors (Becklake, 2003). In a study in France, shortness of breath was 
more frequently reported by adult women than adult men across all quintile levels of FEV1 
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(Becklake, 2003), suggesting a differential perception. Whether differences in hospital 
admissions, as documented in several earlier studies (Prescott et al., 1997; Skobeloff et al., 
1992; Yunginger et al., 1992) reflect differences in asthma severity or differential help 
seeking behavior is not completely clear neither. However, evidence suggests that diagnostic 
bias affects the diagnoses of asthma and COPD: Gender biases in diagnosis of asthma have 
been reported for children, with girls being less likely to be diagnosed with asthma and to 
receive medication for their asthma (Kühni and Sennhauser, 1995). Despite a reversal in 
prevalence of asthma symptoms from a higher prevalence in boys at age 7 to a higher 
prevalence in girls at age 15, the diagnostic label of asthma was twice as high in boys than in 
girls at any age (Sennhauser and Kühni, 1995). Girls with symptoms were less likely than 
boys to see a doctor and to be labeled as having asthma (Wright et al., 2006). Diagnostic 
bias has however not been found in all settings and Venn suggested that girls may over-
report asthma-symptoms and boys to deny them, resulting in an overestimation of the gender 
difference observed at age 12  (Venn et al., 1998). Few studies have investigated the 
possibility of a differential diagnosis in adults (Adams et al., 2003; Becklake and Kauffmann, 
1999; Eagan et al., 2005; Redline and Gold, 1994). It has been reported that primary care 
physicians under-utilize spirometry (Franks et al., 1995) and that women are less likely to be 
referred to specialists than men (Watson et al., 2004). Given similar presenting of symptoms, 
women were more likely to be diagnosed with asthma, men were more likely to be diagnosed 
with COPD (Dodge and Burrows, 1980). This was confirmed in an experimental setting, 
where physicians were given a case history with half obtaining the information that the case 
would be a male patient, the other half it would be a female patient. The likelihood that – with 
the identical case history - physicians assigned a diagnosis of asthma was higher for female 
patients, the likelihood that they assigned a diagnosis of COPD higher for male patients 
(Chapman et al., 2001a).The differential diagnosis of asthma is difficult in older adults and 
asthma is under recognized and undertreated in the older population (Lindner et al., 2007). 
Future studies should investigate the potential role for differential diagnosis and 
misclassification of COPD and asthma. Asthma may be misdiagnosed, especially in the 
elderly. By asthma, one commonly thinks of episodic wheezing (with dyspnea) but in the 
elderly, symptoms which commonly occur such as cough, sputum production and shortness 
of breath can quite easily be mistaken for chronic bronchitis, occupational lung disease or 
decompensated heart failure, conditions which often coexist (Banerjee et al., 1987). 
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7.4 Implications for policy and practice 
I. Asthma-onset in adulthood should be recognized, particularly in women.  The 
finding that 5% of men and 7% of women aged 18-60 years at baseline newly develop 
asthma over a time span of 20 years underscores the importance to recognize the  risk of 
new-onset of asthma in adulthood. Awareness of this risk is warranted especially in 
women, as their confounder-adjusted risk is twice as high as in men. 
II. Adult-onset of asthma is modified by age and atopy. A higher asthma incidence was 
seen among atopic persons, particulary in younger women. With a probability of 
developing new onset asthma of around 20%, young atopic women have to be 
recognized as a particular risk group for asthma-onset. Establishing the respective 
diagnosis appears relevant for the choice of the therapeutic procedure: The reported 
excess decline in lung function in those with asthma can be reduced by regular use of 
inhaled steroids (Lange et al., 2006), particularly those with high total IgE (de Marco et 
al., 2007). This should be consequently applied in young women with atopic asthma. 
Furthermore, an early start of treatment seems crucial, since it has been shown that early 
initiation of low dose ICS in patients with asthma leads to a greater improvement in lung 
function than if symptoms have been present more than 2-4 years (Busse et al., 2008; 
Selroos et al., 1995). One study even showed that after this time, higher ICS doses were 
required, and lower lung function was achieved (Selroos, 2008). Overall however, women 
are more likely than men to have non-allergic asthma. Women with non-allergic asthma 
often require higher doses of ICS (GINA, 2016) or are relatively refractory to 
corticosteroid treatment (O’Byrne et al., 2009). For these women, other therapeutic 
strategies or approaches might be more adequate.  
III. III. Obesity should be targeted as a modifiable risk factor for new-onset of asthma, 
especially in late adulthood. We found that a larger body silhouette later in life, but not 
at young ages, increases the risk of new-onset of asthma in men, and even more so in 
women. Awareness is crucial that women as well as men who are overweight/obese, are 
at risk for adult-onset of asthma in later adulthood, with women’s elevated risk starting 
already with the menopausal transition. Given that asthma in obese patients is difficult to 
treat (Koczulla et al., 2016) and adults who are obese are more likely to have higher 
asthma-related emergency room visits than their non-obese counterparts (Becerra, 
2016), prevention of overweight/obesity in later adulthood appears crucial. The number of 
older people with asthma will rise in the next 20 years because of the worldwide 
population trend towards enhanced longevity, with  a disproportionate increase in 
individuals aged older than 64 years (Gibson et al., 2010). On this background it is 
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important to know that those aged >60 are at risk of newly developing asthma if they are 
overweight/obese, women even more so than men.   
7. 5 Conclusion & outlook 
This study is among the few to report the cumulative incidence of adult-onset asthma by 
sex/gender in a population-based study with a high proportion of people aged >50 years of 
age. The more pronounced decrease of asthma incidence by age among atopic compared to 
non-atopic women, and the decreasing sex differences with age are novel findings. Our 
study is also the first to assess the role of overweight/obesity as measured by body 
silhouettes for asthma incidence in men and women.  We found that a larger body silhouette 
later in life, but not at young ages, increases the risk of new-onset of asthma in men, and 
even more so in women. Given the importance of asthma in terms of disease burden as well 
as the epidemic of obesity, knowledge on these sex/gender related pathways is crucial and 
adds a further argument for obesity prevention strategies.  
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Appendix 3: Women’s Health Questionnaire SAPALDIA 2 
FRAUEN-FRAGEBOGEN 
 
  JAHRE 
1.Wie alt waren Sie, als Sie Ihre erste Monatsblutung hatten? 1.  1.  
 
 NEIN JA 
2.Haben Sie jemals ein Kind geboren ? (tot geborene Kinder eingeschlossen)    
 
 
Wenn „NEIN“ gehen Sie zu Frage 3; wenn „JA“ fahren Sie bitte hier fort: 
 
                ANZAHL 
 2.1 Wie viele Kinder (tot geborene eingeschlossen, falls zutreffend)?   
  
ANZAHL 
2.2     Wie viele in den letzten 10 Jahren (tot geborene  
           eingeschlossen, falls zutreffend)? 
  
 
      TAG  MONAT  JAHR 
 2.3 Wann hatten Sie die letzte Geburt?         
 
   NEIN      JA 
3. Sind Sie zur Zeit schwanger?    
  
 
Wenn „JA“ haben Sie diesen Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „NEIN“ fahren Sie bitte hier fort: 
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 TAG  MONAT  JAHR 
4. Wann hatten Sie den ersten Tag Ihrer letzten   
    Monatsblutung? 
        
 
 
War die letzte Blutung in den vergangenen 6 Monaten?  
    Wenn „JA“, gehen Sie bitte zu Frage 5.  
 
    Wenn „NEIN“, fahren Sie bitte hier fort. 
 
Wenn die letzte Monatsblutung mehr als 6 Monate zurückliegt:  
 
 4.1 Wie haben Ihre Monatsblutungen aufgehört?  
                                                                                                           BITTE KREUZEN SIE NUR EIN FELD AN 
 Natürlicherweise   1  
 Aufgrund einer Operation    (Gebärmutterentfernung, Eierstockentfernung) 2  
 Anderes 3  
(Wenn Anderes, bitte 
erklären).............................................................................................................................. 
 
 
  NEIN       JA 
 4.2 Haben Sie jemals eine Hormonersatzbehandlung gehabt?    
 
Wenn „NEIN“ gehen Sie zu Frage 4.3, wenn „JA“ fahren Sie hier fort: 
 
   MONATE 
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4.2.1.Während wie vieler Monate in den letzten 10 Jahren haben Sie   
         eine Hormonersatzbehandlung gehabt? (Gesamtdauer) 
   
   NEIN       JA 
  4.2.2. Haben Sie diese Hormonersatzbehandlung während des  
                            letzten Monats gehabt? 
   
 
 
Wenn „NEIN“ gehen Sie zu Frage 4.3, wenn „JA“ fahren Sie bitte hier fort: 
 
   
         4.2.2.1. Welches Hormonersatzpräparat  benutzen Sie?                                                            
 
       MONATE 
               4.2.2.1.1. Wie viele Monate wenden Sie dieses Präparat bereits an?    
 
   NEIN JA 
        4.3.Haben Sie jemals hormonelle Empfängnis-Verhütungsmittel eingenommen  
       (z. B. die „Pille“)? 
   
 
 
Wenn „NEIN“ haben Sie den Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „JA“ fahren Sie bitte hier fort: 
 
   MONATE 
4.3.1 Wieviele Monate in den letzten 10 Jahren haben Sie  
         hormonelle Empfängnis-Verhütungsmittel eingenommen?  
   
                          (Gesamtdauer)  
Sie haben den Fragebogen vollständig beantwortet. Herzlichen Dank! 
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Wenn die letzte Monatsblutung innerhalb der vergangenen 6 Monate war:  
 
5. Sind Ihre Monatsblutungen regelmässig?   
                                                                                         BITTE KREUZEN SIE NUR EIN FELD AN 
 Ja 1  
 Nein, sie waren nie regelmässig 2  
 Nein, sie waren während einiger Monate unregelmässig 3  
 
 
6. Wie gross ist der übliche Abstand zwischen ihren Monatsblutungen? (vom ersten Tag der  
    einen Blutung bis zum ersten Tag der darauf folgenden) 
  
                                                                                 BITTE KREUZEN SIE NUR EIN FELD AN 
 Weniger als 24 Tage 1  
 24-26 Tage 2  
 27-29 Tage 3  
 30-32 Tage 4  
 Mehr als 32 Tage 5  
       Keine der angegebenen Kategorien: die Blutungen sind zu unregelmässig  6  
 
   NEIN JA 
7. Haben Sie jemals hormonelle Empfängnis-Verhütungsmittel eingenommen (z. B.  
    die „Pille“)? 
   
  
Wenn „NEIN“ gehen Sie zu Frage 8; wenn „JA“ fahren Sie bitte hier fort: 
 
   MONATE 
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7.1.Wieviele Monate lang in den letzten 10 Jahren haben Sie hormonelle  
       Verhütungsmittel eingenommen? (Gesamtdauer) 
   
  
   NEIN JA 
7.2 Haben Sie hormonelle Verhütungsmittel innerhalb des letzten Monats 
      eingenommen? 
   
 
Wenn „NEIN“ gehen Sie zu Frage 8; wenn „JA“ fahren Sie bitte hier fort: 
 
 
  7.2.1 Welches Verhütungsmittel?    
       MONATE 
  7.2.2 Wieviele Monate lang nehmen Sie dieses Mittel bereits?    
   NEIN JA 
8. Haben Sie in den letzten 10 Jahren eine Hormonbehandlung aus irgend 
einem anderen Grund als zur Verhütung gehabt? 
   
  
 
Wenn „NEIN“ haben Sie den Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „JA“ fahren Sie bitte hier fort: 
 
   NEIN JA 
8.2. Haben Sie während des vergangenen Monats eine Hormonbehandlung   
           gehabt, um schwanger zu werden? 
   
    
Wenn „JA“ haben Sie den Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „NEIN“ fahren Sie bitte hier fort: 
 
   NEIN JA 
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8.2.      Haben Sie in den letzten 10 Jahren eine Hormonersatzbehandlung für die  
          Menopause gehabt? 
   
    
 
Wenn „NEIN“ haben Sie den Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „JA“ fahren Sie bitte hier fort: 
 
            MONATE 
8.2.1 Wieviele Monate lang in den letzten 10 Jahren haben Sie  
         ein Hormonersatzpräparat angewendet? (Gesamtdauer) 
   
   NEIN   JA 
8.2.2 Haben Sie Hormonersatzpräparate innerhalb des letzten Monats  
         angewendet? 
   
 
 
Wenn „NEIN“ haben Sie den Fragebogen vollständig beantwortet. Herzlichen Dank! 
 
Wenn „JA“ fahren Sie bitte hier fort: 
 
 
       8.2.2.1. Welche Hormonersatzpräparate?    
 
       MONATE 
       8.2.2.2. Wieviele Monate lang wenden Sie dieses Präparat bereits an?    
 
 
Sie haben den Fragebogen vollständig beantwortet. Herzlichen Dank! 
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_______________________________________________________________________________ 
 
   Frauenspezifische Gesundheitsthemen 
Es folgen nun einige Fragen zu frauenspezifischen Gesundheitsthemen. 
_______________________________________________________________________________ 
 
 Beanworten Sie die folgenden Fragen bitte nur, wenn Sie eine Frau sind, ansonsten: vielen Dank für Ihre 
Mitarbeit! 
 
383 [S3WOA3810]: Wie alt waren Sie, als Sie Ihre erste Monatsblutungen 
hatten? 
 
Bitte schreiben Sie Ihre Antwort hier:       Jahre alt 
 
_______________________________________________________________________________ 
 
 Wenn Sie nie eine Monatsblutung gehabt haben, gehen sie bitte weiter zu Frage 410, Seite 64. 
 
384 [S3WOA3820]: Haben Sie regelmässige Monatsblutungen? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Ja 
 Nein, meine Monatsblutungen waren nie regelmässig 
 Nein, meine Monatsblutungen waren in den letzten Monaten unregelmässig 
 Nein, ich habe keine Monatsblutung mehr 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
385 [S3WOA3830]: Was ist das normale Intervall zwischen Ihren 
Monatsblutungen oder was war das normale Intervall zwischen Ihren 
Monatsblutungen bevor sie aufgehört haben? (vom ersten Tag einer 
Monatsblutung bis zum ersten Tag der nächsten) 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Weniger als 24 Tage 
 24-26 Tage 
 27-29 Tage 
 30-32 Tage 
 33-35 Tage 
 Mehr als 35 Tage 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
386 [S3WOA3840]: Verspüren Sie (oder verspürten Sie) üblicherweise in den 
Tagen vor der Monatsblutung oder in den ersten Tagen nach Einsetzen der 
Blutung die folgenden Beschwerden: 
 
Wut /Gereiztheit? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
387 [S3WOA3850]: Ängstlichkeit oder Anspannung? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
 
388 [S3WOA3860]: Weinerlichkeit oder erhöhte Empfindlichkeit bei 
Zurückweisungen? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
389 [S3WOA3870]: Gefühl von Niedergeschlagenheit oder Hoffnungslosigkeit? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
390 [S3WOA3880]: Schlafprobleme? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
391 [S3WOA3890]: Bauchschmerzen (so dass Sie Schmerzmittel nehmen 
mussten)? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
392 [S3WOA3930]: Wann war Ihre letzte Monatsblutung? 
 
Bitte schreiben Sie Ihre Antwort hier: (Tag/ Monat/ Jahr) 
 
Datum:   /  /   
_______________________________________________________________________________ 
 
 Bitte nur beantworten, wenn Ihre letzte Monatsblutung innerhalb der letzten 12 Monate war, sonst 
gehen Sie weiter zu Frage 402. 
 
393 [S3WOA3950]: Wie viele Monatsblutungen hatten Sie in den letzten 12 
Monaten? 
Bitte schreiben Sie Ihre Antwort hier:  
_______________________________________________________________________________ 
 
394 [S3WOA3900]: Haben Ihre Menstruationsprobleme Sie während den letzten 
12 Monaten jemals in Ihrer Arbeit beeinträchtig?  
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
395 [S3WOA3910]: Mussten Sie auf Grund Ihrer Menstruationsprobleme 
während der letzten 12 Monate an der Arbeit wegen Krankheit fehlen? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
396 [S3WOA3920]: Haben Sie Ihre Menstruationsprobleme während der letzten 
12 Monaten jemals in Ihren Aufgaben zu Hause beeinträchtigt? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
 
_______________________________________________________________________________ 
 
 
397 [S3WOA3960]: Dauert Ihr Monatszyklus in den letzten 12 Monaten oft, 
d.h.(mehr als zwei Mal im Jahr) länger als 35 Tage? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
398 [S3WOA3970]: Waren Ihre Monatsblutungen in den letzten 12 Monaten 
unregelmässig? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein  gehen Sie bitte zu Frage 406, Seite 64 
 Ja 
 Ich weiss nicht  gehen Sie bitte zu Frage 406, Seite 64 
_______________________________________________________________________________ 
 
399 [S3WOA3980]: Wie lange sind Ihre Monatsblutungen unregelmässig 
gewesen? 
 
Bitte schreiben Sie Ihre Antwort hier:  Monate 
_______________________________________________________________________________ 
 
400 [S3WOA3990]: Sind Sie zurzeit schwanger? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
401 [S3WOA4000]: Stillen Sie zurzeit? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
 
 
 Beanworten Sie die folgenden Fragen bitte nur, wenn Sie in den letzten 12 Monaten keine 
Monatsblutung hatten, ansonsten gehen Sie zu Frage 406. 
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_______________________________________________________________________________
402 [S3WOA4010]: Welche Aussage beschreibt den Grund für das Ausbleiben 
Ihrer Monatsblutungen in den letzten 12 Monaten am besten? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Menopause 
 Hysterektomie (operative Entfernung der Gebärmutter) 
 Entfernung der Eierstöcke 
 Schwanger/Stillend 
 Medikamenten (z.B. Hormonspirale, Verhütungsimplantat, Chemotherapie) 
 Andere 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
 Beanworten Sie diese Frage bitte nur, wenn ein Medikament der Grund für das Ausbleiben der 
Monatsblutungen war, ansonsten gehen Sie zu Frage 404. 
 
403 [S3WOA4020]: Welches Medikament war das:  
 
Bitte schreiben Sie Ihre Antwort hier: 
 
Name des Medikaments: _________________________________________________ 
 
_______________________________________________________________________________ 
 
404 [S3WOA4030] : Sind Ihre Monatsblutungen unregelmässig geworden, 
bevor sie aufgehört haben? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein   gehen Sie bitte zu Frage 406 
 Ja 
 Ich weiss nicht     gehen Sie bitte zu Frage 406 
_______________________________________________________________________________ 
 
405 [S3WOA4040]: Wie alt waren Sie, als Ihre Monatsblutungen unregelmässig 
wurden? 
 
Bitte schreiben Sie Ihre Antwort hier:  Jahre alt 
_______________________________________________________________________________ 
 
406 [S3WOA4050]: Es gibt Frauen, die in der Zeit der Wechseljahre 
Hitzewallungen (oder nächtliche Schweissausbrüche) haben, auch wenn sie 
noch Monatsblutungen haben. Hatten Sie jemals irgendeines dieser Symptome? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein  gehen Sie bitte zu Frage 410 
 Ja 
 Ich weiss nicht  gehen Sie bitte zu Frage 410 
_______________________________________________________________________________ 
407 [S3WOA4060]: Wie alt waren Sie als diese Symptome angefangen haben? 
 
Bitte schreiben Sie Ihre Antwort hier:  Jahre alt 
_______________________________________________________________________________ 
408 [S3WOA4070]: Wie alt waren Sie als Sie diese Symptome das letzte Mal 
hatten? (Falls Sie diese Symptome zurzeit noch haben, geben Sie bitte Ihr 
jetziges Alter an) 
 
Bitte schreiben Sie Ihre Antwort hier:  Jahre alt  
 
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
409 [S3WOA4080]: Wie oft hatten Sie Hitzewallungen/nächtliche 
Schweissausbrüche in den letzten 6 Monaten? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nie 
 Weniger als einmal die Woche 
 Öfter als einmal die Woche, aber nicht jeden Tag 
 Jeden Tag 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
410 [S3WOA4090]: Nehmen Sie zurzeit irgendwelche Hormonpräparate Zur 
Verhütung (z.B. die Pille) 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein  gehen Sie bitte zu Frage 414 
 Ja 
 Ich weiss nicht     gehen Sie bitte zu Frage 414 
_______________________________________________________________________________ 
 
411 [S3WOA4100]: Wie ist der Name des Hormonpräparates, das Sie zurzeit 
einnehmen 
 
Bitte schreiben Sie Ihre Antwort hier: 
 
      _______________________________________________________________ 
______________________________________________________________________________ 
 
412 [S3WOA4110]: Um welche Art Medikament handelt es sich? (z.B. Tabletten, 
Pflaster, Spritze, Implantat, Hormonspirale) 
 
Bitte schreiben Sie Ihre Antwort hier: 
 
      _______________________________________________________________ 
_______________________________________________________________________________ 
413 [S3WOA4120]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit    Monaten 
_______________________________________________________________________________ 
 
414 [S3WOA4130]: Nehmen Sie zurzeit irgendwelche Hormonpräparate zur 
Behandlung von Wechseljahresbeschwerden (z.B. Hormonersatztherapie) 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein  gehen Sie bitte zu Frage 422 
 Ja 
 Ich weiss nicht     gehen Sie bitte zu Frage 422 
_______________________________________________________________________________ 
 
415 [S3WOA4140]: Was ist der Name des Hormonpräparates, das Sie zur Zeit 
einnehmen 
 
Bitte schreiben Sie Ihre Antwort hier: 
 
      _______________________________________________________________ 
_______________________________________________________________________________ 
 
416 [S3WOA4150]: Um welche Art Medikament handelt es sich? (z.B. Tabletten, 
Pflaster) 
 
Bitte schreiben Sie Ihre Antwort hier: 
 
      _______________________________________________________________ 
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
417 [S3WOA4160]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit    Monaten 
_______________________________________________________________________________ 
 
418 [S3WOA4170]: Nehmen Sie weitere Hormonpräparate zur Behandlung von 
Wechseljahresbeschwerden ein? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein  gehen Sie bitte zu Frage 422 
 Ja 
 Ich weiss nicht  gehen Sie bitte zu Frage 422 
_______________________________________________________________________________ 
 
419 [S3WOA4180]: Was ist der Name des Hormonpräparates, das Sie zur Zeit 
einnehmen 
Bitte schreiben Sie Ihre Antwort hier: 
 
          _______________________________________________________________ 
____________________________________________________________________________ 
 
420 [S3WOA4190]: Um welche Art Medikament handelt es sich? (z.B. Tabletten, 
Pflaster) 
Bitte schreiben Sie Ihre Antwort hier: 
 
          _______________________________________________________________ 
____________________________________________________________________________ 
 
421 [S3WOA4200]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit   Monaten 
_______________________________________________________________________________ 
 
 Beanworten Sie diese Frage bitte nur, wenn Sie unter 50 Jahre alt sind, ansonsten gehen Sie weiter zu 
Frage 430. 
 
422 [S3WOA4210]: Nehmen Sie zur Zeit irgendwelche Hormonpräparate um 
schwanger zu werden 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein   gehen Sie bitte zu Frage 430 
 Ja 
 Ich weiss nicht  gehen Sie bitte zu Frage 430 
_______________________________________________________________________________ 
 
 
423 [S3WOA4220]: Was ist der Name des Hormonpräparates, das Sie zur Zeit 
einnehmen? 
Bitte schreiben Sie Ihre Antwort hier: 
 
          _______________________________________________________________ 
______________________________________________________________________________ 
 
424 [S3WOA4230]: Um welche Art Medikament handelt es sich? (z.B. Tabletten, 
Spritze) 
Bitte schreiben Sie Ihre Antwort hier: 
 
          _______________________________________________________________ 
_______________________________________________________________________________ 
 
425 [S3WOA4240]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit     Monaten 
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
426 [S3WOA4250]: Nehmen Sie weitere Hormonpräparate um schwanger zu 
werden? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein  gehen Sie bitte zu Frage 430  
 Ja 
 Ich weiss nicht     gehen Sie bitte zu Frage 430 
_______________________________________________________________________________ 
 
427 [S3WOA4260]: Was ist der Name des Hormonpräparates, das Sie zur Zeit 
einnehmen 
Bitte schreiben Sie Ihre Antwort hier: 
 
          _______________________________________________________________ 
____________________________________________________________________________ 
 
428 [S3WOA4270]: Um welche Art Medikament handelt es sich? (z.B. Tabletten, 
Spritze) 
Bitte schreiben Sie Ihre Antwort hier: 
  
          _______________________________________________________________ 
____________________________________________________________________________ 
429 [S3WOA4280]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit    Monaten 
_______________________________________________________________________________
__ 
 
430 [S3WOA4290]: Nehmen Sie zur Zeit irgendwelche Hormonpräparate um 
gynäkologische oder andere Krankheiten zu behandeln 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein  gehen Sie bitte zu Frage 434 
 Ja 
 Ich weiss nicht  gehen Sie bitte zu Frage 434 
_______________________________________________________________________________
__ 
 
431 [S3WOA4300]: Was ist der Name des Hormonpräparates, das Sie zur Zeit 
einnehmen 
Bitte schreiben Sie Ihre Antwort hier: 
 
          ____________________________________________________________ 
_______________________________________________________________________________ 
 
432 [S3WOA4310] : Um welche Art Medikament handelt es sich? 
Bitte schreiben Sie Ihre Antwort hier: 
 
          ____________________________________________________________ 
_______________________________________________________________________________ 
 
 
433 [S3WOA4320]: Seit wie vielen Monaten verwenden Sie dieses Medikament? 
 
Bitte schreiben Sie Ihre Antwort hier:     seit   Monaten 
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_______________________________________________________________________________ 
 
434 [S3WOA4330]: Habe Sie jemals hormonelle Verhütungsmittel verwendet 
(z.B. die Pille, Hormonpflaster, Spritzen, Implantate, Hormonspirale, z.B. 
Mirena)? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein  gehen Sie bitte zu Frage 450, Seite 68 
 Ja 
 Ich weiss nicht     gehen Sie bitte zu Frage 450, Seite 68 
_______________________________________________________________________________ 
 
435 [S3WOA4340]S: Wie alt waren Sie, als Sie das erste Mal ein hormonelles 
Verhütungsmittel verwendet haben? 
 
Bitte schreiben Sie Ihre Antwort hier:  Jahre alt 
_______________________________________________________________________________ 
 
436 [S3WOA4350]: Waren Ihre Monatsblutungen unregelmässig, bevor Sie 
angefangen haben ein hormonelles Verhütungsmittel zu verwenden? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
437 [S3WOA4360]: Welcher der folgenden Gründe war für Sie der Hauptgrund, 
hormonelle Verhütungsmittel zu verwenden (z.B. die Pille, Hormonspirale)? 
 
Verhütung 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein 
 Ja 
 Ich weiss nicht 
____________________________________________________________________________ 
 
438 [S3WOA4370]: Unregelmässige Monatsblutungen 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein 
 Ja 
 Ich weiss nicht 
____________________________________________________________________________ 
 
439 [S3WOA4380]: Menstruationsschmerzen 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein 
 Ja 
 Ich weiss nicht 
____________________________________________________________________________ 
 
440 [S3WOA4390]: Starke Menstruationsblutung 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein 
 Ja 
 Ich weiss nicht 
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____________________________________________________________________________ 
 
441 [S3WOA4400]: Polyzystisches Ovarien Syndrom 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
442 [S3WOA4410]: Akne 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
____________________________________________________________________________ 
 
443 [S3WOA4420]: Endometriose 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
444 [S3WOA4430]: Wie alt waren Sie, als Sie das letzte Mal hormonelle 
Verhütungsmittel verwendet haben? (falls Sie zurzeit hormonelle 
Verhütungsmittel verwenden, geben Sie bitte Ihr jetziges Alter an.) 
 
Bitte schreiben Sie Ihre Antwort hier:  Jahre alt 
_______________________________________________________________________________ 
 
445 [S3WOA4440]: Alles zusammengezählt, wie lange nehmen Sie/nahmen Sie 
die folgenden Arten von hormonellen Verhütungsmitteln? (Falls Sie diese 
Verhütungsmittel nicht durchgehend genommen haben, schätzen Sie bitte die 
totale Anzahl an Jahren) 
 
Tabletten: 
 
Bitte schreiben Sie Ihre Antwort hier:       Jahre 
____________________________________________________________________________ 
 
446 [S3WOA4450]: Pflaster: 
 
Bitte schreiben Sie Ihre Antwort hier:       Jahre 
____________________________________________________________________________ 
 
447 [S3WOA4460]: Vaginalring: 
 
Bitte schreiben Sie Ihre Antwort hier:       Jahre  
____________________________________________________________________________ 
 
448 [S3WOA4470]: Spritzen/Implantate: 
 
Bitte schreiben Sie Ihre Antwort hier:       Jahre 
____________________________________________________________________________ 
 
449 [S3WOA4480]: Hormonspirale: 
 
Bitte schreiben Sie Ihre Antwort hier:      Jahre  
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
450 [S3WOA4490]: Haben Sie jemals eine Hormonbehandlung wegen der 
Wechseljahre gehabt (Tabletten, Pflaster, Vaginalcremen, Vaginalpessarien)? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein  gehen Sie bitte zu Frage 456 
 Ja 
 Ich weiss nicht      gehen Sie bitte zu Frage 456 
_______________________________________________________________________________ 
 
451 [S3WOA4500]: Wie alt waren Sie, als Sie das erste Mal eine hormonelle 
Behandlung wegen Ihrer Wechseljahre hatten? 
 
Bitte schreiben Sie Ihre Antwort hier:      Jahre alt 
_______________________________________________________________________________ 
 
452 [S3WOA4510]: Wie häufig waren Ihre Monatsblutungen zu der Zeit, als Sie 
angefangen haben, Hormone wegen Ihrer Wechseljahre zu nehmen? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Ich hatte keine Monatsblutungen während der vorangehenden 12 Monaten 
 Ich hatte mindestens eine Monatsblutung in den vorangehenden 12 Monaten, aber  
    meine Monatszyklen waren unregelmässig geworden 
 Meine Monatsblutungen waren regelmässig in den vorangehenden 12 Monaten 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
453 [S3WOA4520]: Hatten Sie Hitzewallungen/nächtliche Schweissausbrüche 
zu der Zeit, als Sie angefangen haben diese Medikamente zu nehmen? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
454 [S3WOA4530]: Wie alt waren Sie, als Sie das letzte Mal eine 
Hormonbehandlung wegen der Menopause hatten? (Falls Sie zu Zeit Hormone 
wegen der Wechseljahre nehmen, geben Sie bitte Ihr jetziges Alter an) 
 
Bitte schreiben Sie Ihre Antwort hier:      Jahre alt  
_______________________________________________________________________________ 
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_______________________________________________________________________________ 
 
455 [S3WOA4540]: In welchem Alter zwischen 40 Jahren und jetzt haben Sie 
eines der folgenden Arten von Hormonen wegen der Menopause genommen? 
 
 Kreuzen Sie bitte die entsprechenden Kästchen an: 
 Falls Sie die entsprechenden Hormone nicht durchgehend genommen haben, kreuzen Sie bitte nur die Jahre 
an, 
    in welchen Sie die Hormonbehandlung hatten, und lassen Sie die anderen Kästchen leer.  
 Falls Sie im gleichen Alter unterschiedliche Behandlungen hatten, kreuzen Sie in dieser Alterskolonne 
mehrere  
    Kästchen an  
 
 
 
456 [S3WOA4550] : Welche der folgenden Aussagen beschreibt am besten Ihre 
Situation bezüglich Schwangerschaft? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Ich habe nie versucht Schwanger zu werden 
 Ich war ein oder mehrere Male natürlich Schwanger geworden 
 Ich wurde nach einer Hormonbehandlung wegen Unfruchtbarkeit Schwanger 
 Mir wurde gesagt, dass ich auf Grund eines medizinisches Problems nicht Schwanger  
    werden kann 
 Mir wurde gesagt, dass es für mich auf Grund eines medizinisches Problems gefährlich 
ist Schwanger zu werden 
 Keines der vorher genannten trifft zu 
 Ich möchte es nicht sagen 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
457 [S3WOA4560]: Hatten Sie jemals eine Fehlgeburt? 
 
Bitte wählen Sie nur eine der folgenden Antworten aus: 
 
 Nein 
 Ja 
 Ich möchte nicht antworten 
 Ich weiss nicht 
_______________________________________________________________________________ 
 
 Beanworten Sie die folgende Frage bitte nur, wenn Sie jemals eine Fehlgeburt hatten, ansonsten: vielen 
Dank für Ihre Mitarbeit! 
 
458 [S3WOA4570] : Wie viele Fehlgeburten hatten Sie? 
 
Bitte schreiben Sie Ihre Antwort hier:  
_______________________________________________________________________________ 
 
 
Vielen Dank für Ihre Mitarbeit! 
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